METHODS OF TREATMENT WITH LXR MODULATORS

Disclosed are methods of using compounds that modulate LXR.
METHODS OF TREATMENT WITH LXR MODULATORS

FIELD OF THE INVENTION

This invention relates to novel treatments and, in particular, to methods for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, injury or impaired plasticity.

BACKGROUND OF THE INVENTION

The process of neurodegeneration is an important factor in many neurological diseases including acute disease such as stroke, traumatic brain injury and spinal cord injury as well as chronic disease including Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis. Agents offering neuroprotection, reduction of inflammatory response or enhancement of functional recovery may be useful in the treatment of these diseases. At present there are no treatments available which promote regeneration following neuronal damage due to such CNS diseases.

The mechanisms underlying functional recovery are currently unknown. Mechanisms thought to promote functional recovery include the sprouting of injured or non-injured axons, enhanced synaptic plasticity, differentiation of endogenous stem cells, activation of redundant pathways, changes in receptor distribution or excitability of neurons or glia (1,2).

Additionally, inflammation in the brain is increasingly seen as an important contributor to neurodegenerative disease mechanisms. Experimental and clinical damage to the brain leads to rapid upregulation of an array of pro-inflammatory mediators such as prostaglandin E2 (PGE2), tumour necrosis factor alpha (TNFα), nitric oxide (NO) and interleukin 6 (IL6). These factors are predominantly secreted by activated glia and exert many neurotoxic actions. Thus preventing or reducing inflammatory processes may also promote functional recovery (3).

Following the onset of stroke, some degree of spontaneous functional recovery is observed in many patients, suggesting that the brain has the ability to repair and/or remodel following injury. Agents that have the potential to enhance this recovery may therefore allow intervention to be made much later (potentially days) following the onset of cerebral ischaemia. Therapies that elicit axon sprouting following injury may therefore be valuable in restoring functional synaptic connections lost by the degenerating CNS in chronic and acute neurodegenerative diseases.
Finally, diseases where increased synaptic plasticity may also be beneficial are the psychiatric disorders including schizophrenia and depression. It has been reported that patients undergoing chronic treatment with effective anti-depressants display increased markers of synaptic plasticity. Compounds which enhance the ability of neurons to extend neurites and potentially increase neuroplasticity may therefore be effective in the prophylaxis and treatment of these disorders.

LXRα and LXRβ (collectively LXR) are nuclear hormone receptors that regulate the metabolism of several important lipids, including cholesterol (4). The nucleotide and amino acid sequences of LXRα are shown in Figures 3 and 4 (SEQ ID NOs: 1 and 2), respectively. The nucleotide and amino acid sequences of LXRβ are shown in Figures 5 and 6 (SEQ ID NOs: 3 and 4), respectively. The LXRs regulate the expression of target genes by binding to short stretches of DNA, termed LXR response elements (LXREs), as heterodimers with the retinoid X receptors (RXR)(5-8). LXREs have been identified in the regulatory regions of a number of genes involved in cholesterol homeostasis including CYP7A1 (9), which catalyses the first and rate-limiting step in bile acid biosynthesis, the cholesterol ester transport protein (10), the transcription factor SREBP-1C (11,12), apolipoprotein E (apoE)(13). LXREs have also been identified in the genes encoding the ATP binding cassette transporters (ABC) A1 and G1(14-18), which mediate the efflux of phospholipids and cholesterol from macrophages, intestinal enterocytes and other cell types.

Currently, patients with elevated levels of cholesterol are treated using the compounds that inhibit the body’s endogenous cholesterol synthesis. As important components of the complex system that regulates cholesterol levels in the body the LXRs have also been proposed as targets for the prophylaxis and treatment of hypercholesteraemia (raised levels of plasma cholesterol) and its associated atherosclerotic diseases.

Schmidt, et al. (19) found that LXRβ activators 5-tetradecyloxy-2-furancarboxylic acid (TOFA) and 22(R)-hydroxycholesterol stimulated transcription from promoters under the control of AP-1 or NF-KB transcription factor binding sites and induced neuronal differentiation in rat pheochromocytoma cells.

It has now been found that LXR mRNA levels are elevated following transient middle cerebral artery occlusion (tMCAO) in the rat.

Administration of LXR agonists enhances neurite outgrowth in primary cultures of hippocampal and cortical neurons, limits the inflammatory response in microglial cells and upregulates the expression of LXR target genes in glial cells. LXR agonist administration also leads to increased cholesterol efflux from primary cell cultures of astrocytes and thus may promote synaptic plasticity.
The LXR target genes ABCA1, ApoE, ABCG1 and SREBP1c are known to be expressed in the CNS. *In vivo* the central administration of LXR agonists has been found to increase gene expression of some LXR target genes in the CNS.

**SUMMARY OF THE INVENTION**

In one aspect, the present invention provides the use of an LXR agonist in the manufacture of medicaments for the treatment and/or prevention of diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity.

In another aspect, the present invention provides a method for treating a patient suffering from a disease selected from the group consisting of: stroke, Alzheimer’s disease, fronto-temporal dementias, peripheral neuropathy, Parkinson’s disease, dementia with Lewy bodies, Huntington’s disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.

In yet another aspect, the present invention provides a method for promoting cholesterol efflux in at least one astroglial cell, said method comprising the step of: contacting said at least one astroglial cell with a cholesterol-efflux-promoting effective amount of an LXR modulator in combination with a carrier.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows that LXR alpha mRNA levels were elevated in brains from tMCAO animals compared to sham-operated controls at 1 and 2 weeks post-surgery. The timepoints at which this elevation in mRNA levels is seen corresponds to the recovery period following MCAO in the rat in which a degree of spontaneous recovery is observed (20).

Figure 2 shows that an LXR agonist (Example 1) can inhibit the secretion of pro-inflammatory mediators (IL-6, PGE2, TNF-α and NO) from LPS \ INF-γ stimulated microglia cells.

Figure 3 shows the nucleotide sequence of human LXRα (SEQ ID NO:1) from Genebank, accession NM_005693.

Figure 4 shows the deduced amino acid sequence of human LXRα (SEQ ID NO:2) from Genebank accession NP_005684.

Figure 5 shows the nucleotide sequence of human LXRβ (SEQ ID NO:3) from Genbank accession XM_046419.
Figure 6 shows the deduced amino acid sequence of human LXRβ (SEQ ID NO:4) from Genebank accession XP_046419.

**DETAILED DESCRIPTION OF THE INVENTION**

In a preferred aspect of the invention, the LXR agonists are selected from those disclosed in International Patent Applications WO 01/54759 (Tularik Inc. US), PCT/US01/27622 (SmithKline Beecham plc UK), WO 01/41704 (Merck & CO., INC) and WO97/28137 (Merck & CO., INC).

International Patent Application WO 00/54759 (Tularik Inc. US) discloses compounds of formula (I):

![Chemical Structure](image)

(I)

wherein:

- Ar represents an aryl group; R¹ is -OH, -O-(C₁₋C₇)alkyl, -OC(O)-(C₁₋C₇)alkyl,
- -O-(C₁₋C₇)heteroalkyl, -OC(O)-(C₁₋C₇)heteroalkyl, -CO₂H, -NH₂,
- -NH(C₁₋C₇)alkyl, -N((C₁₋C₇)alkyl)₂ or -NH-S(O)₂-(C₁₋C₇)alkyl;
- R² is (C₁₋C₇)alkyl, (C₁₋C₇)heteroalkyl, aryl and aryl(C₁₋C₇)alkyl;
- X¹, X², X³, X⁴, X⁵ and X⁶ are each independently H, (C₁₋C₅)alkyl, (C₁₋C₅)heteroalkyl, F or Cl, with the proviso that no more than three of X¹ through X⁶ are H,
- (C₁₋C₅)alkyl or (C₁₋C₅)heteroalkyl; and
- Y is -N(R¹₂)S(O)ₘ⁺, -N(R¹₂)S(O)ₘ⁻N(R¹₃)₂⁻, -N(R¹₂)C(O)₂⁻, -N(R¹₂)C(O)N(R¹₃)₂⁻,
- -N(R¹₂)C(S)⁻ or -N(R¹₂)C(O)O⁻, wherein R₁₂ and R₁₃ are each independently hydrogen, (C₁₋C₇)aryl, (C₁₋C₇)heteroalkyl, aryl and aryl(C₁₋C₇)alkyl, and optionally when Y is -N(R¹₂)S(O)ₘ⁻ or -N(R¹₂)S(O)ₘ⁻N(R¹₃)⁻, R₁₂ forms a five, six or seven-membered ring fused to Ar or to R² through covalent attachment to Ar or R², respectively. In the above Y groups, the subscript m is an integer of from 1 to 2,

as being useful as agonists of LXR and their use in pharmaceutical formulations to reverse cholesterol transport and treat atherosclerotic cardiovascular diseases and related diseases.
With respect to the compounds of formula (I) the term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multi-radicals, having the number of carbons designated (i.e., C\(_1\)-C\(_{10}\) means one to ten carbons). Examples of saturated hydrocarbon radicals include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. The term "alkyl", unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below as "cycloalkyl" and "alkylene". The term "alkylene" by itself or as part of another substituent means a divalent radical derived from alkane, as exemplified by -CH\(_2\)CH\(_2\)CH\(_2\)CH\(_2\)-. Typically, an alkyl group will have from 1 to 24 carbon atoms, with those having 10 or fewer carbon atoms being preferred. A "lower alkyl" or "lower alkyne" is a shorter chain alkyl or alkyne group, generally having eight or fewer carbon atoms, preferably four or fewer carbon atoms.

The term "alkoxy", employed alone or in combination with other terms means, unless otherwise stated, an alkyl group, as defined above, connected to the remainder of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy, and the higher homologs and isomers.

The term "heteroalkyl", by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si, S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quarternized. The heteroatom(s) O, N and S may be placed at any position of the heteroalkyl group except for the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH\(_2\)-CH\(_2\)-O-CH\(_3\), -CH\(_2\)-CH\(_2\)-NH-CH\(_3\), -CH\(_2\)-CH\(_2\)-N(CH\(_3\))\(_2\), -CH\(_2\)-S-CH\(_2\)-CH\(_3\), -CH\(_2\)-CH\(_2\)-O-S(CH\(_3\))\(_2\), and -CH\(_2\)-S(OC\(_2\)H\(_5\))-CH\(_2\)-CH\(_2\)-O-Si(CH\(_3\))\(_3\). Up to two heteroatoms may be consecutive, such as, for example, -CH\(_2\)-NH-CH\(_2\)-O-CH\(_3\) and -CH\(_2\)-O-Si(CH\(_3\))\(_3\). Also included in the term "heteroalkyl" are those radicals described in more detail below as "heteroalkylene" and "heterocycloalkyl."
term "heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by -CH₂-CH₂-S-CH₂-CH₂- and
-CH₂-S-CH₂-CH₂-NH-CH₂-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini. Still further, for alkylene and heteroalkylene linking groups, as well as all other linking groups described herein, no specific orientation of the linking group is implied.

The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalky" respectively. The terms "cycloalkyl" and "heterocycloalkyl" are also meant to include bicyclic, tricyclic and polycyclic versions thereof. Additionally, for heterocycloalkyl, a heteroatom may occupy the position at which the heterocyclol is attached to the remainder of the molecule. Examples of cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexyl, 3-cyclohexyl, cyclopentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, and the like. Example of heterocycloalkyl include

1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholiny, 3-morpholiny, 1,4-diazabiciclo[2.2.2]octyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.

The terms "halo" or "halogen" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine or iodine atom. Additionally, terms such as "fluoroalkyl", are meant to include monofluoroalkyl and polyfluoroalkyl.

The term "aryl", employed alone or in combination with other terms (e.g., aryloxy, arylthioxy, aroyalkyl) means, unless otherwise stated, an aromatic substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The rings may each contain from zero to four heteroatoms selected from N, O and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The aryl groups that contain heteroatoms may be referred to as "heteroaryl" and can be attached to the remainder of the molecule through a carbon atom or a heteroatom. Non-limiting examples of aryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolinyl, 5-isoquinolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolinyl, and 6-quinolinyl. Substituents for each of the above noted aryl ring systems are selected from the group of acceptable substituents described below.
The terms "arylalkyl" and "arylheteroalkyl" are meant to include those radicals in which an aryl group is attached to an aryl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) or a heteroalkyl group (e.g., phenoxyethyl, 2-pyridylxymethyl, 1-naphthoxy-3-propyl, and the like). The arylalkyl and arylheteroalkyl groups will typically contain from 1 to 3 aryl moieties attached to the alkyl or heteroalkyl portion by a covalent bond or by fusing the ring to, for example, a cycloalkyl or heterocycloalkyl group. For arylheteroalkyl groups, a heteroatom can occupy the position at which the group is attached to the remainder of the molecule. For example, the term "arylheteroalkyl" is meant to include benzylxoy, 2-phenylethoxy, phenethylamine, and the like.

Each of the above terms (e.g., "alkyl", "heteroalkyl", "aryl" etc) is meant to include both substituted and unsubstituted forms of the indicated radical. Preferable substituents for each type of radical are provided below.

Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heterolethenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a variety of groups selected from: -OR, =O, =NR', N-OR', NR'R", -SR', -halogen, -SiR'R"R", -OC(O)R', -CO₂R', -CONR'R", OC(O)NR'R", -NR'R'C(O)R', -NR'N(C(O)NR'R"), -NR'C(O)₂R', NHC(NH₂)=NH, -NR'C(NH₂)=NH, -NH₂, C(NH₂)=NR', S(O)₂R', -S(O)₂N'R'R", -CN and -NO₂ in a number ranging from zero to (2N+1), where N is the total number of carbon atoms in such a radical. Preferably, substituted alkyl groups will have from one to six independently selected substituents, more preferably from one to four independently selected substituents, most preferably from one to three independently selected substituents. In the substituents listed above, R', R" and R" each independently refer to hydrogen, unsubstituted (C₁₋₈)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups or aryl-(C₁₋₄)alkyl groups. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl.

Similarly, substituents for the aryl groups are varied and selected from: -halogen, -OR, -OC(O)R', -NR'R", -SR', -CN, -NO₂, -CO₂R', -CONR'R", -OC(O)NR'R", -NR'C(O)R', -NR'C(O)₂R', -NR'C(NH₂)=NH, -NH₂, C(NH₂)=NR', S(O)₂R', -S(O)₂N'R'R", -N₃, -CH(Ph)₂, perfluor(C₁₋₄)alkoxy, and perfluoro(C₁₋₄)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R' and R" are independently selected from
hydrogen, (C_{1-8})alkyl and heteroalkyl, unsubstituted aryl, (unsubstituted aryl)-(C_{1-4})alkyl, and (unsubstituted aryl)oxy-(C_{1-4})alkyl. Preferably, substituted aryl groups will have from one to four independently selected substituents, more preferably from one to three independently selected substituents, most preferably from one to two independently selected substituents.

Two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula \(-T-C(O)-(CH_2)_q-U-\), wherein \(T\) and \(U\) are independently \(-\text{NH}_2\), \(-\text{O}_2\), \(\text{CH}_2\) or a single bond, and \(q\) is an integer of from 0 to 2. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of formula \(-A-(CH_2)_r-B-\), wherein \(A\) and \(B\) are independently \(-\text{CH}_2\), \(-\text{O}_2\), \(-\text{NH}_2\), \(-\text{S}_2\), \(-\text{S(O)}_2\), \(-\text{S(O)}_2\text{NR}_2\) or a single bond, and \(r\) is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl ring may optionally be replaced with a substituent of the formula \(-(CH_2)_s-X-(CH_2)_t\), where \(s\) and \(t\) are integers of from 0 to 3, and \(X\) is \(-\text{O}_2\), \(-\text{NR}_2\), \(-\text{S}_2\), \(-\text{S(O)}_2\), \(-\text{S(O)}_2\text{NR}_2\), or \(-\text{S(O)}_2\text{NR}_2\). The substituent \(R'\) in \(-\text{NR}_2\) and \(-\text{S(O)}_2\text{NR}_2\) selected from hydrogen or unsubstituted (C_{1-6})alkyl.

The term "heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).

The term, "LXR modulator," as used herein, means a small molecule that modulates the biological activities of LXRα and/or LXRβ. More specifically, such an LXR modulator either enhances or inhibits the biological activities of LXR. If such a modulator partially or completely enhances the biological activities of LXR, it is a partial or complete LXR agonist, respectively. Conversely, if such a modulator either partially or completely inhibits the biological activities of LXR, it is a partial or complete LXR antagonist, respectively.

Example 1 of WO 00/54759 (Tularik Inc. US) has the following structure:

![Chemical structure](image)

Compounds of formula (I) can be prepared using readily available starting materials or known intermediates. WO 00/54759 describes a number of possible synthetic routes for the production of such compounds, such as those depicted in scheme 1.
As shown in Scheme 1, aniline (I) (as representative of substituted anilines and other arylamines) can be alkylated, acylated or arylated (general addition of R group) to form (ii), or the aromatic ring can be derivatized with, for example, hexafluoroacetone to form (iii). Treatment of (iii) with an appropriate alkylating group, acylating group or arylating group provides (iv), which can be sulfonylated with, for example, an appropriate sulfonyl halide to form (vi). Alternatively, the aniline derivative can be sulfonlated to form (v), which can then be alkylated or acylated to form compounds of formula (vi).

Other compounds of formula (I) can be formed by treating the substituted aniline (iv) (or iii), with reagents suitable for the formation of amides (vii), carbamates (viii) and ureas (ix). Various reagents are useful in the above scheme and can be found in, for example March, Advanced Organic Chemistry 4th ed. John Wiley & Sons, New York NY (1992)
discloses compounds of formula (II):

\[
\begin{array}{c}
\text{X} \quad \text{CR}^1\text{R}^p \\
\text{O} \quad \text{CH}_2\text{n} \\
\text{N} \quad \text{CHR}^q \\
\text{A} \\
\text{B} \quad \text{B}
\end{array}
\]

wherein:

5 \( X \) is OH or NH₂;
\( p \) is 0-6;

each \( R^1 \) and \( R^2 \) are the same or different and are each independently selected from the group consisting of H, C₁₈-alkyl, C₁₈-alkoxy and C₁₈-thioalkyl;

Z is CH or N;

10 when \( Z \) is CH, \( k \) is 0-4;
when \( Z \) is N, \( k \) is 0-3;

each \( R^3 \) is the same or different and is independently selected from the group consisting of halo, –OH, C₁₈-alkyl, C₂₈-alkenyl, C₁₈-alkoxy, C₂₈-alkenyloxy, –S(O)₂R⁶, –NR⁸R⁸, –COR⁶, COOR⁶, R¹⁰COR⁶, OR¹⁰COOR⁶, CONR⁷R⁸, –OC(O)R⁹, –R¹⁰NR⁷R⁸, –

15 OR¹⁰NR⁷R⁸, 5-6 membered heterocycle, nitro, and cyano;

\( a \) is 0, 1 or 2;

\( R^6 \) is selected from the group consisting of H, C₁₈-alkyl, C₁₈-alkoxy and C₂₈-alkenyl;

each \( R^7 \) and \( R^8 \) are the same or different and are each independently selected from the group consisting of H, C₁₈-alkyl, C₂₈-alkenyl, C₃₈-alkynyl;

20 \( R^9 \) is selected from the group consisting of H, C₁₈-alkyl and -NR²R³;

\( R^{10} \) is C₁₈-alkyl;

\( n \) is 2-8;

\( q \) is 0 or 1;

\( R^4 \) is selected from the group consisting of H, C₁₈-alkyl, C₁₈-alkenyl, and alkenyloxy;

25 Ring A is selected from the group consisting of C₃₈-cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C₃₈-cycloalkyl and aryl,
as being useful as agonists of LXR and their use in pharmaceutical formulations to reverse cholesterol transport and treat atherosclerotic cardiovascular diseases and related diseases.
With respect to compounds of formula (II) the term “alkyl” refers to aliphatic 
straight or branched saturated hydrocarbon chains containing the specified number of 
carbon atoms. Examples of “alkyl” groups as used herein include but are not limited to 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the 
like. The term “alkyl” also refers to substituted alkyl wherein the substituents are selected 
from the group consisting of halo, -OR\(^7\) and -SR\(^7\), where R\(^7\) is H or C\(_1\)-alkyl. This 
definition of “alkyl” is also applicable to terms such as “thioalkyl” which incorporate the 
“alkyl” term. Thus, a “thioalkyl” as used herein refers to the group S-Ra where Ra is 
“alkyl” as defined.

The term “halo” refers to any halogen atom i.e., fluorine, chlorine, bromine or 
iodine.

The term “alkenyl” refers to an aliphatic straight or branched unsaturated 
hydrocarbon chain containing at least one and up to three carbon-carbon double bonds. 
Examples of “alkenyl” groups as used herein include, but are not limited to, ethenyl and 
propenyl. The term “alkenyl” also refers to substituted alkenyl wherein the substituents are 
selected from the group consisting of halo, -OR\(^7\) and -SR\(^7\), where R\(^7\) is H or C\(_1\)-alkyl.

The term “alkoxy” refers to a group O-Ra where Ra is “alkyl” as defined above.

The term “alkenylxy” refers to a group O-Rb where Rb is “alkenyl” as defined 
above.

The term “cycloalkyl” refers to a non-aromatic carbocyclic ring having the specified 
number of carbon atoms and up to three carbon-carbon double bonds. “Cycloalkyl” 
includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 
cyclooctyl, cyclodibutyl, cyclooctyl, cyclohexenyl and bicyclic cycloalkyl groups such 
as bicycloheptane and bicyclo(2.2.1)heptene. The term “cycloalkyl” also refers to 
substituted cycloalkyl wherein the ring bears one or more substituents selected from the 
group consisting of halo, -OH, C\(_1\)-alkyl, C\(_2\)-alkenyl, C\(_1\)-alkoxy, C\(_2\)-alkenylxy, S(O)\(_2\)R\(^6\), 
-NR\(^7\)R\(^8\), -COR\(^6\), -COOR\(^6\), -R\(^{10}\)COOR\(^6\), -OR\(^{10}\)COOR\(^6\), -CONR\(^7\)R\(^8\), -OC(O)R\(^9\), -R\(^{10}\)NR\(^7\)R\(^8\), 
-OR\(^{10}\)NR\(^7\)R\(^8\), nitro, and cyano, wherein a is 0, 1 or 2; R\(^6\) is selected from the group 
consisting of H, C\(_1\)-alkyl, C\(_1\)-alkoxy and C\(_2\)-alkenyl; each R\(^7\) and R\(^8\) is the same or 
different and is independently selected from the group consisting of H, C\(_1\)-alkyl, C\(_2\)-alkenyl 
and C\(_3\)-alkynyl; R\(^9\) is selected from the group consisting of H, C\(_1\)-alkyl and -NR\(^7\)R\(^8\); and 
R\(^{10}\) is C\(_1\)-alkyl. As will be appreciated by those skilled in the art, the number of possible 
substituents on the cycloalkyl ring will depend upon the size of ring. In one preferred 
embodiment, the cycloalkyl is a cyclohexyl which may be substituted as described above.

The term “aryl” refers to aromatic groups selected from the group consisting of 
phenyl, 1-naphthyl and 2-naphthyl. The term “aryl” also refers to substituted aryl wherein
the phenyl or naphthyl ring bears one or more substituents selected from the group consisting of halo, -OH, C_{1,8}alkyl, C_{2,8}alkenyl, C_{1,8}alkoxy, C_{2,8}alkenyloxy, S(O)_{2}R^{6}, -NR^{7}R^{8}, -COR^{6}, -COOR^{6}, -R^{10}COOR^{6}, -OR^{10}COOR^{6}, -CONR^{7}R^{8}, -OC(O)R^{9}, -R^{10}NR^{7}R^{8}, -OR^{10}NR^{7}R^{8}, nitro, and cyano, wherein a is 0, 1 or 2; R^{6} is selected from the group consisting of H, C_{1,8}alkyl, C_{1,8}alkoxy and C_{2,8}alkenyloxy; each R^{7} and R^{8} is the same or different and is independently selected from the group consisting of H, C_{1,8}alkyl, C_{2,8}alkenyl and C_{3,8}alkynyl; R^{9} is selected from the group consisting of H, C_{1,8}alkyl and -NR^{7}R^{8}; and R^{10} is C_{1,8}alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the aryl ring will depend upon the size of ring. For example, when the aryl ring is phenyl, the aryl ring may have up to 5 substituents selected from the foregoing list. One skilled in the art will readily be able to determine the maximum number of possible substituents for a 1-naphthyl or 2-naphthyl ring. A preferred aryl ring according to formula (II) is phenyl, which may be substituted as described above.

The term "heterocycle" refers to a monocyclic saturated or unsaturated non-aromatic carbocyclic rings and fused bicyclic non-aromatic carbocyclic rings, having the specified number of members in the ring and containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of particular heterocyclic groups include but are not limited to tetrahydrofuran, dihydropyran, tetrahydropyran, pyran, oxetane, thietane, 1,4-dioxane, 1,3-dioxane, 1,3-dioxalane, piperidine, piperazine, tetrahydropyrimidine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene, and the like. The term "heterocycle" also refers to substituted heterocycles wherein the heterocyclic ring bears one or more substituents selected from the group consisting of halo, -OH, C_{1,8}alkyl, C_{2,8}alkenyl, C_{1,8}alkoxy, C_{2,8}alkenyloxy, S(O)_{2}R^{6}, -NR^{7}R^{8}, -COR^{6}, -COOR^{6}, -R^{10}COOR^{6}, -OR^{10}COOR^{6}, -CONR^{7}R^{8}, -OC(O)R^{9}, -R^{10}NR^{7}R^{8}, -OR^{10}NR^{7}R^{8}, nitro, and cyano, wherein a is 0, 1 or 2; R^{6} is selected from the group consisting of H, C_{1,8}alkyl, C_{1,8}alkoxy and C_{2,8}alkenyloxy; each R^{7} and R^{8} is the same or different and is independently selected from the group consisting of H, C_{1,8}alkyl, C_{2,8}alkenyl and C_{3,8}alkynyl; and R^{9} is selected from the group consisting of H, C_{1,8}alkyl and -NR^{7}R^{8}; and R^{10} is C_{1,8}alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the heterocyclic ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in the heterocycles. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of possible substituents for any given heterocycle. A preferred heterocycle according to the invention is piperidine, which may be substituted as described above.
The term “heteroaryl” refers to aromatic monocyclic heterocyclic rings and aromatic fused bicyclic rings having the specified number of members in the ring, having at least one aromatic ring and containing 1, 2 or 3 heteroatoms selected from N, O and S.

Examples of particular heteroaryl groups include, but are not limited to, furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzo[b]furan, benzothiophene, indole, and indazole. The term “heteroaryl” also refers to substituted heteroaryls wherein the heteroaryl ring bears one or more substituents selected from the group consisting of halo, -OH, C_{1-8}alkyl, C_{2-8}alkenyl, C_{1-8}alkoxy, C_{2-8}alkenyl, S(O)_{n}R^{5}, -NR^{7}R^{8}, -COR^{6}, -COOR^{6}, -R^{10}COO \cdot R^{6}, -COOR^{6}, -CONR^{7}R^{8}, -OC(O)R^{5}, -R^{10}NR^{7}R^{8}, -OR^{10}NR^{7}R^{8}, nitro, and cyano, wherein n is 0, 1 or 2; R^{5} is selected from the group consisting of H, C_{1-8}alkyl, C_{1-8}alkoxy and C_{2-8}alkenyl; each R^{7} and R^{8} is the same or different and is independently selected from the group consisting of H, C_{1-8}alkyl, C_{2-8}alkenyl and C_{3-8}alkynyl; and R^{6} is selected from the group consisting of H, C_{1-8}alkyl and -NR^{7}R^{8}; and R^{10} is C_{1-8}alkyl. As will be appreciated by those skilled in the art, the number of possible substituents on the heteroaryl ring will depend upon the size of ring. There are no restrictions on the positions of the optional substituents in heteroaryls. Thus, the term encompasses rings having a substituent attached to the ring through a heteroatom. One skilled in the art will readily be able to determine the maximum number and locations of possible substituents for any given heteroaryl. A preferred heteroaryl according to the invention is pyridine, which may be substituted as described above.

The term “protecting group” refers to suitable protecting groups useful for the synthesis of compounds of formula (I) wherein X is OH. Suitable protecting groups are known to those skilled in the art and are described in Protecting Groups in Organic Synthesis, 3rd Edition, Greene, T. W.; Wuts, P. G. M. Eds.; John Wiley & Sons; NY, 1999. Examples of preferred protecting groups include but are not limited to methyl, ethyl, benzyl, substituted benzyl, and tert-butyl. In one embodiment the protecting group is methyl.
Example 16 of PCT/US01/27622 (Smith Kline Beecham plc) has the following structure:

Compounds of formula II can be made according to any suitable method of organic chemistry. One method given in the specification is a solid phase synthesis process as depicted in Scheme 2.

\[ \text{Scheme 2} \]
wherein $X^0$ is -O- or -NH-, SP is solid phase, $R^{15}$ is H or a protecting group, and all other variables are as defined above in connection with the description of compounds of formula (II).

In general, the reaction proceeds by a) reacting a solid phase-bound amine (where X in the compound of formula (II) is NH$_2$) or alcohol (where X in the compound of formula (II) is OH) with a compound of formula (x) and a coupling agent to produce a solid phase-bound compound of formula (xi); b) in the embodiment wherein $R^{15}$ is a protecting group, deprotecting the solid phase bound compound to prepare the compound of formula (xi); c) alkylating the solid phase-bound compound of formula (xi) with an alcohol of formula (xii) to produce a solid phase-bound compound of formula (xiii); d) reacting the solid-phase-bound compound of formula (xiii) with a compound of formula (xiv) to produce the solid-phase bound compound of formula (xv); and e) reacting the solid phase-bound compound of formula (xv) with a compound of formula (xvi) under reductive amination conditions to produce the solid phase-bound compound of formula (II). The process may optionally further comprise the step of cleaving the solid phase-bound compound of formula (II) from the solid phase using conventional techniques such as treatment with mild acid.

Compounds of formula (II) are commercially available or can be prepared using conventional techniques such as those described in European Patent No. 303,742.

Compounds of formula (II) are commercially available or can be prepared using conventional techniques such as those described in European Patent No. 303,742.
Compounds of formula (III) are described in U.S. Provisional Application Nos. 09/368,427, 60/368,425 and 60/368,426, each filed March 27, 2002:

\[
\begin{align*}
W^2 & \quad W^3 \\
W^1 & \\
(R^3)_k & \quad (CR^1R^2)_p \quad (CR^6R^7)_m \quad (CR^4R^5)_n \quad (CR^9R^8)_q \\
X & \quad Y \quad O_h \quad Q
\end{align*}
\]

(III)

wherein:

5. X is selected from C_1-C_8 alkyl, halo, -OR^{10}, -NR^{14}R^{15}, nitro, cyano, -COOR^{10}, -COR^{13}, -OCOR^{13}, -CONR^{14}R^{15}, -N(R^{17})COR^{13}, -N(R^{17})CONR^{14}R^{15}, -N(R^{17})COOR^{13}, -SO_{2}H, -SO_{2}NR^{14}R^{15}, -C(=NR^{17})NR^{14}R^{15}, -N(R^{17})SO_{2}R^{16}, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R^3, taken together with the atoms to which they are bonded, form an alkenylenedioxy moiety;

Z is CH, CR^3 or N, wherein when Z is CH or CR^3, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -N(R^{10})-, and -C(R^4)(R^5)-;

W^1 is selected from C_1-C_6 alkyl, C_7-C_8 cycloalkyl, aryl and Het, wherein said

15 C_1-C_8 alkyl, C_5-C_8 cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C_1-C_6 alky1, C_5-C_6 alkenyl, C_3-C_6 alkynyl, -C_6-C_6 alkyl-CO_{2}R^{10}, -C_6-C_6 alkyl-C(O)SR^{10}, -C_6-C_6 alkyl-CONR^{13} R^{12}, -C_6-C_6 alkyl-COR^{13}, -C_6-C_6 alkyl-NR^{11} R^{12}, -C_6-C_6 alkyl-SR^{10}, -C_6-C_6 alkyl-OR^{10}, -C_6-C_6 alkyl-SO_{2}H, -C_6-C_6 alkyl-SO_{2}NR^{11} R^{12}, -C_6-C_6 alkyl-SO_{2}R^{10}, -C_6-C_6 alkyl-SOR^{13}, -C_6-C_6 alkyl-OC(O)R^{13}, -C_6-C_6 alkyl-OC(O)OR^{13}, -C_6-C_6 alkyl-NR^{11} C(O)OR^{13}, -C_6-C_6 alkyl-NR^{11} C(O)NR^{11} R^{12}, and -C_6-C_6 alkyl-NR^{11} COR^{13}, where said C_1-C_6 alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W^2 is selected from H, halo, C_1-C_6 alky1, C_2-C_6 alkenyl, C_2-C_6 alkynyl,

25 -C_6-C_6 alkyl-NR^{11} R^{12}, -C_6-C_6 alkyl-SR^{10}, -C_6-C_6 alkyl-OR^{10}, -C_6-C_6 alkyl-CO_{2}R^{10}, -C_6-C_6 alkyl-C(O)SR^{10}, -C_6-C_6 alkyl-CONR^{13} R^{12}, -C_6-C_6 alkyl-COR^{13}, -C_6-C_6 alkyl-OCOR^{13}, -C_6-C_6 alkyl-OCOR^{13} R^{12}, -C_6-C_6 alkyl-NR^{11} CONR^{11} R^{12}, -C_6-C_6 alkyl-NR^{11} COR^{13}, -C_6-C_6 alkyl-Het, -C_6-C_6 alkyl-Ar and

-C_6-C_6 alkyl-C_5-C_7 cycloalkyl, wherein said C_1-C_6 alkyl is optionally unsubstituted or
substituted by one or more halo substituents, and wherein the C₅-C₇ cycloalkyl, Ar and Het moieties of said -C₆₋₇ alkyl-Het, -C₆₋₇ alkyl-Ar and -C₆₋₇ alkyl-C₅₋₇ cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₆₋₇ alkyl-CO₂R₁⁰,

-Ç₀₋₆ alkyl-C(O)SR₁⁰, -Ç₀₋₆ alkyl-C(ONR)₁¹R₁², -Ç₀₋₆ alkyl-COR₁³,
-Ç₀₋₆ alkyl-NR₁¹R₁², -Ç₀₋₆ alkyl-SR₁⁰, -Ç₀₋₆ alkyl-OR₁⁰, -Ç₀₋₆ alkyl-SO₂H, -Ç₀₋₆ alkyl-SO₂NR₁¹R₁², -Ç₀₋₆ alkyl-SO₂R₁⁰, -Ç₀₋₆ alkyl-SOR₁³, -Ç₀₋₆ alkyl-OCOR₁³, -Ç₀₋₆ alkyl-OC(O)NR₁¹R₁², -Ç₀₋₆ alkyl-OC(O)OR₁³, -Ç₀₋₆ alkyl-NR₁¹C(O)OR₁³,
-Ç₀₋₆ alkyl-OC(O)NR₁¹R₁², and -Ç₀₋₆ alkyl-NR₁¹COR₁³, where said C₁₋₆ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

W³ is selected from the group consisting of: H, halo, C₁₋₆ alkyl,

-Ç₀₋₆ alkyl-NR₁¹R₁², -Ç₀₋₆ alkyl-SR₁⁰, -Ç₀₋₆ alkyl-OR₁⁰, -Ç₀₋₆ alkyl-CO₂R₁⁰,
-Ç₀₋₆ alkyl-C(O)SR₁⁰, -Ç₀₋₆ alkyl-C(ONR)₁¹R₁², -Ç₀₋₆ alkyl-COR₁³,
-Ç₀₋₆ alkyl-OCOR₁³, -Ç₀₋₆ alkyl-OC(O)NR₁¹R₁², -Ç₀₋₆ alkyl-NR₁¹C(O)OR₁³,
-Ç₀₋₆ alkyl-NR₁¹C(O)NR₁¹R₁², -Ç₀₋₆ alkyl-NR₁¹COR₁³, -Ç₁₋₆ alkyl-Het, -Ç₁₋₆ alkyl-Ar and

-Ç₁₋₆ alkyl-C₅₋₇ cycloalkyl, wherein said C₁₋₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

Q is selected from C₃₋₇ cycloalkyl, Ar and Het; wherein said C₃₋₇ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl,

-Ç₀₋₆ alkyl-CO₂R₁⁰, -Ç₀₋₆ alkyl-C(O)SR₁⁰, -Ç₀₋₆ alkyl-C(ONR)₁¹R₁², -Ç₀₋₆ alkyl-COR₁³,
-Ç₀₋₆ alkyl-NR₁¹R₁², -Ç₀₋₆ alkyl-SR₁⁰, -Ç₀₋₆ alkyl-OR₁⁰, -Ç₀₋₆ alkyl-SO₂H, -Ç₀₋₆ alkyl-SO₂NR₁¹R₁², -Ç₀₋₆ alkyl-SO₂R₁⁰, -Ç₀₋₆ alkyl-SOR₁³, -Ç₀₋₆ alkyl-OCOR₁³, -Ç₀₋₆ alkyl-OC(O)NR₁¹R₁², -Ç₀₋₆ alkyl-OC(O)OR₁³, -Ç₀₋₆ alkyl-NR₁¹C(O)OR₁³,
-Ç₀₋₆ alkyl-NR₁¹C(O)NR₁¹R₁², and -Ç₀₋₆ alkyl-NR₁¹COR₁³, where said C₁₋₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;
n is 2-8;
m is 0 or 1;
q is 0 or 1;
t is 0 or 1;
each R¹ and R² are independently selected from H, halo, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, -Ç₀₋₆ alkyl-NR₁¹R₁², -Ç₀₋₆ alkyl-OR₁⁰, -Ç₀₋₆ alkyl-SR₁⁰, -Ç₁₋₆ alkyl-Het, -Ç₁₋₆ alkyl-Ar and -Ç₁₋₆ alkyl-C₅₋₇ cycloalkyl, or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O,
and S, where any of said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

    each R² is the same or different and is independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het,
    -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰,
    -C₀-C₆ alkyl-COR¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-SR¹₀,
    -C₀-C₆ alkyl-OR¹₀, -C₀-C₆ alkyl-SO₂H, -C₀-C₆ alkyl-SO₂NR¹¹R¹², -C₀-C₆ alkyl-SO₂R¹₀,
    -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹₃, -C₀-C₆ alkyl-OC(O)NR¹¹R¹²,
    -C₀-C₆ alkyl-OC(O)OR¹², -C₀-C₆ alkyl-NR¹¹C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and
    -C₀-C₆ alkyl-NR¹¹COR¹³, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

    each R⁴ and R⁵ is independently selected from H, halo, C₁-C₆ alkyl,
    -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl;
    R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl,
    -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

    R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl,
    -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

    R¹⁰ is selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, or R¹¹ and R¹² together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

    each R¹¹ and each R¹² are independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

    R¹³ is selected from C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

    R¹⁴ and R¹⁵ are each independently selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-O-Ar, -C₀-C₆ alkyl-O-Het, -C₀-C₆ alkyl-O-C₅-C₇ cycloalkyl,
    -C₀-C₆ alkyl-S(O)ₓ-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-S(O)ₓ-Ar, -C₀-C₆ alkyl-S(O)ₓ-Het,
    -C₀-C₆ alkyl-S(O)ₓ-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Ar, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Het,
    -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, where x is 0, 1 or 2, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein
said C1-C6 alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH2, -NH(unchanged C1-C6 alkyl), -N(unchanged C1-C6 alkyl)(unchanged C1-C6 alkyl), unchanged -OC1-C6 alkyl, -CO2H, -CO2(unchanged C1-C6 alkyl), -CONH2, -CONH(unchanged C1-C6 alkyl), -CON(unchanged C1-C6 alkyl)(unchanged C1-C6 alkyl), -SO2H, -SO2NH(unchanged C1-C6 alkyl) and -SO2N(unchanged C1-C6 alkyl)(unchanged C1-C6 alkyl);

R16 is C1-C6 alkyl, -C0-C6 alkyl-Ar or -C0-C6 alkyl-Het; and

R17 is H, C1-C6 alkyl, -C0-C6 alkyl-Ar or -C0-C6 alkyl-Het;

or a pharmaceutically acceptable salt or solvate thereof.

Compounds of formula (IV) are described in U.S. Provisional Application No. 60/368,415, filed March 27, 2002:

wherein:

X is CH or N;

Y is N(R10), O, or S, wherein t is 0 or 1 when Y is N(R10) or O, and t is 0 when Y is S;

U is selected from halo, -OR10, -NR14R15, nitro, cyano, -COOR10, -COR13, -OCOR13, -CONR14R15, -N(R14)COR13, -SO2H, -SO2NR14R15, -C(=NR17)NR14R15, -N(R14)SO2R16, and a 5 or 6-membered heterocyclic group;

A is a phenyl fused ring moiety or a pyridyl fused ring moiety, wherein when A is a phenyl ring moiety, k is 0-3 and t is 0 or 1 and when A is a pyridyl ring moiety, k is 0-2 and t is 0;

W1 is selected from C3-C8 cycloalkyl, aryl and Het, wherein said C3-C8 cycloalkyl,
-C₉-C₆ alkyl- SO₃R¹¹R¹², -C₉-C₆ alkyl- SO₃R¹⁰, -C₉-C₆ alkyl- SOR¹³, -C₉-C₆ alkyl- OCOR¹³, 
-C₉-C₆ alkyl- OC(O)NR¹¹R¹², -C₉-C₆ alkyl- OC(O)OR¹³, -C₉-C₆ alkyl- NR¹¹C(O)OR¹³, 
-C₉-C₆ alkyl- NR¹¹C(O)NR¹¹R¹₂, and -C₉-C₆ alkyl- NR¹¹COR¹³, where said Cₙ-Cₙ alkyl, is 
optionally unsubstituted or substituted by one or more halo substituents;

5  
W² is selected from H, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, 
-C₉-C₆ alkyl- NR¹¹R¹₂, -C₉-C₆ alkyl- SR¹⁰, -C₉-C₆ alkyl- OR¹⁰, -C₉-C₆ alkyl- CO₂R¹⁰, 
-C₉-C₆ alkyl- C(O)SR¹⁰, -C₉-C₆ alkyl- CONR¹¹R¹₂, -C₉-C₆ alkyl- COR¹³, 
-C₉-C₆ alkyl- OCOR¹³, -C₉-C₆ alkyl- OCONR¹¹R¹₂, -C₉-C₆ alkyl- NR¹¹CONR¹¹R¹₂, 
-C₉-C₆ alkyl- NR¹¹COR¹³, -C₉-C₆ alkyl- Het, -C₉-C₆ alkyl- Ar and

10  -C₉-C₆ alkyl- Cₙ-Cₙ cycloalkyl, wherein said Cₙ-Cₙ alkyl is optionally unsubstituted or 
substituted by one or more halo substituents, and wherein the Cₙ-Cₙ cycloalkyl, Ar and Het 
moieties of said -C₉-C₆ alkyl-Het, -C₉-C₆ alkyl-Ar and -C₉-C₆ alkyl- Cₙ-Cₙ cycloalkyl are 
optionally unsubstituted or substituted with one or more groups independently selected from 
halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₂-C₆ alkynyl, -C₉-C₆ alkyl- CO₂R¹⁰,

15  -C₉-C₆ alkyl- C(O)SR¹⁰, -C₉-C₆ alkyl- CONR¹¹R¹₂, -C₉-C₆ alkyl- COR¹³, 
-C₉-C₆ alkyl- NR¹¹R¹₂, -C₉-C₆ alkyl- SR¹⁰, -C₉-C₆ alkyl- OR¹⁰, -C₉-C₆ alkyl- SO₃H, 
-C₉-C₆ alkyl- SO₃NR¹¹R¹₂, -C₉-C₆ alkyl- SO₂R¹⁰, -C₉-C₆ alkyl- SOR¹³, -C₉-C₆ alkyl- OCOR¹³, 
-C₉-C₆ alkyl- OC(O)NR¹¹R¹₂, -C₉-C₆ alkyl- OC(O)OR¹³, -C₉-C₆ alkyl- NR¹¹C(O)OR¹³, 
-C₉-C₆ alkyl- NR¹¹C(O)NR¹¹R¹₂, and -C₉-C₆ alkyl- NR¹¹COR¹³, where said Cₙ-Cₙ alkyl, is 
optionally unsubstituted or substituted by one or more halo substituents;

20  W³ is selected from the group consisting of: H, halo, C₁-C₆ alkyl, 
-C₉-C₆ alkyl- NR¹¹R¹₂, -C₉-C₆ alkyl- SR¹⁰, -C₉-C₆ alkyl- OR¹⁰, -C₉-C₆ alkyl- CO₂R¹⁰, 
-C₉-C₆ alkyl- C(O)SR¹⁰, -C₉-C₆ alkyl- CONR¹¹R¹₂, -C₉-C₆ alkyl- COR¹³, 
-C₉-C₆ alkyl- OCOR¹³, -C₉-C₆ alkyl- OCONR¹¹R¹₂, -C₉-C₆ alkyl- NR¹¹CONR¹¹R¹₂,

25  -C₉-C₆ alkyl- NR¹¹COR¹³, -C₉-C₆ alkyl- Het, -C₉-C₆ alkyl-Ar and 
-C₁-C₆ alkyl- Cₙ-Cₙ cycloalkyl, wherein said Cₙ-Cₙ alkyl is optionally unsubstituted or 
substituted by one or more halo substituents;

Q is selected from Cₙ-Cₙ cycloalkyl, Ar and Het; wherein said Cₙ-Cₙ cycloalkyl, Ar 
and Het are optionally unsubstituted or substituted with one or more groups independently 
selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₂-C₆ alkynyl,

30  -C₉-C₆ alkyl- CO₂R¹⁰, -C₉-C₆ alkyl- C(O)SR¹⁰, -C₉-C₆ alkyl- CONR¹¹R¹², -C₉-C₆ alkyl- COR¹³, 
-C₉-C₆ alkyl- NR¹¹R¹₂, -C₉-C₆ alkyl- SR¹⁰, -C₉-C₆ alkyl- OR¹⁰, -C₉-C₆ alkyl- SO₃H, 
-C₉-C₆ alkyl- SO₂R¹⁰, -C₉-C₆ alkyl- SOR¹³, -C₉-C₆ alkyl- OCOR¹³, 
-C₉-C₆ alkyl- OC(O)NR¹¹R¹₂, -C₉-C₆ alkyl- OC(O)OR¹³, -C₉-C₆ alkyl- NR¹¹C(O)OR¹³, 
-C₉-C₆ alkyl- NR¹¹C(O)NR¹¹R¹₂, and -C₉-C₆ alkyl- NR¹¹COR¹³, where said C₁-C₆ alkyl is 
optionally unsubstituted or substituted by one or more halo substituents;
p is 0-8;
n is 2-8;
m is 0 or 1;
q is 0 or 1;
t is 0 or 1;

each R¹ and R² are independently selected from H, halo, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkylnyl, -C₀-C₆ alkyl-NR¹¹R¹², -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SR¹⁰, -C₁-C₆ alkyl-Het, -C₁-C₆ alkyl-Ar and -C₁-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R³ is the same or different and is independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₁-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het,

-C₀-C₆ alkyl-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰,

-C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl,

-C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl,

-C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

R¹⁰ is selected from H, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar,

-C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl;

each R¹¹ and each R¹² are independently selected from H, C₁-C₆ alkyl,

C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and

-C₀-C₆ alkyl-C₃-C₇ cycloalkyl, or R¹¹ and R¹² together with the carbon to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R¹³ is selected from C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar,

-C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₃-C₇ cycloalkyl.
R¹⁴ and R¹⁵ are each independently selected from H, C₁-C₅ alkyl, C₃-C₆ alkenyl, C₆-C₁₅ alkynyl, -C₀-C₅ alkyl-Ar, -C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-O-Ar, -C₀-C₆ alkyl-O-Het, -C₀-C₆ alkyl-O-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-S(O)ₓ-C₁-C₆ alkyl, -C₀-C₆ alkyl-S(O)ₓ-Ar, -C₀-C₆ alkyl-S(O)ₓ-Het, -C₀-C₆ alkyl-S(O)ₓ-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-NH-Ar, -C₀-C₆ alkyl-NH-Het, -C₀-C₆ alkyl-NH-C₃-C₇ cycloalkyl, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Ar, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-Het, -C₀-C₆ alkyl-N(C₁-C₄ alkyl)-C₅-C₇ cycloalkyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het and -C₀-C₆ alkyl-C₅-C₇ cycloalkyl, where x is 0, 1 or 2, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₅ alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsubstituted C₁-C₅ alkyl), -N(unsubstituted C₁-C₅ alkyl)(unsubstituted C₁-C₅ alkyl), unsubstituted -OC₁-C₆ alkyl, -CO₂H, -CO₂(unsubstituted C₁-C₅ alkyl), -CONH₂, -CONH(unsubstituted C₁-C₆ alkyl), -CON(unsubstituted C₁-C₆ alkyl)(unsubstituted C₁-C₅ alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsubstituted C₁-C₅ alkyl) and -SO₂N(unsubstituted C₁-C₅ alkyl)(unsubstituted C₁-C₆ alkyl); R¹⁶ is C₁-C₅ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het; and R¹⁷ is H, C₁-C₅ alkyl, -C₀-C₆ alkyl-Ar or -C₀-C₆ alkyl-Het; or a pharmaceutically acceptable salt or solvate thereof.

Unless otherwise provided, each alkyl, alkoxy, alkenyl, alkylnyl, cycloalkyl, aryl or Het (including any 3-5-membered, 4-7-membered or 5-7-membered carbocyclic or heterocyclic rings or ring moieties) in the compounds of formula (III) and (IV) is independently unsubstituted or substituted with one or more substituents defined hereinafter.

In the compounds of formula (IV), group A is defined as a phenyl or a pyridyl fused ring moiety and is exemplified by the following:

Group A fused ring moiety:

phenyl:  
pyridyl:  

As used to define the compounds of formulas (III) or (IV), the term "alkyl" represents a straight-or branched-chain saturated hydrocarbon, containing 1 to 10 carbon atoms, unless otherwise provided, which may be unsubstituted or substituted by one or more...
of the substituents described below. Exemplary alkyls include, but are not limited to methyl (Me), ethyl (Et), n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, neopentyl and hexyl and structural isomers thereof. Any "alkyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH( unsubstituted C₁-C₆ alkyl), -N( unsubstituted C₁-C₆ alkyl)( unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

When combined with another substituent term as used to define the compounds of formulas (III) or (IV) (e.g., aryl or cycloalkyl as in -alkyl-Ar or -alkyl-cycloalkyl), the "alkyl" term therein refers to an alkylene moiety, that is, an unsubstituted divalent straight-or branched-chain saturated hydrocarbon moiety, containing 1 to 10 carbon atoms, unless otherwise provided. For example, the term "-C₅-C₆ alkyl-Ar", where C is 1-6 is intended to mean the radical -alkyl-aryl (e.g., -CH₂-aryl or -CH(CH₃)-aryl) and is represented by the bonding arrangement present in a benzyl group. The term "C₅ alkyl" in a moiety, such as -C₀-C₆ alkyl-Ar or -O-(C₅-C₆ alkyl)-Ar, provides for no alkyl/alkylene group being present in the moiety. Thus, when C is zero, -C₀-C₆ alkyl-Ar is equivalent to -Ar and -O-(C₀-C₆ alkyl)-Ar is equivalent to -O-Ar.

As used to define the compounds of formulas (III) or (IV), the term "alkenyl" represents a straight-or branched-chain hydrocarbon, containing 2 to 10 carbon atoms, unless otherwise provided, and one or more carbon-carbon double bonds. Alkenyl groups may be unsubstituted or substituted by one or more of the substituents described below. Exemplary alkenyls include, but are not limited ethenyl, 1-propenyl, 2-propenyl, 1-butynyl, 2-butynyl, isobutenyl, butadienyl, pentenyl and hexenyl and structural isomers thereof. Both cis (Z) and trans (E) isomers of each double bond that may be present in the compounds of formula (III) or (IV) are included within the scope of this definition. Any "alkenyl" herein may be optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH( unsubstituted C₁-C₆ alkyl), -N( unsubstituted C₁-C₆ alkyl)( unsubstituted C₁-C₆ alkyl), unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

As used to define the compounds of formulas (III) or (IV), the term "alkynyl" represents a straight- or branched-chain hydrocarbon, containing 2 to 10 carbon atoms, unless otherwise provided, and one or more carbon-carbon triple bonds and, optionally, one or more carbon-carbon double bonds. Both cis (Z) and trans (E) isomers of each double bond that may be present in the compounds of formula (III) or (IV) are included within the scope of this definition. Exemplary alkynyls include, but are not limited ethynyl, propynyl (propargyl, isopropynyl), 1-butylnyl, 2-butylnyl, 3-butylnyl, pentylnyl and hexynyl and structural isomers thereof. Any "alkynyl" herein may be optionally substituted by one or
more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, 
-NH(unsubstituted C₃-C₆ alkyl), -N(unsubstituted C₃-C₆ alkyl)(unsubstituted C₃-C₆ alkyl), 
unsubstituted -OC₁-C₆ alkyl, and -CO₂H.

As used to define the compounds of formulas (III) or (IV), when an alkenyl or 
alkynyl group is a substituent on an oxygen, nitrogen or sulfur atom (e.g., as in o xo (-OR), 
thio (-SR), ester (-CO₂R or -C(O)SR), amino (-NRR) or amido (-CONRR) moieties and the 
like), it is understood that a double or triple bond of the alkenyl or alkynyl group is not 
located on carbons that are α,β to the oxygen, nitrogen or sulfur atom. Compounds 
containing ene-amino or enol-type moieties (-NR-CR=CR- or -O-CR=CR-) are not intended 
to be included within the scope of the definition of the compounds of formula (III) or (IV).

As used to define the compounds of formulas (III) or (IV), the term "cycloalkyl" 
represents a non-aromatic monocyclic, bicyclic, or tricyclic hydrocarbon containing from 3 
to 10 carbon atoms which may be unsubstituted or substituted by one or more of the 
substituents described below and may be saturated or partially unsaturated. Exemplary 
cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such 
as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, 
cyclohexenyl and cycloheptyl. Any "cycloalkyl" herein may be optionally substituted by 
one or more of the substituents independently selected from the group halo, cyano, 
C₃-C₆ alkyl (which specifically includes C₃-C₆ haloalkyl, -C₆-C₆ alkyl-OH, -C₆-C₆ alkyl-SH 
and -C₆-C₆ alkyl-NR'R''), C₅-C₆ alkyl, oxo, -OC₁-C₆ alkyl, -OC₁-C₆ alkyl, 
-C₆-C₆ alkyl-COR', -C₆-C₆ alkyl-CO₂R', -C₆-C₆ alkyl-CONR'R'', -OC₆-C₆ alkyl-CO₂H, 
-OC₁-C₆ alkyl-NR'R'', and -OC₆-C₆ alkyl-SO₂NR'R'', wherein each R' and R'' are 
independently selected from H or unsubstituted C₃-C₆ alkyl.

As used to define the compounds of formulas (III) or (IV), the terms "Ar" or "aryl" 
is used interchangeably at all occurrences mean a substituted or unsubstituted carbocyclic 
areic group, which may be optionally fused to another carbocyclic aromatic group 
moiety or to a cycloalkyl group moiety, which may be optionally substituted or 
unsubstituted. Examples of suitable Ar or aryl groups include phenyl, naphthyl indenyl, 1-
oxo-1H-indenyl and tetrahydroanaphthyl. Any "Ar", "aryl" or "phenyl" herein may be 
optionally unsubstituted or substituted by one or more of the substituents independently 
selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes 
C₁-C₆ haloalkyl, -C₆-C₆ alkyl-OH, -C₆-C₆ alkyl-SH and -C₆-C₆ alkyl-NR'R''), C₃-C₆ alkyl, 
-OC₁-C₆ alkyl, -OC₁-C₆ alkyl, -C₆-C₆ alkyl-COR', -C₆-C₆ alkyl-CO₂R', 
-C₆-C₆ alkyl-CONR'R'', -OC₆-C₆ alkyl-CO₂H, -OC₁-C₆ alkyl-NR'R'', 
-C₆-C₆ alkyl-C(=NR')NR'R'', and -C₆-C₆ alkyl-SO₂NR'R'', wherein each R' and R'' are 
independently selected from H or unsubstituted C₁-C₆ alkyl.
As used to define the compounds of formulas (III) or (IV), the term "Het" means a stable 5- to 7-membered monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-membered tricyclic heterocyclic ring group, all of which are saturated, unsaturated or aromatic, and consist of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and which includes bicyclic and tricyclic rings containing one or more fused cycloalkyl, aryl (e.g., phenyl) or heteroaryl (aromatic Het) ring moieties.

As used herein the term "Het" is also intended to encompass heterocyclic groups containing nitrogen and/or sulfur where the nitrogen or sulfur heteroatoms are optionally oxidized or the nitrogen heteroatom is optionally quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. Any "Het" herein may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C1-C6 alkyl (which specifically includes C1-C6 haloalkyl, -C0-C6 alkyl-OH, -C0-C6 alkyl-SH and -C0-C6 alkyl-NR'R"), C1-C6 alkynyl, oxo, -OC1-C6alkyl, -OC1-C6 alkenyl, -C0-C6 alkyl-COR', -C0-C6 alkyl-CO2R', -C0-C6 alkyl-CONR'R", -OC0-C6 alkyl-CO2H, -OC0-C6 alkyl-NR'R", -C0-C6 alkyl-C(=NR)NR'R" and -C0-C6 alkyl-SO2NR'R", wherein each R' and R" are independently selected from H or unsubstituted C1-C6 alkyl.

Examples of such heterocyclic groups include, but are not limited to piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepanyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, 1,3-benzodioxolyl (e.g., methylenedioxy-substituted phenyl), 1,4-benzodioxolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropranyl, thielenyl, benzoxazolyl, benzo furyl, benzothienyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydroindolyl, tetrazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiaziazolyl, oxadiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which are available by routine chemical synthesis and are stable.

Examples of the 4-7 membered heterocyclic rings useful in the compounds of formula (III) or (IV), include, but are not limited to azetidinyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, azepanyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolinyl, oxazolyl, isoaxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropranyl, thielenyl, tetrazolyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiaziazolyl, oxadiazolyl, isoxazolyl,
isoxazolyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which are available by routine chemical synthesis and are stable. The 4-7 membered heterocyclic group may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR¹, -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", -C₀-C₆ alkyl-C(=NR')NR'R" and -C₀-C₆ alkyl-SO₂NR'R", wherein each R¹ and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

Examples of 5 or 6 membered heterocyclic groups include, but are not limited to piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolyl, thiazolyl, furyl, pyranyl, tetrahydrofuryl, tetrahydropyranyl, thiényl, tetrazolyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, and oxadiazolyl, as well as triazolyl, thiadiazolyl, oxadiazoyl, isothiazolyl, imidazolyl, pyridazinyl, pyrimidinyl and triazinyl which are available by routine chemical synthesis and are stable. The 5-6 membered heterocyclic group may be attached at any heteroatom or carbon atom that results in the creation of a stable structure. The 5-6 membered heterocyclic group may be optionally unsubstituted or substituted by one or more of the substituents independently selected from the group halo, cyano, C₁-C₆ alkyl (which specifically includes C₁-C₆ haloalkyl, -C₀-C₆ alkyl-OH, -C₀-C₆ alkyl-SH and -C₀-C₆ alkyl-NR'R"), C₃-C₆ alkenyl, oxo, -OC₁-C₆alkyl, -OC₁-C₆ alkenyl, -C₀-C₆ alkyl-COR¹, -C₀-C₆ alkyl-CO₂R', -C₀-C₆ alkyl-CONR'R", -OC₀-C₆ alkyl-CO₂H, -OC₂-C₆ alkyl-NR'R", -C₀-C₆ alkyl-C(=NR')NR'R" and -C₀-C₆ alkyl-SO₂NR'R", wherein each R¹ and R" are independently selected from H or unsubstituted C₁-C₆ alkyl.

In the compounds of formulas (III) and (IV), the terms "halogen" and "halo" represent chloro, fluoro, bromo or iodo substituents; "alkoxy" is intended to mean the radical –ORᵣ, where Rᵣ is an alkyl group, wherein alkyl is as defined above, provided that -O-C₁ alkyl may be optionally substituted by one or more of the substituents independently selected from the group halo and -CO₂H. (Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and the like); "phenoxy" is intended to mean the radical –ORᵣᵣ, where Rᵣᵣ is a phenyl group; "acetoxy" is intended to mean the radical –O-C(=O)-methyl; "benzoyloxy" is intended to mean the radical –O-C(=O)-phenyl; and "oxo" is intended to mean the keto diradical =O, such as present on a pyrrolidin-2-one ring.
A method for the preparation of compounds of formula (III), comprises the steps of:

(a) reacting an alcohol having the formula: HY-\((CR^4R^5)_{n-L}\), where \(Y\) is -O-, -S-, -NH or protected -NH and L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), with an alcohol having the formula:

\[
\begin{array}{c}
\text{X} \quad (CR^4R^5)_b \quad \text{OH} \\
\end{array}
\]

where \(X\) is a protected carboxylic acid moiety, to form a compound having the formula:

\[
\begin{array}{c}
\text{X} \quad (CR^4R^5)_b \\
\end{array}
\]

(b) reacting the compound formed in step (a) with a secondary amine having the formula

\[
\begin{array}{c}
Q \quad (CR^4R^5)_a \\
\end{array}
\]

\[
\begin{array}{c}
\text{W}^1 \\
\text{W}^2 \\
\text{W}^3
\end{array}
\]

to form a compound having the formula:

\[
\begin{array}{c}
\text{X} \quad (CR^4R^5)_b \\
\end{array}
\]

(c) converting the protected carboxylic acid moiety into a desired amide moiety; and

(d) optionally oxidizing the compound, formed in step (b) to the N-oxide thereof.

Another method for the preparation of compounds of formula (III), comprises the steps of:

(a) reacting an acetylene having the formula: \(R'O-(CR^4R^5)_{n-1}-C\equiv C-H\), where \(R'\) is a hydroxyl protecting group, with a halogen-containing aromatic compound having the formula
where X is a protected carboxylic acid moiety and Halo is bromo or iodo, in the presence of a catalyst to form a compound having the formula:

(b) reducing the compound formed in step (a) and converting the protected hydroxyl group into a leaving group, L, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), to form a compound having the formula:

(c) reacting the compound formed in step (b) with an amine having the formula:

Q-(CR\text{R}^q)_p-N-(CR\text{R}^r)_m-W^1 W^2 W^3
to form a compound having the formula:

(d) converting the protected carboxylic acid moiety into a desired amide moiety; and
(e) optionally oxidizing the compound, formed in step (b) to the N-oxide thereof.
Another method for the preparation of compounds of formula (III), comprises the steps of:

(a) reacting an alcohol having the formula: \( \text{L'}-(\text{CR}^4\text{R}^5)_n\text{L} \), where \( \text{L'} \) and \( \text{L} \) are leaving groups, which may be the same or different, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), with a compound having the formula:

\[
\begin{array}{c}
\text{X} \quad \text{CR}^1\text{R}^2_R_p \quad \text{Y}-\text{H} \\
\text{CR}^4\text{R}^5_h \quad \text{L}
\end{array}
\]

where \( \text{Y'} \) is \(-\text{O}-, -\text{S}-, \) or \(-\text{NH}- \) and \( \text{X} \) is defined as above or a protected form thereof, to form a compound having the formula:

\[
\begin{array}{c}
\text{X} \quad \text{CR}^1\text{R}^2_R_p \\
\text{Y}-\text{CR}^4\text{R}^5_h \quad \text{L}
\end{array}
\]

(b) reacting the compound formed in step (a) with a secondary amine having the formula

\[
\begin{array}{c}
\text{Q} \quad \text{CR}^4\text{R}^5_h \quad \text{N} \quad \text{CR}^5\text{R}^6_m \\
\text{W}\_1 \quad \text{W}\_2 \quad \text{W}\_3
\end{array}
\]

to form a compound having the formula:

\[
\begin{array}{c}
\text{X} \quad \text{CR}^1\text{R}^2_R_p \\
\text{Y}-\text{CR}^4\text{R}^5_h \quad \text{N} \quad \text{CR}^5\text{R}^6_m \quad \text{Q} \\
\text{W}\_1 \quad \text{W}\_2 \quad \text{W}\_3
\end{array}
\]

(c) removing any protecting groups; and

(d) optionally oxidizing the compound formed in step (b) or (c) to the N-oxide thereof.
Another method for the preparation of compounds of formula (III), comprises the steps of:

(a) reacting a compound having the formula:

\[
\begin{array}{c}
N \equiv \underset{\text{Het}}{\left(\text{CR}^1\text{R}^2\right)} \underset{\text{P}}{\text{H}} \\
\end{array}
\]

where \( Y' \) is \(-\text{O}, -\text{S}, \text{or} -\text{NH} \) and \( R' \) is a suitable protecting group for \(-\text{OH}, -\text{SH}, \text{or} -\text{NH}_2 \), with a hydrazide or azide to form a heterocyclic-containing compound having the formula:

\[
\begin{array}{c}
\underset{\text{Het}}{\left(\text{CR}^1\text{R}^2\right)} \\
\end{array}
\]

(b) optionally protecting the \( \text{NH} \) moiety of the heterocyclic group with a protecting group, and removing the \( R' \) protecting group;

(c) reacting the compound formed in step (b) with a compound having the formula: \( \text{L'}\underset{\text{L}}{\left(\text{CR}^4\text{R}^5\right)} \), where \( \text{L'} \) and \( \text{L} \) are leaving groups, which may be the same or different, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), to form a compound having the formula:

\[
\begin{array}{c}
\text{P}\underset{\text{Het}}{\left(\text{CR}^1\text{R}^2\right)} \underset{\text{L}}{\text{H}} \\
\end{array}
\]

where \( \text{P} \) is an optional protecting group or \( \text{H} \);

(d) reacting the compound formed in step (c) with an amine having the formula:

\[
\begin{array}{c}
\text{W}\overset{\text{W}^1}{\underset{\text{W}^2}{\text{W}^3}} \underset{\text{W}^3}{\left(\text{CR}^8\text{R}^9\right)} \\
\end{array}
\]
to form a compound having the structure:

\[
\text{Het} \rightarrow \text{(CR}\text{R}\text{)}_p \rightarrow Y \rightarrow \text{(CR}\text{R}\text{)}_n \rightarrow \text{N} \rightarrow \text{(CR}\text{R}\text{)}_q \rightarrow Q \rightarrow \text{W}_1 \rightarrow \text{W}_2 \rightarrow \text{W}_3
\]

\[; \text{ and}\]

(e) removing any protecting groups.

Another method for the preparation of compounds of formula (III), comprises the 5 steps of:

(a) reacting an acetylene having the formula: \(R'O-(\text{CR}\text{R})_{n-1}-C\equiv C-H\), where \(R'\) is a hydroxyl protecting group, with a halogen-containing aromatic compound having the formula

\[
\text{Z} \rightarrow \text{(CR}\text{R}\text{)}_p \rightarrow \text{X} \rightarrow \text{Halo}\]

where Halo is bromo or iodo, in the presence of a catalyst to form a compound having the formula:

\[
\text{Z} \rightarrow \text{(CR}\text{R}\text{)}_p \rightarrow \text{X} \rightarrow \text{Y} \rightarrow \text{(CR}\text{R}\text{)}_{n-1} \rightarrow \text{OR'}
\]

(b) reducing the compound formed in step (a) and converting the protected hydroxyl group into a leaving group, \(L\), such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol) to form a compound having the formula:

\[
\text{Z} \rightarrow \text{(CR}\text{R}\text{)}_p \rightarrow \text{X} \rightarrow \text{CH}_2\text{CH}_2 \rightarrow \text{(CR}\text{R}\text{)}_{n-1} \\
\]

\[;\]
(c) reacting the compound formed in step (b) with an amine having the formula:

\[ Q - (CR^iR^j)^i_N - (CR^kR^l)_m \]

\[ W^1 \quad W^2 \quad W^3 \]

to form a compound having the formula:

\[ (CR^iR^j)_m \]
\[ W^1 \quad W^2 \quad W^3 \]

\[ X - (CR^iR^j)_p \]
\[ CH_2CH_2 - (CR^kR^l)_m N \]
\[ (CR^iR^j)_q \]
\[ Q \]

(d) removing any protecting groups; and

(e) optionally oxidizing the compound formed in step (c) or (d) to the N-oxide thereof.

Another method for the preparation of compounds of formula (III), comprises the steps of:

(a) reacting an alcohol having the formula: HO-(CR^iR^j)_n-L, where L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or a group that is converted to a leaving group (e.g., an alcohol) with a phenol having the formula:

\[ R^{10}_O - (CR^iR^j)_p \]
\[ Z \]

\[ OH \]

to form an aryl ether having the formula:

\[ R^{10}_O - (CR^iR^j)_p \]
\[ Z \]
\[ O - (CR^iR^j)_n-L \]

\[ W^1 \quad W^2 \]
\[ W^3 \]

(b) reacting an amine having the formula \( H_2N \) with and an aldehyde having the formula Q-CHO or a ketone to form a secondary amine having the formula:

\[ Q - (CR^iR^j)_q - NH - (CR^kR^l)_m \]
\[ W^1 \]
\[ W^2 \]

\[ W^3 \]
(c) reacting the ether formed in step (a) with the secondary amine formed in step (b) to form a compound of this invention having the formula:

(d) when R\(^10\) is other than H, optionally converting the compound formed in step (c) to the compound of this invention, wherein R\(^10\) is H.

Another method for the preparation of compounds of formula (III), comprises the steps of:
(a) reacting an alcohol having the formula: HO-(CR\(^4\)R\(^5\))\(_n\)-L, where L is a leaving group, such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), with an amine having the formula:

\[
\begin{align*}
Q & \quad \text{amine having the formula:} \\
\text{HO-} & \quad \text{as described} \\
\text{to form a tertiary amine having the formula:}
\end{align*}
\]

(b) reacting the tertiary amine formed in step (a) with a phenol having the formula:

\[
\begin{align*}
\text{to form a compound of this invention having the formula:}
\end{align*}
\]
(c) when \( R^{10} \) is other than H, optionally converting the compound, formed in step (b) to the compound of this invention, wherein \( R^{10} \) is H.

Another method for the preparation of compounds of formula (III), comprises the steps of:

5 (a) reacting an alcohol having the formula: \( \text{HO-(CR}^{4}R^{5})_{n}-L \), where \( L \) is a leaving group, such as a halogen (iodide, bromide or chloride) or sulfonate (tosylate, mesylate, triflate, etc.), with a phenol having the formula:

\[
\begin{array}{c}
R^{10} \quad \text{O} \\
\text{(CR}^{1}R^{2})_{p} \\
\text{OH}
\end{array}
\]

and to form an ether-alcohol having the formula:

\[
\begin{array}{c}
R^{10} \quad \text{O} \\
\text{(CR}^{1}R^{2})_{p} \\
\text{O-}-(CR}^{4}R^{5})_{n}-\text{OH}
\end{array}
\]

(b) converting alcohol moiety of the ether-alcohol formed in step (a) into \( L' \), where \( L' \) is a leaving group such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or a group that is converted to a leaving group (e.g., an alcohol) and treating the resulting compound with an amine having the formula:

\[
\begin{array}{c}
\text{Q} \\
-(CR}^{6}R^{9})_{q} \\
\text{NH} \\
-(CR}^{6}R^{7})_{r} \\
\text{W}^{1} \\
\text{W}^{2}
\end{array}
\]

to form a compound of this invention having the formula:

\[
\begin{array}{c}
R^{10} \quad \text{O} \\
\text{(CR}^{1}R^{2})_{p} \\
\text{O-}-(CR}^{4}R^{5})_{n}-\text{N} \\
\text{Q} \\
\text{R}^{8} \\
\text{W}^{1} \\
\text{W}^{2} \\
\text{W}^{3} \\
\text{W}^{4}
\end{array}
\]

, and

(c) when \( R^{10} \) is other than H, optionally converting the compound, formed in step (b) to the compound of this invention, wherein \( R^{10} \) is H.
The method for the preparation of compounds of formula (IV), comprises the steps of:

(a) coupling an acetylene having the formula: with a phenol having the formula:

\[
\begin{array}{c}
\text{Halo} \\
\text{OH} \\
\text{U}-(\text{R}^p)_h
\end{array}
\]

where Halo is a halogen selected from iodo or bromo, in the presence of a metal catalyst to form an aryl-alcohol having the formula:

\[
\begin{array}{c}
\text{A} \\
\text{U}-(\text{R}^p)_h-(\text{R}^q)_n-\text{OH}
\end{array}
\]

(b) converting alcohol moiety of the aryl-alcohol formed in step (a) into L', where L' is a leaving group such as a halogen (iodide, bromide or chloride), sulfonate (tosylate, mesylate, triflate, etc.) or is a group that is converted to a leaving group (e.g., an alcohol), and treating the resulting compound with an amine having the formula:

\[
\begin{array}{c}
\text{Q}-(\text{R}^p)_q-\text{NH}-(\text{R}^q)_r
\end{array}
\]

\[
\begin{array}{c}
\text{W}^1 \\
\text{W}^2
\end{array}
\]

to form the compound of formula (IV):

(c) optionally converting the compound of formula (IV) from step (b) into another compound of formula (IV); and

(d) optionally oxidizing the compound formed in step (c) to the N-oxide thereof.
Alternatively, the compounds of formula (IV) may be prepared by

(a) coupling an acetylene having the formula: with a phenol having the formula:

\[
\text{OH}
\]

\[
\text{Halo}
\]

\[
\begin{array}{c}
\text{U} - \text{(CR\text{I}R\text{I})_p} \\
\text{(R\text{I})_k}
\end{array}
\]

where Halo is a halogen selected from iodo or bromo, in the presence of a metal catalyst to form an aryl-alcohol having the formula:

\[
\begin{array}{c}
\text{A} \\
\text{(CR\text{I}R\text{I})_p} \\
\text{U} - \text{(CR\text{I}R\text{I})_p}
\end{array}
\]

(b) converting alcohol moiety of the aryl-alcohol formed in step (a) into L', where L' is a leaving group such as a halogen (iodide, bromide or chloride) or a sulfonate (tosylate, mesylate, triflate, etc.) and treating the resulting compound with sodium azide, followed by hydrogenation in the presence of a palladium catalyst to form a primary amine having the formula:

\[
\begin{array}{c}
\text{A} \\
\text{(CR\text{I}R\text{I})_p} \\
\text{U} - \text{(CR\text{I}R\text{I})_p}
\end{array}
\]

(c) treating the primary amine with a first aldehyde in the presence of a reducing agent, to form a secondary amine and treating the secondary amine with a second aldehyde in the presence of a reducing agent to form the compound of formula (IV);

\[
\begin{array}{c}
\text{W} \\
\text{W'} \\
\text{W''}
\end{array}
\]

\[
\begin{array}{c}
\text{A} \\
\text{(CR\text{I}R\text{I})_p} \\
\text{U} - \text{(CR\text{I}R\text{I})_p}
\end{array}
\]

\[
\begin{array}{c}
\text{X} \\
\text{Y} \\
\text{Z}
\end{array}
\]

(d) optionally converting the compound of formula (IV) from step (b) into another compound of formula (IV); and

(e) optionally oxidizing the compound formed in step (b) or (c) to the N-oxide thereof.
International Patent Application WO 01/41704 (Merck & Co., Inc.) discloses a compound of formula (V):

![Chemical Structure](image)

(V)

the use of compound (VI):

![Chemical Structure](image)

(VI)

and related compounds alongside methods for their production as described in International Patent Application WO97/28137 (Merck & Co., Inc), along with methods for making them, as being useful as an agonist of LXR and their use in pharmaceutical formulations to reverse cholesterol transport and treat atherosclerotic cardiovascular diseases and related diseases.

Other LXR agonists may be identified by assays such as those described in the above referenced patent applications, for example, the assays described in Examples 1 and 2 of PCT/US01/27622. Biotinylated LXRβ protein was incubated for 20-25 minutes at a concentration of 25nM in assay buffer (50mM KCl, 50mM Tris-pH8, 0.1mg/ml FAF-BSA, 10mM DTT) with equimolar amounts of streptavidin-AlloPhycoCyanin (APC, Molecular Probes). At the same time, the biotinylated peptide comprising amino acids 675-699 of SRC-1 (CPSSHSSLTERHKILHRRLLQEGSPS-CONH2) (SEQ ID No. 2) at a concentration of 25nM was incubated in assay buffer with a ½ molar amount of streptavidin-labelled Europium (Wallac) for 20-25 minutes. After the initial incubations are completed, a 10
molar excess (250nM) of cold biotin was added to each of the solutions to block the unattached streptavidin reagents. After 20 min at room temp, the solutions were mixed yielding a concentration of 12.5nM for the dye-labelled LXRβ protein and SRC-1 peptide. 80μL of the protein/peptide mixture was added to each well of an assay plate containing 20μL of test compound. The final volume in each well was 0.1mL, and the concentration in the well for the dye-labelled protein and peptide was 10nM. The final test compound concentrations were between 56pM and 10μM. The plates were incubated at room temp in the dark for 4-12 hours and then counted on a Wallac Victor fluorescent plate reader. In this assay 1μM 24(S),25-epoxycholesterol gave a reading of 20000 fluorescence units over a background reading of 10000 fluorescence units. The assay for LXRα was run according to the procedures described above using his-tagged LXRα ligand binding domain (amino acids 183-447 of Genbank accession number U22662, with the 14th amino acid corrected to A from R).

The invention provides the use of a LXR agonist in the preparation of a medicament for the treatment and/or prophylaxis of diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity.

The invention also provides a method of treating or preventing diseases or disorders characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity which comprises administering to a subject in need thereof an effective non-toxic and pharmaceutically acceptable amount of a LXR agonist, such as compounds of formula (I), (II), (III), (IV), (V) and (VI) or a pharmaceutically acceptable derivative thereof.

Furthermore, the invention provides the use of a LXR agonist in the preparation of a medicament for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a LXR agonist, such as compounds of formula (I), (II), (III), (IV), (V) and (VI) or a pharmaceutically acceptable derivative thereof.

The invention also provides a method for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a LXR agonist, such as compounds of formula (I), (II), (III), (IV), (V) and (VI) or a pharmaceutically acceptable derivative thereof.

Suitable diseases or conditions are those characterised by neuron degeneration.

Suitable diseases or conditions are those characterised by neuron injury.
Suitable diseases or conditions are those characterised by impaired plasticity.

Suitable diseases or conditions are those characterised by inflammation in the CNS.

Particular diseases or conditions are characterised by neuron degeneration and inflammation, and thus benefiting from the growth and/or repair of neurons including stroke, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis.

Diseases or conditions characterised by neuron degeneration and/or impaired plasticity include psychiatric disorders such as schizophrenia and depression.

Particular diseases or conditions characterised by neuronal injury include those conditions associated with brain and/or spinal cord injury, including trauma.

Accordingly, the present invention also provides a pharmaceutical composition for the promotion of growth and/or repair of neurons in diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity, which composition comprises a LXR agonist and a pharmaceutically acceptable carrier therefor.

Suitable pharmaceutically acceptable salts include salts of salts derived from appropriate acids, such as acid addition salts, or bases.

Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyidine type such as pyridine, collidine, quinine or quinoline.

Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a-glycerophosphate.

The LXR agonists referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed.

The salts and/or solvates of the LXR agonists may be prepared and isolated according to conventional procedures for example those disclosed in the, above mentioned, patent publications.
In the above mentioned method the LXR agonist, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

In the treatment of the invention, the LXR agonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned patent applications and patents.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.

Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.

In accordance with conventional pharmaceutical practice, the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.

Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.

The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated
coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.

Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

The compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington’s Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) and Harry’s Cosmeticology (Leonard Hill Books).

One index of synaptic plasticity is increased synaptic transmission. This can be measured in cultured hippocampal neurons using electrophysiological recordings as described by Levine E S, Crozier R A, Black I B, Plummer M R. "Brain derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D aspartic acid receptor activity", in Proc. Natl. Acad. Sci USA Vol 95 pp10235-10239 (1998). Thus the neurons would be treated with the compound under test and then their synaptic transmission determined against a control following glutamate exposure.

No adverse toxicological effects are expected for the compositions or methods of the invention in the above mentioned dosage ranges.

Although the central nervous system (CNS) accounts for <10% of total body mass, it contains roughly a quarter of all the unesterified cholesterol present in the body (29). Virtually all of the cholesterol present in the brain is derived from in situ biosynthesis. The
conversion of cholesterol to the LXR ligand 24(S)-hydroxycholesterol, which can cross the blood brain barrier (BBB) and enter the general circulation, represents an important mechanism for cholesterol flux out of the CNS (30-32). Importantly, the dysregulation of cholesterol balance in the brain may be related to the onset of neurological disease (29).

Cholesterol turnover across the brain is increased in neurodegenerative disorders such as Alzheimer's disease (AD) and Niemann-Pick Type C disease (33-34). Moreover, there is clinical evidence that patients with elevated cholesterol levels have increase susceptibility to AD (35, 36), and, conversely, that treatment with the statin class of cholesterol-lowering drugs reduces the incidence of AD (37,38). Finally, the E2 and E4 isoforms of apoE, which transports cholesterol throughout the body, have been genetically linked to either a decreased or increased risk of AD, respectively (39-41). Thus, understanding the mechanisms regulating cholesterol balance in the brain may provide important insights into the etiology and treatment of neurodegenerative disorders.

In recent years, great strides have been made in understanding the functions of LXRα and LXRβ in the regulation of cholesterol homeostasis. The LXRs regulate a number of genes involved in the biosynthesis, transport, and excretion of cholesterol and thus are likely to have important implications in human diseases such as hypercholesterolemia and atherosclerosis (25). However, the potential role that the LXRs might play in the CNS has remained largely undefined. The brain is the most cholesterol-rich organ in the body, and dysregulation of cholesterol homeostasis may influence the neurological disorders such as AD (35-38, 42, 43). The brain also produces virtually all of the body's 24(S)-hydroxycholesterol, a cholesterol metabolite that serves as an efficacious agonist of both LXR subtypes (27, 28, 30). The expression patterns of cholesterol-24-hydroxylase, the enzyme that synthesizes 24(S)-hydroxycholesterol, and LXRβ within the CNS are remarkably similar (26, 44). These observations suggest that the LXRs might serve as integral components of a regulatory loop that modulates cholesterol levels and/or cholesterol partitioning in the brain.

In summary, in Examples 6-11 below, the inventors of the present invention demonstrate that LXR regulates a series of genes involved in cholesterol homeostasis in the CNS, both in vitro and in vivo, as well as cholesterol efflux from cultured astroglial cells. There is mounting evidence that cholesterol balance has an important impact on the onset and/or progression of various CNS disorders, including AD. Thus, it is believed that LXR ligands and agonists will have utility in the treatment of a range of CNS disorders caused by either trauma or disease, including AD.
The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way; the present invention being defined by the appended claims.

5 EXAMPLES

Example 1: 2-(3-[[2-Chloro-3-(trifluoromethyl)benzyl][2,2-diphenylethyl]aminol propoxy]- phenyl)acetic acid

Argogel-MB-OH (6.0 g, 2.40 mmol, Argonaut Technologies) was treated with a solution of (3-[[tert-butyldimethylsilyloxy]phenyl]acetic acid (5.40 g, 19.2 mmol, Eur. Pat. Appl. (1987) Application: EP 87-303742 19870428) in 50 mL of anhydrous dichloromethane followed by dicyclohexylcarbodiimide (4.16 g, 19.2 mmol) and 4-dimethylaminopyridine (2.50 g, 19.2 mmol). After rotating at room temperature for 15 hours, the resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL), dichloromethane (3 x 25 mL) and diethyl ether (2 x 25 mL). After drying under house vacuum overnight at 40°C, the resin was treated with 1.0 M tetrabutylammonium fluoride (24 mL, 23.4 mmol) in tetrahydrofuran, and the mixture was rotated for 4 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 25 mL), dimethylformamide (2 x 25 mL), dichloromethane (3 x 25 mL), methanol (3 x 25 mL), and dichloromethane (3 x 25 mL) to give the deprotected phenol. The dry resin was treated with 90 mL of anhydrous toluene followed by triphenylphosphine (15.8 g, 60.0 mmol) and 3-bromo-1-propanol (8.4 g, 60.0 mmol). Upon cooling to 0°C, diisopropyl azodicarboxylate (12.1 g, 60.0 mmol) in 20 mL of anhydrous toluene was added in a dropwise fashion. The reaction was allowed to warm to room temperature and stirred for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (2 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum. The bromide functionalized resin was treated with a solution of diphenethylamine (25.0 g, 127 mmol) in 60 mL of anhydrous dimethylsulfoxide, and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50
mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum at 40°C. The secondary amine resin (5.75 g, 2.0 mmol) was treated with a solution of 2-chloro-3-trifluoromethylbenzaldehyde (8.32 g, 40.0 mmol) in 80 mL of 8% acetic acid in dimethylformamide. Solid sodium triacetoxyborohydride (8.5 g, 40.0 mmol) was added, and the reaction was rotated for 15 hours. The resin was filtered, washed sequentially with dichloromethane (2 x 50 mL), dimethylformamide (2 x 50 mL), dichloromethane (3 x 50 mL), methanol (3 x 50 mL) and dichloromethane (3 x 50 mL), and dried under house vacuum overnight at 50°C. The resin-bound product was treated with 30 mL of trifluoroacetic acid/dichloromethane (15/85) for 15 minutes, and the filtrate was collected. The cleavage procedure was repeated again, and the combined filtrates were concentrated under reduced pressure. The crude product was purified by preparative thin layer chromatography (silica gel, 1 mm plates, Merck 20 x 20 cm silica gel 60 F254) eluting with methanol:dichloromethane (3:97) to give 7.0 mg of the title compound (5% yield based on theoretical loading of secondary amine resin) of a viscous oil: 1H NMR (CDCl3, 400MHz) δ 7.42 (d, 1 H, J = 7.6), 7.23-7.10 (m, 2 H), 6.85 (t, 2 H, J = 8.1), 6.63 (s, 1 H), 6.61 (s, 1 H), 4.11 (t, 1 H, J = 7.8), 3.75 (s, 2 H), 3.63 (t, 2 H, J = 6.0), 3.59 (s, 2 H), 2.12 (d, 2 H, J = 7.8), 2.67 (t, 2 H, J = 6.6), 1.81 (tt, 2 H, J = 6.2); MS (ESP+) m/z 582 (MH+); TLC (EtOAc:hexanes/1:1) Rf = 0.58.

Example 2: N-(2,2,2-trifluoroethyl)-N-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide (T0901317).
12.1 Preparation of N-trifluoroethylaniline derivative.

Suspension of 4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]aniline (9.07 g, 35.0 mmol) in CH2CL2 (100 ml) was added to solution of trifluoroacetic anhydride (5.7 ml, 40.2 mmol) in CH2Cl2 (50 ml) dropwise at room temperature. The solution was stirred for 3 hours, the solution cleared and TLC indicated that the reaction was completed. The reaction mixture was washed with water, aqueous NaHCO3, and brine. The organic layer was drawn off, dried over MgSO4, filtered and concentrated to give 12.1 g of the intermediate trifluoroacetonitrile (12.1a). The intermediate 12.1a was taken up in the THF (50 ml) and treated with LiAIH4 (4.00 g, 106 mmol) at reflux for 10 hours. The reaction was quenched sequentially adding 4 ml of water, 4 ml of 15% NaOH and 12 ml of water. The resulting suspension was stirred for an additional 30 minutes, filtered through a celite pad, which was then rinsed with THF. The combined filtrate and rinse was concentrated under reduced pressure. The residue was taken up in EtOAc, washed with brine, dried over MgSO4, filtered and concentrated. The resulting crude product was purified by chromatography on SiO2 (4:1 hexane:EtOAc as eluant) to provide 11.0 g (92%) of the title compound (12.1b).

1H NMR (CDCl3): δ 7.52 (J=8.6 Hz, 2H), 6.72 (d, J=8.6 Hz, 2H), 4.10 (bs, 1H), 3.80 (q, J=8.5 Hz, 2H), 3.31 (bs, 1H). MS (ES+): 342 (M+H, 100).

12.2 Sulfonylation of 12.1b

A sample of 12.1b from above (1.87 g, 5.48 mmol) was treated with benzenesulfonyl chloride (1.18 g, 6.68 mmol) in pyridine (10 ml) at room temperature for 10 days. The reaction mixture as diluted with EtOAc, washed with aqueous NaHCO3, and brine. The organic layer was dried over MgSO4, filtered and concentrated. The crude product was purified by chromatography on SiO2 (4:1 hexane:EtOAc as eluant) to provide 1.65 g (62%) of compound 12.

1H NMR (CDCl3): δ 7.78 (J=8.8 Hz, 2H), 7.61 (t, J=7.6 Hz, 1H), 7.58 (d, J=7.6 Hz, 2H), 7.46 (t, J= Hz, 2H), 4.24 (q, J=8.2 Hz, 2H), 3.41 (s, 1H). MS (ES+): 480 (M-H, 100). Anal. Calcd. for C17H12F9NO3S: C, 42.42; H, 2.51; N, 2.91; S, 6.66. Found: C, 42.70; H, 2.55; N, 2.84; S, 6.61.
Example 3: (R)-2-(3-[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino)-1-methyl-propoxy]-phenyl)acetic acid methyl ester

5 a) Toluene-4-sulfonic acid-(S)-3-hydroxy-buty1 ester

To a stirring solution of (S)-1,3-butanediol (1.0 g, 0.01 mmol) and triethylamine (1.39 g, 0.014 mmol) in dichloromethane (10 mL) at -20°C was added dropwise p-toluenesulfonfyl chloride and the mixture was stirred for 2 h. The reaction mixture was then warmed to RT and stirred overnight. The reaction mixture was poured into cold H2O (20 mL), and extracted three times with dichloromethane. The organic extracts were then washed with brine. The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to give 2.6 g (96% yield) of title compound as an oil. MS(ESI) 244.8(M+). The crude tosylate was used without further purification.

10 b) (S)-4-[N-(2,2-Diphenylethyl)-N-(2-chloro-3-trifluoromethyl)amino]-butan-2-ol

To a stirring solution of N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethyl)amine (160 mg, 0.409 mmol) and toluene-4-sulfonic acid-(S)-3-hydroxy-buty1 ester (100 mg, 0.409 mmol) in acetonitrile (5 mL) was added solid K2CO3 (170 mg, 1.23 mmol) and NaI (184 mg 1.23 mol). The reaction mixture was heated to reflux and stirred overnight. The mixture was cooled to RT, filtered, and the filtrate was concentrated. The crude product was purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, acetonitrile : H2O, UV detection at 254 nm) to give 110 mg (58% yield) of the title compound as an oil. MS(ESI) 462.0(M+H+).

15 c) (R)-2-(3-[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-1-methyl-propoxy]-phenyl)acetic acid methyl ester

To a stirring solution of (3-hydroxy-phenyl)-acetic acid methyl ester (36 mg, 0.217 mmol) in anhydrous toluene (5 mL) was added (S)-4-[N-(2,2-diphenylethyl)-N-(2-chloro-3-trifluoromethyl)amino]-butan-2-ol (100 mg, 0.217 mmol). Polymer bound triphenylphosphine (115 mg, 0.346 mmol, 3 mmol/g, Fluka Chemie) was then added, and the mixture was stirred for 15 minutes. The reaction mixture was then cooled to 0°C and
diisopropylazodicarboxylate (54 mg, 0.269 mmol) was added in a dropwise fashion. The reaction mixture was stirred overnight at room temperature. The reaction mixture was next filtered and the remaining solid was washed with toluene. The filtrate was concentrated and the crude product was purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, A: acetonitrile B: H2O, A: 85 to 100% during 10 min, UV detection at 254 nm) to give 56 mg (42% yield) of title compound as a viscous oil. MS(ESI) 610.0(M+).

Example 4: (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-[3-(1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl]-amine

\[
\text{HN} \quad \begin{array}{c}
\text{Cl} \\
\text{O} \\
\text{N}
\end{array} \\
\text{F} \quad \text{F}
\]

10 a) 5-(Benzyloxy-benzyl)-1,2,3,4-tetrazole

To a stirring solution of 3-benzyloxyphenylacetonitrile (2.0 g, 8.95 mmol) in toluene (17 ml) was added trimethylsilylazide (2.37 g, 17.9 mmol) and di-n-butyltin oxide (0.22 g, 0.9 mmol). The mixture was heated at 110 °C for 48 h, and was concentrated. The reaction mixture was dissolved in ethyl acetate (100 ml) and washed two times with 10% aqueous sodium bicarbonate. The basic extracts were acidified to pH < 2 with conc. HCl, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude product (2.0 g, 89%) was used in the next step without further purification. MS (ESI) 267.0 (M+H+).

b) 5-(Benzyloxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole
(mixture of regioisomers for ethoxymethyl include 1- and 2-)

To a stirring solution of 3-(3-benzyloxy-benzyl)-1,2,3,4-tetrazole (2.12 g, 7.96 mmol) in DMF (40 ml) at 0 °C was added NaH (0.38 g, 9.55 mmol). To this mixture was added chloromethyl ethyl ether (0.81 ml, 8.75 mmol), and the solution was stirred at RT overnight. The reaction mixture was poured into water (120 ml) and extracted three times with ethyl acetate. The ethyl acetate extracts were dried over Na2SO4, filtered, and concentrated. The crude mixture was subjected to column chromatography (silica gel, ethyl acetate/hexane) to provide the title compounds as a mixture of regioisomers as a light yellow oil (1.39 g, 55%). MS (ESI) 324.8 (M+).
c) 5-(3-Hydroxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole
(mixture of regioisomers for ethoxymethyl include 1- and 2-)

To a stirring solution of 5-(3-benzoyloxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole
(mixture of regioisomers, 0.23 g, 0.71 mmol) in MeOH (5 ml) was added palladium on
carbon (20 mg). The mixture was stirred for 7h under H₂ atmosphere, filtered, and
concentrated. The crude phenol was purified by preparative HPLC (TMC CombiPrep PDS,
75X30 mm, 25mL/min, acetonitrile:H₂O, UV detection at 254 nm) to afford the desired
phenol as a clear oil (0.14 g, 84%). MS (ESI) 235.0 (M+H⁺).

10
d) 5-[3-(3-Bromo-propoxy)-benzyl]-(ethoxymethyl)-1,2,3,4-tetrazole
(mixture of regioisomers for ethoxymethyl include 1- and 2-)

A solution of 5-(3-hydroxy-benzyl)-ethoxymethyl-1,2,3,4-tetrazole (mixture of
regioisomers, 132 mg, 0.56 mmol) in anhydrous toluene (5 ml) was treated with 3-bromo-
propanol (117 mg, 0.84 mmol). Polymer bound triphenylphosphine (0.56 mg, 1.7 mmol, 3
mmol/g, Fluka Chemie) was then added, and the mixture stirred for 15 minutes. The
reaction mixture was then cooled to 0 °C and diisopropylazodicarboxylate (166 ul, 0.84
mmol) was added dropwise. The reaction mixture was stirred at RT overnight, filtered, and
the filtrate was concentrated in vacuo to give 200 mg (100% yield) of a 1:1 mixture of the
title compounds as a yellow oil. MS (ESI) 356.8 (M+2H⁺).

20
e) (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)\{-3-[3-(ethoxymethyl-1,2,3,4-
tetrazol-5-ylmethyl)-phenoxy]-propyl\}-amine
(mixture of regioisomers for ethoxymethyl include 1- and 2-)

A solution of (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-\{3-[3-
(ethoxymethyl-1,2,3,4-tetrazol-5-ylmethyl)-phenoxy]-propyl\}-amine (mixture of
regioisomers, 0.2 g, 0.56 mmol) and (2,2-diphenylethyl)-(2-chloro-3-trifluoromethyl)amine
(0.43 g, 1.12 mmol) in acetonitrile (10 ml) was treated with solid potassium carbonate (0.23
g, 1.7 mmol) and NaI (0.25 g, 1.7 mmol). The reaction was heated at reflux and stirred
overnight. The mixture was cooled to RT, filtered, and concentrated. The crude product was
purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, acetonitrile:
water, UV detection at 254 nm) to give 125 mg (33% yield) of the title compound as a
viscous oil. MS (ESI) 664.2 (M⁺).
f) (2-Chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-[3-(1,2,3,4-tetrazol-5-y1methyl]-phenoxy]-propyl]-amine

To a stirring solution of (2-chloro-3-trifluoromethyl-benzyl)-(2,2-diphenyl-ethyl)-[3-[3-(ethoxymethyl-1,2,3,4-tetrazol-5-ylmethyl]-phenoxy]-propyl]-amine (mixture of regioisomers, 125 mg, 0.19 mmol) in dichloromethane (11 ml) was added triethylsilane (116 mg, 1.08 mmol). The reaction mixture was treated with TFA (3 ml) and then stirred overnight. Solvent was removed and the residue was purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, acetonitrile:water, UV detection at 254 nm) to afford 50 mg (44%) the title compound as a yellow oil. MS (ESI) 607.0(M+H+).

Example 5: (S)-2-(3-[3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy]-phenyl)-acetamide

![Chemical structure](image)

15 a) (S)-(2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-amine

To a solution of (S)-2-phenyl propylamine (0.5g, 3.7mmol) in dry dichloromethane was added acetic acid followed by 2-chloro-3-trifluoromethylbenzaldehyde (1.1g, 5.5mmol) and sodium triacetoxyborohydride (1.5g, 7.4mmol). After the resulting mixture was stirred for 1.5h at RT water was added to quench the reaction. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The crude mixture was purified by column chromatograph (Ethyl acetate:Hexane/25:75) to give the title compound as an oil (0.55g, 45%). MS (ESI) 327.6 (M+H)+.

b) (S)-3-[[2-Chloro-3-(trifluoromethyl)benzyl](2-phenyl-propyl)amino]propoxy]-phenyl)acetic acid methyl ester

A solution of (3-[[3-bromo-propoxy]-phenyl]acetic acid methyl ester (0.55g, 1.5mmol) and (S)-2-Chloro-3-trifluoromethyl-benzyl)-(2-phenyl-propyl)-amine (0.55g, 1.6mmol) in acetonitrile (10 ml) was treated with solid potassium carbonate(0.4g, 2.4mmol). The reaction was heated to reflux and stirred for 48h. Upon cooling to RT, the reaction was filtered through a pad of celite, washed with ethyl acetate, and the filtrate was concentrated in vacuo. The crude product was purified by column chromatograph (Ethyl
acetate:Hexane/20:80) to give the title compound as an oil (0.6g, 67%). MS (ESI) 534.6 (M+H)+.

c) (S)-2-(3-[[2-Chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetic acid
A solution of (S)-2-(3-[[2-chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetic acid methyl ester (0.6g, 1.1mmol) in THF (9 ml) and water (6ml) was treated with aqueous LiOH (1.0 N, 1.0ml, 1.0mmol). After stirring at RT for 2h, additional LiOH (1.0ml, 1.0mmol) was added and stirring was continued for 2h. The reaction was neutralized with acetic acid and poured into water and ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated in vacuo. The crude mixture was purified by HPLC to give the title compound as an oil (0.4g, 75%). MS (ESI) 520.2 (M+H)+.

d) (S)-2-(3-[[2-Chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetic acid hydrochloride salt
To a solution of the (S)-2-(3-[[2-chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetic acid in ethyl ether was added HCl in diethyl ether (1.0M). The suspension was filtered and dried to give the title compound as a white solid (99%). NMR(400MHz, CD3OD) δ: 8.0 (d, J = 4.0Hz, 1H), 7.9 (d, J = 4.0Hz, 1H), 7.7-7.3 (m, 7H), 7.1 (d, J = 8.0 Hz, 1H), 6.8 (m, 2H), 4.1-3.4 (m, 11H), 2.3 (m, 2H), 1.5 (d, J = 4.0 Hz, 3H).

(e) (S)-2-(3-[[2-Chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetamide
To a solution (S)-2-(3-[[2-chloro-3-(trifluoromethyl)benzyl][2-phenyl-propyl]amino]propoxy)-phenyl)acetic acid hydrochloride salt (50 mg, 0.1 mmol) in dichloromethane, 1,2-dichloroethane (EDC, 19.2 mg, 0.1 mmol), 1-hydroxybenzotriazole hydrate (HOBt, 13.6 mg, 0.1 mmol), triethylamine (Et3N, 14µl, 0.1 mmol) and ammonia (1.0M in dioxane, 0.24 ml) were added. After the resulting mixture was stirred at room temperature for over night it was washed with 0.1N HCl, saturated NaHCO3, water and brine. The organic layer was dried over Na2SO4 and concentrated under vacuum. The residue was purified with HPLC to give the tittle compound as a light yellow oil 30 mg, yield 60%. MS m/e519.0 (M+H)+.
Example 6: 2-{2-[[2-Chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-

ethyl}-6-benzofuran acetic acid hydrochloride

a) (3-hydroxy-4-iodo-phenyl)-acetic acid methyl ester

To a stirring solution of (3-hydroxy-phenyl)-acetic acid (5.0 g, 0.033 mole) in aqueous NH₂OH (100 mL NH₂OH (aqueous) and 50 mL H₂O) at 0 °C was added solid KI (7.6 g, 0.36 mole) and solid I₂ (6.0 g, 0.030 mole). The reaction mixture was stirred for 2 h, and then poured into H₂O. The aqueous mixture was extracted three times with Et₂O, and the organic extracts were combined. The ether extracts were dried over Na₂SO₄, filtered, and concentrated. The crude product was dissolved in MeOH (100 mL), conc. HCl (2 mL) was added, and the mixture was heated at reflux overnight. The reaction was cooled to RT and concentrated. The crude methyl ester was dissolved in EtOAc, and washed two times with H₂O (50 mL). The EtOAc layer was dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, acetonitrile : H₂O, UV detection at 254 nm) to give 2.67 g (29% yield) of title compound as a white solid. MS(ESI) 292.8 (M⁺).

b) 2-(2-hydroxy-ethyl)-6-benzofuran acetic acid methyl ester

To a stirring solution of (3-hydroxy-4-iodo-phenyl)-acetic acid methyl ester (1.04 g, 0.0035 mole) and 3-butyln-1-ol (0.5 g, 0.007 mole) in a 3:1 solution of toluene/ Et₃N (25 mL) was added PPh₃ (70 mg, 0.26 mmol), CuI (68 mg, 0.35 mmol), and Pd(PPh₃)₃Cl₂ (50 mg, 0.07 mmol). The mixture was heated at 118 °C for 1 h and then cooled to RT. To the reaction mixture was added florisoril (2 g) and the mixture was filtered through a fritted funnel. The crude benzofuran was concentrated and subjected to column chromatography over silica gel (silica gel 60, EM Science) using 40% EtOAc:hexane as eluent to afford 0.59 g (71% yield) of the title compound as an oil. MS (ESI) 235.0 (M+H⁺).

c) 2-{2-[2,2-diphenylethyl]amino}-ethyl]-6-benzofuran acetic acid methyl ester

To a stirring solution 2-{2-(2-hydroxy-ethyl)-benzofuran]acetic acid methyl ester (0.33 g, 0.0014 mole) in CH₂Cl₂ (15 mL) at 0 °C was added Et₃N (0.21 mL, 0.0015 mole) and methanesulfonyl chloride (0.12 mL, 0.0015 mole). The reaction mixture was stirred for
3 h at 0 °C. The mixture was then poured into cold H₂O, and extracted two times with CH₂Cl₂ (30 mL). The CH₂Cl₂ extracts were washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, and concentrated in vacuo. The crude mesylate (prepared above) was dissolved in CH₂CN (25 mL), and the following reagents were added to the solution: solid K₂CO₃ (194 mg, 1.41 mmol) and N-2,2-diphenylethylamine (0.55 g, 0.0014 mole). The reaction mixture was heated overnight at 88 °C. The mixture was filtered through a fritted funnel and concentrated. The crude product was purified by preparative HPLC (TMC CombiPrep PDS, 75X30 mm, 25mL/min, acetonitrile : H₂O, UV detection at 254 nm) to give 125 mg (15% yield) of the title compound as a viscous oil. MS(ESI) 400.0 (M+H⁺).

d) 2-[(2-Chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino]-ethyl]-6-benzofuran acetic acid methyl ester

To a stirring solution of 2-[(2,2-diphenylethyl)amino]-ethyl]-6-benzofuran acetic acid methyl ester (160 mg, 0.39 mmol) and 2-chloro-3-trifluoromethylbenzaldehyde (81 mg, 0.39 mmol) in CH₂Cl₂ (4 mL) was added sodium triacetoxoborohydride (91 mg, 0.43 mmol) and two drops of glacial acetic acid. The mixture was stirred for 4 h, and was diluted with EtOAc (10 mL). The mixture was washed with saturated aqueous NH₄Cl, saturated aqueous NaHCO₃, and saturated aqueous NaCl. The organic layer was dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by column chromatography over silica (Silica gel 60, EM Science) using 10% EtOAc : Hexane as eluent to afford 0.15 g (64%) of the title compound as an oil. MS(ESI) 606.2 (M⁺).

e) 2-[(2-Chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino]-ethyl]-6-benzofuran acetic acid hydrochloride

To a stirring solution of 2-[(2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)amino]-ethyl]-6-benzofuran acetic acid methyl ester (150 mg, 0.25 mmol) in a 4:1 H₂O/THF (3 mL) solution at 0 °C was added LiOH·H₂O (23 mg, 0.55 mmol). The reaction mixture was warmed to RT and stirred overnight. The reaction mixture was concentrated to remove the THF and was diluted with H₂O (5 mL). The aqueous solution was acidified with 1 N HCl (10 mL) and extracted three times with EtOAc. The EtOAc extracts were dried over Na₂SO₄, filtered, and concentrated. The resulting tertiary amine was dissolved in Et₂O and acidified with 1 N HCl in Et₂O. The solution was stirred for 20 min. and then concentrated to afford 122 mg (78% yield) of the title compound as a white solid. MS(ESI) 592.0 (M⁺).
Example 7: LXR alpha mRNA levels are elevated following transient middle cerebral artery occlusion (tMCAO) in the rat.

tMCAO: Transient (90 min) focal cerebral ischaemia was induced in male Sprague Dawley rats, each weighing between 300-350g. The animals were initially anaesthetised with a mixture of 5% halothane, 60% nitrous oxide and 30% oxygen, placed on a facemask and anaesthesia subsequently maintained at 1.5% halothane. Middle cerebral artery occlusion (MCAO) was carried out using the intraluminal thread technique as described previously (Zea Longa, et. al., 1989). Parallel groups (n=3 per group) of animals were received either MCA occlusion or sham surgery, in which an identical procedure was followed but without insertion of the filament Animals were maintained normothermic throughout the surgical procedure, allowed to recover for 1h in an incubator, before being singly housed. Only those animals with a neurological score of 3 1h post-occlusion were included in the study (as assessed using a 5-point scoring system: 0, no deficit; 1, contralateral reflex; 2, weakened grip; 3, circling; 4, immobile; 5, dead). Animals were maintained for up to 4 weeks.

SYBRman quantitative PCR: The left (lesioned) cerebral cortex was dissected from each rat. All tissues were snap frozen in liquid nitrogen immediately after dissection and stored at -80°C. Tissue samples from each group were homogenised in TRIzol reagent (Life Technologies Inc., Gaithersburg, MD, USA) using 1 ml of TRIzol per 50 mg of tissue.

Total RNA was extracted from the tissue according to the manufacturer’s suggested protocol with the addition of an extra chloroform extraction step and phase separation, and an extra wash of the isolated RNA in 70% ethanol. The RNA was resuspended in PCR grade water and the concentration calculated by A260 measurement. RNA quality was assessed by electrophoresis on a 1% agarose gel. Equal quantities of RNA from each animal in a group were pooled. First strand cDNA was synthesised from 1 μg of each RNA sample; 0.01M DTT, 0.5mM each dNTP, 0.5 μg oligo(dT) primer, 40 U RNaseOUT ribonuclease inhibitor (Life Technologies Inc.), 200 U SuperscriptII reverse transcriptase (Life Technologies Inc.). Triplicate reverse transcription reactions were performed along with an additional reaction in which the reverse transcriptase enzyme was omitted to allow for assessment of genomic DNA contamination in each sample. The resulting cDNA products were divided into twenty aliquots using a Hydra 96 robot (Robbins Scientific, Sunnyvale, CA, USA) for parallel SYBRman PCR reactions using different primer sets for quantification of multiple cDNA sequences. SYBRman PCR was carried out using an ABI prism 7700 sequence detector (Applied Biosystems, Foster City, CA, USA) on the cDNA samples; using SYBRgreen PCR Master Mix (Applied Biosystems) 50°C for 2 minutes,
95°C for 10 minutes followed by forty cycles of 95°C for 15 seconds, 60°C for 1 minute. Additional reactions were performed on each 96 well plate using known dilutions of rat genomic DNA (Clontech Laboratories Inc., Palo Alto, CA, USA) as a PCR template to allow construction of a standard curve relating threshold cycle to initial template copy number.

Primer sequences were as follows:
LXR-alpha left primer: AGTGGTTGCACTTCGCCTGC
LXR-alpha right primer: GTAAGCTTCAGCTGCCTGGC

Example 8: LXR agonists promote neurite outgrowth

Hippocampal neurons: The hippocampi of gestational day 18 rat embryos were dissected out, incubated in trypsin (0.08%, 30min at 37 °C) and dissociated mechanically (16). Hippocampal cells were resuspended in neurobasal medium supplemented with B27, anti-oxidants, 1mM glutamine, 25μM glutamate, 1 mM pyruvate. For outgrowth assays, cells were plated at a density of 3000 cells/well into 96 well dishes that had previously been coated with poly-D-lysine followed by 10% FCS and cultured for 48 hours.

Cortical neurons: Cortex from gestational day 18-20 rat embryos were collected in HBSS on ice. Cells were dissociated as described for hippocampal neurons. Cells were pelleted (200g, 5 mins and resuspended in medium as described for hippocampal cells. Cells were plated at 6000 cells/well and cultured for 24 hours.

The test compound was solubilised in DMSO and added to culture medium at time of cell plating at a dilution of 1:1000. Vehicle only (1:1000) was added to culture medium of untreated controls. Cells were fixed with 4% paraformaldehyde for 1 hour on ice, washed with PBS and stained using Coomassie. Assays were quantified using a KS300 image analysis system (Imaging Associates, UK). For each cell measured, the length from the edge of the cell to the end of the longest neurite was measured for 100 cells/well for each treatment in triplicate. All data are means and SEM pooled from three independent experiments. Results are expressed as a percentage of the length of neurites of cells treated with vehicle alone.
Table 1 shows the neurite outgrowth of murine hippocampal (HC) and cortical (CR) neurons treated with Example 1 or the natural LXR agonist 22(R) hydroxycholesterol, expressed as a percentage of the untreated cells.

<table>
<thead>
<tr>
<th>Concentration of test compound (µm)</th>
<th>HC neurons</th>
<th>CR neurons</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Example 1</td>
<td>22(R) hydroxy chol.</td>
</tr>
<tr>
<td>0</td>
<td>100 (6.2)</td>
<td>100 (5.4)</td>
</tr>
<tr>
<td>0.3</td>
<td>109 (6.25)</td>
<td>115.9 (6.02)</td>
</tr>
<tr>
<td>1.0</td>
<td>113 (5.05)</td>
<td>116 (7.45)</td>
</tr>
<tr>
<td>3.0</td>
<td>120 (7.75)</td>
<td>129.9 (4.12)</td>
</tr>
<tr>
<td>10.0</td>
<td>147 (11.8)</td>
<td>127.9 (6.18)</td>
</tr>
</tbody>
</table>

Figures in parentheses represent the standard error from pooled data from three independent experiments (HC) or from triplicate wells in a single experiment (CR).

**Example 9: LXR agonists are anti-neuroinflammatory**

NTW8 mouse microglial cells were plated into a 96 well plate at a density of 2x10^5 cells/well in DMEM supplemented with 10% FCS, 2 mM glutamine, 10 ng/ml basic fibroblast growth factor (R&D Systems) and N-2 (Gibco). Next day, cell were stimulated for 24hrs in DMEM containing 10ng/ml LPS (Sigma) and 20U/ml IFN-γ (Gibco) in the presence of increasing concentrations of the test compound solubilised in DMSO. Media was removed after 24hrs and analysed by ELISA for secreted IL-6, TNF-α (R&D systems) and PGE2 (Amersham) or via a Greiss assay for nitric oxide (NO) production. Cell viability was assessed by an MTT assay (Promega). All data are means and SEM pooled from two independent experiments. Results are expressed as a percentage of the LPS \ INF-γ stimulated control cells treated with DMSO alone.

Figure 2 shows that Example 1 inhibited the secretion of pro-inflammatory mediators (IL-6, PGE2, TNF-α and NO) from LPS \ INF-γ stimulated microglia cells.

**Example 10: LXR agonists promote astroglial cell cholesterol efflux.**

It has recently been reported that astroglial cells increase synapse plasticity by secreting cholesterol-rich lipoprotein particles (22). These particles are internalized by neurons, leading to an increase in the number and efficacy of synapses. Therefore it is possible that compounds which stimulate astroglial cell cholesterol efflux would promote synaptogenesis, and thus aid nerve regeneration.
Primary murine neuronal cultures were prepared from C57 Bl/6 mice essentially as described elsewhere (23). In brief, embryonic day 18 fetuses were collected by caesarian section, their brains removed and the cerebral cortices dissected from the rest of the brain. The tissue was rinsed during these steps several times in Ca\(^{2+}\) and Mg\(^{2+}\)-free Hank's balanced salt solution (HBSS, containing 1 mM HEPES, GIBCO). After the meninges were removed with forceps, the tissue was minced and incubated for 15 minutes at 37°C in 0.25% trypsin (Sigma) in HBSS. The tissue was then washed twice in HBSS and twice in neuronal plating media (minimal essential media [MEM] containing 3 mg/ml glucose, 5% fetal bovine serum [FBS; GibcoBRL], 5% horse serum [HS; GibcoBRL], 100 U/ml penicillin/100 µg/ml streptomycin [Irvine Scientific] and 2 mM glutamine [Irvine Scientific]) to which 10 µg/ml DNAseI (Sigma) had been added. The tissue was then triturated and spun at 3000 x g for 10 minutes. The resulting cell pellet was resuspended in plating media, and trypan blue-excluding surviving cells were counted in a hemacytometer. Cells were plated into 6-well plates at 1.35 x 10^6 cells per well and maintained at 37°C in 5% CO\(_2\)/95% air in a humidified incubator. The next morning, the plating media from some cultures was carefully withdrawn and replaced with serum-free media (Neurobasal media containing B27 supplement [both from GibcoBRL], 100 U/ml penicillin/100 µg/ml streptomycin, and 0.5 mM glutamine). These cells were fed by half-volume exchange with fresh serum-free media on day 3 in culture. Serum-free growth conditions restrict glial outgrowth such that the resulting cultures are >95% neuronal. The remaining cells were maintained in the same serum-containing plating media without media exchange to establish cultures composed of neurons and glia in an approximate ratio of 60:40 (23). Cells were used in cholesterol efflux assays starting on culture day 6.

Murine astroglia were obtained from postnatal day 1 pups. Briefly, pups were decapitated, their brains removed, and the cerebral cortices prepared as described previously (45), except that astrocyte plating media was used (Dulbecco's modified eagle media [DMEM] containing 4 mg/ml glucose, 5% FBS and 5% HS [GibcoBRL or Irvine Scientific], 100 U/ml penecillin/100 µg/ml streptomycin, 25 mM HEPES, and 2-4 mM glutamine). Glia were grown in T75 flasks at a density of approximately 2 brains per flask. Cells were fed once weekly by complete media exchange in maintenance media (DMEM containing 4.5 mg/ml glucose, 10% FBS, 100 U/ml penecillin/100 µg/ml streptomycin, 25 mM HEPES, and 6 mM glutamine). By visual inspection, these cultures were nearly entirely astroglial with <1% contamination with microglia. After 7 – 14 days in vitro, cells were collected by trypsinization, counted in a hemacytometer, and plated into 6-well plates.
at 50-100,000 cells per well in maintenance media. Cholesterol efflux assays were begun after 3 days’ growth, by which time the cells were approximately 40% confluent.

Cholesterol efflux assays were performed as described elsewhere (24) with some modifications. For astrocytes, the culture media was removed and replaced with 1 ml/well DMEM containing 4.5 mg/ml glucose, 5% FBS, 100 U/ml penecillin/100 µg/ml streptomycin, 25 mM HEPES, and 6 mM glutamine supplemented with 0.5% BSA and 5µl [1,2-3H(N)]-cholesterol (1 mCi/ml ethanolic stock). Twenty-four hours later, cells were washed once in serum-free DMEM containing glucose, penicillin/streptomycin, HEPES, and glutamine and then incubated for 24 hours in the same media supplemented with 0.5% BSA and various drugs or DMSO vehicle. The next day, cells were washed twice in serum-free media and then incubated for a further 24 hours in 1 ml/ well of serum-free media supplemented with drugs or DMSO. Human ApoA-1 was added to some cultures to serve as an exogenous cholesterol acceptor molecule. At the end of this incubation, culture media was collected and spun in a microfuge. Adherent cells were washed three times in PBS and extracted for 1 hr in 1 ml per well hexane:isopropanol (3:2 vol:vol). Two hundred microliters of the culture media supernatant and 200 µl of the cell extract were counted for tritium in 2 ml Packard Ultima Gold Scint. Cholesterol efflux from neurons was examined in much the same way except that cells were always washed and incubated with the neuronal serum-free culturing media described above. On the first day of the efflux experiment, neurons received a half-volume media change with media containing 10µl [1,2-3H(N)]-cholesterol. Efflux is expressed as percent of the total radiolabeled cholesterol pool present in the cultures.

Table 2 shows the cholesterol efflux from cells stimulated by Example 1 and T0901317

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cholesterol efflux as a percentage of total [3H] cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Astrocytes</td>
</tr>
<tr>
<td>Vehicle</td>
<td>1.835 (0.826)</td>
</tr>
<tr>
<td>Example 1</td>
<td>4.722 (0.783)*</td>
</tr>
<tr>
<td>T0901317</td>
<td>4.370 (0.561)*</td>
</tr>
</tbody>
</table>

Basal efflux from astrocyte cultures was enhanced by each LXR agonists. Data reflect 3 independent determinations and are representative of 4 separate experiments. Figures in parentheses represent the standard deviation. *, p<.05 by t-test relative. LXR agonists promote cholesterol efflux from primary astroglial cells, but not neurons.
Example 11: LXR agonists upregulate target gene expression in murine primary astrocyte and neuron cell cultures

Total RNA was isolated from tissue and cell culture samples using TRIzol reagent (GibcoBRL). Briefly, tissue samples were thawed directly in 1 ml Trizol/50mg tissue and homogenized with a polytron. To facilitate recovery of nucleic acid, 100 µg glycogen (Ambion) was added. Cultured cells were lysed in 1ml Trizol containing 100 µg glycogen per well. Samples were then extracted in chloroform and spun at 4°C at 11,000x g for 15 min. The aqueous phase was collected and the RNA was precipitated with the addition of isopropanol. The samples were then spun at 11,000x g at 4°C for 15 min, the pellet washed in 75% ethanol, dried, and dissolved in water. Samples were stored at -70°C until use.

Total RNA samples were diluted to 100 µg/ml and treated with 40 units/ml RNase-free DNAse-I (Ambion) for 30 min at 37°C followed by inactivation at 75°C for 5 min. Samples were quantitated by spectrophotometry or with the RiboGreen assay (Molecular Probes) and diluted to a concentration of 10 ng/µl. Samples were then assayed in duplicate or triplicate 25-µl reactions using 25 ng RNA per reaction with Perkin Elmer chemistry on an ABI Prism 7700 (Perkin Elmer) according to manufacturer's instructions. Gene-specific primers were used at 7.5 or 22.5 pmol per reaction, optimized for each gene examined, and the gene-specific probe was used at 5 pmol per reaction. Primers and probe were synthesized by Keystone Labs (Camarillo, CA). In this system, the probe is degraded by Taq polymerase during the amplification phase, releasing the fluorescent tag from its quenched state; amplification data is expressed as the number of PCR cycles required to elevate the fluorescence signal beyond a threshold intensity level. Fold induction values were calculated by subtracting the mean threshold cycle number (Ct) for each treatment group from the mean Ct for the vehicle group and raising 2 to the power of this difference.

Total RNA prepared from sister cultures treated in parallel was used to profile the expression of ABCA1, ABCG1, and SREBP1c. Expression levels for each gene in neurons and astrocytes were normalized to the vehicle-treated group and are from 2-3 separate experiments. Target gene expression was more highly induced by drug treatment in astrocyte cultures than neuronal cultures.
Table 3 shows the fold expression of selected LXR target genes in primary murine astrocyte and neuron cell cultures relative to those treated with vehicle.

<table>
<thead>
<tr>
<th>Compound</th>
<th>ABCA1</th>
<th>ABCG1</th>
<th>SREBP-1c</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Astrocytes</td>
<td>Neurons</td>
<td>Astrocytes</td>
</tr>
<tr>
<td>Vehicle</td>
<td>1.0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Example 1</td>
<td>11.8</td>
<td>2.8</td>
<td>14.9</td>
</tr>
<tr>
<td>T0901317</td>
<td>18.4</td>
<td>3.0</td>
<td>12.5</td>
</tr>
</tbody>
</table>

Example 12: LXR agonists upregulate target gene expression in the CNS.

Adult male C57 Bl/6 mice (3 per group) were dosed by oral gavage with the LXR agonists Example 1, T0901317, or vehicle (0.5% methylcellulose). Example 1 was delivered at 10 mg/kg twice daily, while T0901317 was administered at 50 mg/kg once daily. After 3 or 7 days’ treatment, animals were killed and their brains removed. The cerebellum and both hippocampi were dissected and snap frozen in liquid nitrogen for RNA isolation. Total RNA was prepared from the hippocampus and cerebellum (black bars) and analyzed for gene expression patterns using QRT-PCR (as described above). Expression levels for each gene in each tissue were normalized to the average expression level in the vehicle group. Both LXR agonists enhanced ABCA1 expression relative to the vehicle-treated group, with the effect most pronounced in the cerebellum after 3 days’ treatment.

Table 4 shows the fold expression of selected LXR target genes in murine hippocampal (HC) and cerebellum (CB) cells harvested from the CNS after oral gavage for 3 days, relative to those treated with vehicle. Figures in parentheses represent the standard deviation.

<table>
<thead>
<tr>
<th>Compound</th>
<th>ABCA1</th>
<th>ABCG1</th>
<th>SREBP-1c</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HC</td>
<td>CB</td>
<td>HC</td>
</tr>
<tr>
<td>Vehicle</td>
<td>1.0 (0.092)</td>
<td>1.0 (0.049)</td>
<td>1.0 (0.112)</td>
</tr>
<tr>
<td>Example 1</td>
<td>1.57 (0.348)</td>
<td>2.13 (0.354)</td>
<td>1.14 (0.212)</td>
</tr>
<tr>
<td>T0901317</td>
<td>2.70 (0.304)</td>
<td>3.66 (0.389)</td>
<td>1.22 (0.098)</td>
</tr>
</tbody>
</table>
Table 5 shows the fold expression of selected LXR target genes in murine hippocampal (HC) and cerebellum (CB) cells harvested from the CNS after oral gavage for 7 days, relative to those treated with vehicle.

<table>
<thead>
<tr>
<th>Compound</th>
<th>ABCA1</th>
<th></th>
<th>ABCG1</th>
<th></th>
<th>SREBP-1c</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HC</td>
<td>CB</td>
<td>HC</td>
<td>CB</td>
<td>HC</td>
<td>CB</td>
</tr>
<tr>
<td>Vehicle</td>
<td>1.0 (0.122)</td>
<td>1.0 (0.044)</td>
<td>1.0 (0.072)</td>
<td>1.0 (0.060)</td>
<td>1.0 (0.096)</td>
<td>1.0 (0.174)</td>
</tr>
<tr>
<td>Example 1</td>
<td>1.26 (0.162)</td>
<td>1.43 (0.302)</td>
<td>0.89 (0.045)</td>
<td>1.17 (0.142)</td>
<td>0.71 (0.327)</td>
<td>1.75 (0.236)</td>
</tr>
<tr>
<td>T0901317</td>
<td>2.69 (0.175)</td>
<td>2.94 (0.084)</td>
<td>1.37 (0.092)</td>
<td>1.80 (0.116)</td>
<td>2.16 (0.110)</td>
<td>2.97 (0.557)</td>
</tr>
</tbody>
</table>
References


The above description fully discloses how to make and use the present invention. However, this invention is not limited to the particular embodiments described hereinabove, but includes all modification thereof within the scope of the appended claims and their equivalents. Those skilled in the art will recognize through routine experimentation that various changes and modifications can be made without departing from the scope of this invention. The various references to journals, patents and other patent applications that are cited herein are incorporated by reference herein as though fully set forth.
What is claimed is:

1. A method for treating a patient suffering from a disease selected from the group consisting of: stroke, Alzheimer's disease, fronto-temporal dementias, peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.

2. The method as claimed in Claim 1, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

3. A method for promoting cholesterol efflux in at least one astroglial cell, said method comprising the step of contacting said at least one astroglial cell with a cholesterol-efflux-promoting effective amount of an LXR modulator in combination with a carrier.

4. The method according to Claim 3, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

5. A method for treating a patient suffering from a disease or disorder characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.

6. The method according to Claim 5, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

7. The method according to Claim 1 or Claim 4, wherein the disease is selected from psychiatric disorders such as schizophrenia and depression.

8. The method according to Claim 1 or Claim 4, wherein the disease is selected from conditions associated with head or spinal cord injury, including trauma.
9. The method according to any one of Claims 1 to 8, wherein the LXR modulator comprises a compound of formula (I)

\[
\begin{array}{c}
\text{X}^1 \quad \text{X}^2 \quad \text{X}^3 \\
\text{R}^1 \quad \text{Ar} \quad \text{Y} \\
\text{X}^4 \quad \text{X}^5 \quad \text{X}^6
\end{array}
\]

wherein:

5. Ar represents an aryl group; R\(^1\) is -OH, -O-(C\(_1\)–C\(_7\))alkyl, -OC(O)-(C\(_1\)–C\(_7\))alkyl, -O-(C\(_1\)–C\(_7\))heteroalkyl, -OC(O)-(C\(_1\)–C\(_7\))heteroalkyl, -CO\(_2\)H, -NH\(_2\), -NH(C\(_1\)–C\(_7\))alkyl, -N((C\(_1\)–C\(_7\))alkyl)\(_2\) or -NH-S(O)\(_2\)-(C\(_1\)–C\(_7\))alkyl;

R\(^2\) is (C\(_1\)–C\(_7\))alkyl, (C\(_1\)–C\(_7\))heteroalkyl, aryl and aryl(C\(_1\)–C\(_7\))alkyl;

X\(^1\), X\(^2\), X\(^3\), X\(^4\), X\(^5\) and X\(^6\) are each independently H, (C\(_1\)–C\(_5\))alkyl, (C\(_1\)–C\(_5\))heteroalkyl, F or Cl, with the proviso that no more than three of X\(^1\) through X\(^6\) are H, (C\(_1\)–C\(_5\))alkyl or (C\(_1\)–C\(_5\))heteroalkyl; and

Y is -N(R\(^{12}\))S(O)\(_m\)-, -N(R\(^{12}\))S(O)\(_m\)N(R\(^{13}\))-\(m\)-, -N(R\(^{12}\))C(O)-, -N(R\(^{12}\))C(O)N(R\(^{13}\))-\(m\)-, -N(R\(^{12}\))C(S)- or -N(R\(^{12}\))C(O)O-, wherein R\(^{12}\) and R\(^{13}\) are each independently hydrogen, (C\(_1\)–C\(_7\))aryl, (C\(_1\)–C\(_7\))heteroalkyl, aryl and aryl(C\(_1\)–C\(_7\))alkyl, and

optionally when Y is -N(R\(^{12}\))S(O)\(_m\)- or -N(R\(^{12}\))S(O)\(_m\)N(R\(^{13}\))-\(m\), R\(^{12}\) forms a five, six or seven-membered ring fused to Ar or to R\(^2\) through covalent attachment to Ar or R\(^2\), respectively. In the above Y groups, the subscript m is an integer of from 1 to 2;

or a pharmaceutically acceptable derivative thereof.

20
10. The method according to any one of Claims 1 to 8, wherein the LXR modulator comprises a compound of formula (II):

wherein:

5  X is OH or NH₂;

p is 0-6;

each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁₈alkyl, C₁₈alkoxy and C₁₈thioalkyl;

Z is CH or N;

10 when Z is CH, k is 0-4;

when Z is N, k is 0-3;

each R³ is the same or different and is independently selected from the group consisting of

halo, −OH, C₁₈alkyl, C₂₈alkenyl, C₁₈alkoxy, C₂₈alkenloxy,

−S(O)₉R⁶, −NR³R⁶, −COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR³R⁶, −OC(O)R⁹,

15 −R¹⁰NR³R⁶, −OR¹⁰NR³R⁶, 5-6 membered heterocycle, nitro, and cyano;

a is 0, 1 or 2;

R⁵ is selected from the group consisting of H, C₁₈alkyl, C₁₈alkoxy and

C₂₈alkenyl;

each R⁷ and R⁸ are the same or different and are each independently selected from

the group consisting of H, C₁₈alkyl, C₂₈alkenyl,

C₃₈alkynyl;

R⁹ is selected from the group consisting of H, C₁₈alkyl and −NR³R⁶;

R¹⁰ is C₁₈alkyl;

n is 2-8;

25 q is 0 or 1;

R⁴ is selected from the group consisting of H, C₁₈alkyl, C₁₈alkenyl, and alkenloxy;

Ring A is selected from the group consisting of C₃₈cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;
each ring B is the same or different and is independently selected from the group consisting of C₃₋₅ cycloalkyl and aryl:
or a pharmaceutically acceptable derivative thereof.

11. The method according to any one of Claims 1 to 8, wherein the LXR modulator comprises a compound of formula (III):

![Chemical Structure](image)

wherein:

- X is selected from C₁₋₅ alkyl, halo, -OR¹⁰, -NR¹⁴R¹⁵, nitro, cyano, -COOR¹⁰,
- COR¹³, -OCOR¹³, -CONR¹⁴R¹⁵, -N(R¹⁷)COR¹³, -N(R¹⁷)CONR¹⁴R¹⁵, -N(R¹⁷)COOR¹³,
- SO₂H, -SO₂NR¹⁴R¹⁵, C(=NR¹⁷)NR¹⁴R¹⁵, -N(R¹⁷)SO₂R¹⁶, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R³, taken together with the atoms to which they are bonded, form an alkyleneedioxy moiety;

- Z is CH, CR³ or N, wherein when Z is CH or CR³, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

- Y is selected from -O-, -S-, -N(R¹⁰)⁻, and -C(R⁴)²(R⁵)⁻;

- W¹ is selected from C₁₋₅ alkyl, C₃₋₅ cycloalkyl, aryl and Het, wherein said C₁₋₅ alkyl, C₃₋₅ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁₋₅ alkyl, C₃₋₅ alkenyl, C₃₋₅ alkynyl, -C₀₋₅ alkyl-CO₂R¹⁰, -C₀₋₅ alkyl-C(O)SR¹⁰,
- C₀₋₅ alkyl-CONR¹¹R¹², -C₀₋₅ alkyl-COR¹³, -C₀₋₅ alkyl-NR¹¹R¹², -C₀₋₅ alkyl-SR¹⁰,
- C₀₋₅ alkyl-OR¹⁰, -C₀₋₅ alkyl-SO₂H, -C₀₋₅ alkyl-SO₂NR¹¹R¹², -C₀₋₅ alkyl-SO₂R¹⁰,
- C₀₋₅ alkyl-SOR¹³, -C₀₋₅ alkyl-OCOR¹³, -C₀₋₅ alkyl-OC(O)NR¹¹R¹²,
- C₀₋₅ alkyl-OC(O)OR¹³, -C₀₋₅ alkyl-NR¹¹C(O)OR¹³, -C₀₋₅ alkyl-NR¹¹C(O)NR¹¹R¹², and
- C₀₋₅ alkyl-NR¹¹COR¹³, where said C₁₋₅ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;

- W² is selected from H, halo, C₁₋₅ alkyl, C₂₋₅ alkenyl, C₂₋₅ alkynyl,
- C₀₋₅ alkyl-NR¹¹R¹², C₀₋₅ alkyl-SR¹⁰, C₀₋₅ alkyl-OR¹⁰, C₀₋₅ alkyl-CO₂R¹⁰,
-C₆-C₆ alkyl-C(O)SR¹⁰, -C₆-C₆ alkyl-CONR¹¹R¹², -C₆-C₆ alkyl-COR¹³,
-C₆-C₆ alkyl-OCOR¹³, -C₆-C₆ alkyl-OCNR¹¹R¹², -C₆-C₆ alkyl-NR¹¹CONR¹¹R¹²,
-C₆-C₆ alkyl-NR¹¹COR¹³, -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and
-C₆-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₆-C₆ alkyl is optionally unsubsti-
tuted or substituted by one or more halo substituents, and wherein the C₃-C₇ cyclo-
alkyl, Ar and Het moieties of said -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and -C₆-C₆ alkyl-C₃-C₇ cycloalkyl are
optionally unsubsti-
tuted or substituted with one or more groups independently selected from
halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₆-C₆ alkyl-CO₂R¹⁰,
-C₆-C₆ alkyl-C(O)SR¹⁰, -C₆-C₆ alkyl-CONR¹¹R¹², -C₆-C₆ alkyl-COR¹³,
-C₆-C₆ alkyl-NR¹¹R¹², -C₆-C₆ alkyl-SR¹⁰, -C₆-C₆ alkyl-OR¹⁰, -C₆-C₆ alkyl-SO₂H,
-C₆-C₆ alkyl-SO₂NR¹¹R¹², -C₆-C₆ alkyl-SO₂R¹⁰, -C₆-C₆ alkyl-SOR¹³, -C₆-C₆ alkyl-OCOR¹³,
-C₆-C₆ alkyl-OC(O)NR¹¹R¹², -C₆-C₆ alkyl-OC(O)OR¹³, -C₆-C₆ alkyl-NR¹¹C(O)OR¹³,
-C₆-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₆-C₆ alkyl-NR¹¹COR¹³, where said C₆-C₆ alkyl, is
optionally unsubsti-
tuted or substituted by one or more halo substituents;

W³ is selected from the group consisting of: H, halo, C₁-C₆ alkyl,
-C₆-C₆ alkyl-NR¹¹R¹², -C₆-C₆ alkyl-SR¹⁰, -C₆-C₆ alkyl-OR¹⁰, -C₆-C₆ alkyl-CO₂R¹⁰,
-C₆-C₆ alkyl-C(O)SR¹⁰, -C₆-C₆ alkyl-CONR¹¹R¹², -C₆-C₆ alkyl-COR¹³,
-C₆-C₆ alkyl-OCOR¹³, -C₆-C₆ alkyl-OCNR¹¹R¹², -C₆-C₆ alkyl-OC(O)OR¹³,
-C₆-C₆ alkyl-NR¹¹COR¹³, -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and
-C₆-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₆-C₆ alkyl is optionally unsubsti-
tuted or substituted by one or more halo substituents;

Q is selected from C₂-C₆ cycloalkyl, Ar and Het; wherein said C₂-C₆ cycloalkyl, Ar
and Het are optionally unsubsti-
tuted or substituted with one or more groups independently
selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl,
-C₆-C₆ alkyl-CO₂R¹⁰, -C₆-C₆ alkyl-C(O)SR¹⁰, -C₆-C₆ alkyl-CONR¹¹R¹², -C₆-C₆ alkyl-COR¹³,
-C₆-C₆ alkyl-NR¹¹R¹², -C₆-C₆ alkyl-SR¹⁰, -C₆-C₆ alkyl-OR¹⁰, -C₆-C₆ alkyl-SO₂H,
-C₆-C₆ alkyl-SO₂NR¹¹R¹², -C₆-C₆ alkyl-SO₂R¹⁰, -C₆-C₆ alkyl-SOR¹³, -C₆-C₆ alkyl-OCOR¹³,
-C₆-C₆ alkyl-OC(O)NR¹¹R¹², -C₆-C₆ alkyl-OC(O)OR¹³, -C₆-C₆ alkyl-NR¹¹C(O)OR¹³,
-C₆-C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₆-C₆ alkyl-NR¹¹COR¹³, where said C₆-C₆ alkyl is
optionally unsubsti-
tuted or substituted by one or more halo substituents;
p is 0-8;
n is 2-8;
m is 0 or 1;
q is 0 or 1;
t is 0 or 1;
each R¹ and R² are independently selected from H, halo, C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₃₋C₆ alkynyl, -C₀₋C₆ alkyl-NR¹¹R¹², -C₀₋C₆ alkyl-OR¹⁰, -C₀₋C₆ alkyl-SR¹⁰, -C₁₋C₆ alkyl-Het, -C₁₋C₆ alkyl-Ar and -C₁₋C₆ alkyl-C₃₋C₇ cycloalkyl, or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said C₁₋C₆ alkyl is optionally substituted or substituted by one or more halo substituents;

each R² is the same or different and is independently selected from halo, cyano, nitro, C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₃₋C₆ alkynyl, -C₀₋C₆ alkyl- Ar, -C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-CO₂R¹⁰, -C₀₋C₆ alkyl-C(O)SR¹⁰, -C₀₋C₆ alkyl-CONR¹¹R¹², -C₀₋C₆ alkyl-COR¹³, -C₀₋C₆ alkyl-NR¹¹R¹², -C₀₋C₆ alkyl-SR¹⁰, -C₀₋C₆ alkyl-OR¹⁰, -C₀₋C₆ alkyl-SO₂H, -C₀₋C₆ alkyl-SO₂NR¹¹R¹², -C₀₋C₆ alkyl-SO₂R¹⁰, -C₀₋C₆ alkyl-SOR¹³, -C₀₋C₆ alkyl-OC(O)R¹³, -C₀₋C₆ alkyl-OC(O)NR¹¹R¹², -C₀₋C₆ alkyl-OC(O)OR¹³, -C₀₋C₆ alkyl-NR¹¹C(O)OR¹³, -C₀₋C₆ alkyl-NR¹¹C(O)NR¹¹R¹², and -C₀₋C₆ alkyl-NR¹¹COR¹³, wherein said C₁₋C₆ alkyl is optionally substituted or substituted by one or more halo substituents;

each R⁴ and R⁵ is independently selected from H, halo, C₁₋C₆ alkyl, -C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-Ar and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁₋C₆ alkyl,

- C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-Ar and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁₋C₆ alkyl, -C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-Ar and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

R¹⁰ is selected from H, C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₃₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl, or R¹¹ and R¹² together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

R¹³ is selected from C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₃₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

R¹⁴ and R¹⁵ are each independently selected from H, C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₃₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-O-Ar, -C₀₋C₆ alkyl-O-Het, -C₀₋C₆ alkyl-O-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-S(O)ₓC₁-C₆ alkyl, -C₀₋C₆ alkyl-S(O)ₓ-Ar, -C₀₋C₆ alkyl-S(O)ₓ-Het, -C₀₋C₆ alkyl-S(O)ₓ-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-NH-Het, -C₀₋C₆ alkyl-NH-
C_{3-7} cycloalkyl, -C_{0-6} alkyl-N(C_{1-4} alkyl)-Ar, -C_{0-6} alkyl-N(C_{1-4} alkyl)-Het, 
-C_{0-6} alkyl-N(C_{1-4} alkyl)-C_{3-5} cycloalkyl, -C_{0-6} alkyl-Ar, -C_{0-6} alkyl-Het and 
-C_{0-6} alkyl-C_{3-7} cycloalkyl, where x is 0, 1 or 2, or R^{14} and R^{15}, together with the 
nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which 
optionally contains one or more additional heteroatoms selected from N, O, and S, wherein 
said C_{1-6} alkyl is optionally substituted by one or more of the substituents independently 
selected from the group halo, -OH, -SH, -NH_{2}, -NH(unsaturated C_{1-6} alkyl), 
-N(unsaturated C_{1-6} alkyl)(unsaturated C_{1-6} alkyl), unsaturated -OC_{1-6} alkyl, 
-CO_{2}H, -CO_{2}(unsaturated C_{1-6} alkyl), -CONH_{2}, -CONH(unsaturated C_{1-6} alkyl), 
-CO_{2}H(unsaturated C_{1-6} alkyl)(unsaturated C_{1-6} alkyl), -SO_{3}H, -SO_{2}NH_{2}, 
-SO_{2}NH(unsaturated C_{1-6} alkyl) and -SO_{2}N(unsaturated C_{1-6} alkyl)(unsaturated 
C_{1-6} alkyl); 
R^{16} is C_{1-6} alkyl, -C_{0-6} alkyl-Ar or -C_{0-6} alkyl-Het; and 
R^{17} is H, C_{1-6} alkyl, -C_{0-6} alkyl-Ar or -C_{0-6} alkyl-Het; 
or a pharmaceutically acceptable salt or solvate thereof.

12. The method according to any one of Claims 1 to 8, wherein the LXR 
modulator comprises a compound of formula (IV):

![Chemical Structure](image)

wherein:
X is CH or N;
Y is N(R^{10}), O, or S, wherein t is 0 or 1 when Y is N(R^{10}) or O, and t is 0 when Y is 
S;
U is selected from halo, -OR^{10}, -NR^{14}R^{15}, nitro, cyano, -COOR^{10}, -COR^{13}, 
-OCOR^{13}, -CONR^{14}R^{15}, -N(R^{14})COR^{13}, -SO_{2}H, -SO_{2}NR^{14}R^{15}, -C(NR^{17})NR^{14}R^{15}, 
-N(R^{14})SO_{2}R^{16}, and a 5 or 6-membered heterocyclic group;
A is a phenyl fused ring moiety or a pyridyl fused ring moiety, wherein when A is a phenyl ring moiety, \( k \) is 0-3 and \( t \) is 0 or 1 and when A is a pyridyl ring moiety, \( k \) is 0-2 and \( t \) is 0;

\[ W^1 \] is selected from \( C_3-C_8 \) cycloalkyl, aryl and Het, wherein said \( C_3-C_8 \) cycloalkyl,

5 \( Ar \) and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, \( C_1-C_6 \) alkyl, \( C_3-C_6 \) alkenyl, \( C_3-C_6 \) alkynyl,

\(-C_0-C_6 \) alkyl-\( CO_2R^{10} \), \(-C_0-C_6 \) alkyl-\( C(O)SR^{10} \), \(-C_0-C_6 \) alkyl-\( CONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-COR^{13} ,

\(-C_0-C_6 \) alkyl-NR^{11}R^{12} , \(-C_0-C_6 \) alkyl-\( SR^{10} \), \(-C_0-C_6 \) alkyl-\( OR^{10} \), \(-C_0-C_6 \) alkyl-\( SO_2H \),

\(-C_0-C_6 \) alkyl-\( SO_2NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( SO_2R^{10} \), \(-C_0-C_6 \) alkyl-SOR^{13} , \(-C_0-C_6 \) alkyl-\( OCOR^{13} \),

\(-C_0-C_6 \) alkyl-\( (O)NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( (O)OR^{13} \), \(-C_0-C_6 \) alkyl-\( NR^{11}C(O)OR^{13} \),

\(-C_0-C_6 \) alkyl-\( NR^{11}C(O)NR^{11}R^{12} \), and \(-C_0-C_6 \) alkyl-\( NR^{11}COR^{13} \), where said \( C_1-C_6 \) alkyl is optionally unsubstituted or substituted by one or more halo substituents;

\[ W^2 \] is selected from H, halo, \( C_1-C_6 \) alkyl, \( C_3-C_6 \) alkenyl, \( C_2-C_6 \) alkynyl,

\(-C_0-C_6 \) alkyl-\( NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( SR^{10} \), \(-C_0-C_6 \) alkyl-\( OR^{10} \), \(-C_0-C_6 \) alkyl-\( CO_2R^{10} \),

\(-C_0-C_6 \) alkyl-\( C(O)SR^{10} \), \(-C_0-C_6 \) alkyl-\( CONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-COR^{13} ,

\(-C_0-C_6 \) alkyl-\( OCONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( NR^{11}CONR^{11}R^{12} \),

\(-C_0-C_6 \) alkyl-\( NR^{11}COR^{13} \), \(-C_0-C_6 \) alkyl-Het , \(-C_0-C_6 \) alkyl-Ar and

\(-C_0-C_6 \) alkyl-\( C_3-C_7 \) cycloalkyl, wherein said \( C_1-C_6 \) alkyl is optionally unsubstituted or substituted by one or more halo substituents, and wherein the \( C_3-C_7 \) cycloalkyl, \( Ar \) and Het moieties of said \(-C_0-C_6 \) alkyl-Het, \(-C_0-C_6 \) alkyl-Ar and \(-C_0-C_6 \) alkyl-\( C_3-C_7 \) cycloalkyl are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, \( C_1-C_6 \) alkyl, \( C_3-C_6 \) alkenyl, \( C_3-C_6 \) alkynyl, \(-C_0-C_6 \) alkyl-\( CO_2R^{10} \),

\(-C_0-C_6 \) alkyl-\( C(O)SR^{10} \), \(-C_0-C_6 \) alkyl-\( CONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-COR^{13} ,

\(-C_0-C_6 \) alkyl-\( NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( SR^{10} \), \(-C_0-C_6 \) alkyl-\( OR^{10} \), \(-C_0-C_6 \) alkyl-\( SO_2H \),

\(-C_0-C_6 \) alkyl-\( SO_2NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( SO_2R^{10} \), \(-C_0-C_6 \) alkyl-SOR^{13} , \(-C_0-C_6 \) alkyl-\( OCOR^{13} \),

\(-C_0-C_6 \) alkyl-\( (O)NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( (O)OR^{13} \), \(-C_0-C_6 \) alkyl-\( NR^{11}C(O)OR^{13} \),

\(-C_0-C_6 \) alkyl-\( NR^{11}C(O)NR^{11}R^{12} \), and \(-C_0-C_6 \) alkyl-\( NR^{11}COR^{13} \), where said \( C_1-C_6 \) alkyl is optionally unsubstituted or substituted by one or more halo substituents;

\[ W^3 \] is selected from the group consisting of: H, halo, \( C_1-C_6 \) alkyl,

\(-C_0-C_6 \) alkyl-\( NR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( SR^{10} \), \(-C_0-C_6 \) alkyl-\( OR^{10} \), \(-C_0-C_6 \) alkyl-\( CO_2R^{10} \),

\(-C_0-C_6 \) alkyl-\( C(O)SR^{10} \), \(-C_0-C_6 \) alkyl-\( CONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-COR^{13} ,

\(-C_0-C_6 \) alkyl-\( OCONR^{11}R^{12} \), \(-C_0-C_6 \) alkyl-\( NR^{11}CONR^{11}R^{12} \),

\(-C_0-C_6 \) alkyl-\( NR^{11}COR^{13} \), \(-C_0-C_6 \) alkyl-Het , \(-C_1-C_6 \) alkyl-Ar and

\(-C_1-C_6 \) alkyl-\( C_3-C_7 \) cycloalkyl, wherein said \( C_1-C_6 \) alkyl is optionally unsubstituted or substituted by one or more halo substituents;
Q is selected from C₅-C₈ cycloalkyl, Ar and Het; wherein said C₅-C₈ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₅ alkenyl, C₄-C₆ alkylnyl,
- C₀-C₆ alkyl-CO₂R, -C₀-C₆ alkyl-C(O)SR, - C₀-C₆ alkyl-CONR₁R₂, - C₀-C₆ alkyl-COR, 5
- C₀-C₆ alkyl-NR₁R₂, - C₀-C₆ alkyl-SR, - C₀-C₆ alkyl-OR, - C₀-C₆ alkyl-SO₂H, - C₀-C₆ alkyl-SO₂NR₁R₂, - C₀-C₆ alkyl-SO₂R, - C₀-C₆ alkyl-SOR, - C₀-C₆ alkyl-OCOR, 10
- C₀-C₆ alkyl-OC(O)NR₁R₂, - C₀-C₆ alkyl-OC(O)OR, - C₀-C₆ alkyl-NR₁C(O)OR, - C₀-C₆ alkyl-NR₁C(O)NR₁R₂, and - C₀-C₆ alkyl-NR₁COR, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;
m is 0 or 1;

q is 0 or 1;
t is 0 or 1;
each R¹ and R² are independently selected from H, halo, C₁-C₆ alkyl, C₃-C₆ alkenyl, 15
C₄-C₆ alkylnyl, - C₀-C₆ alkyl-NR₁R₂, - C₀-C₆ alkyl-OR, - C₀-C₆ alkyl-SR, - C₁-C₆ alkyl-Het, - C₁-C₆ alkyl-Ar and - C₁-C₆ alkyl-C₅-C₇ cycloalkyl, or R¹ and R² together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O,

and S, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each R³ is the same or different and is independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₄-C₆ alkylnyl, -C₀-C₆ alkyl-Ar, - C₀-C₆ alkyl-Het, - C₀-C₆ alkyl-C(O)SR, 25
-C₀-C₆ alkyl-OC(O)OR, - C₀-C₆ alkyl-NR₁C(O)OR, - C₀-C₆ alkyl-NR₁C(O)NR₁R₂, and - C₀-C₆ alkyl-NR₁COR, wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;
each R⁴ and R⁵ are independently selected from H, halo, C₁-C₆ alkyl, - C₀-C₆ alkyl-Het, - C₀-C₆ alkyl-Ar and - C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl, - C₀-C₆ alkyl-Het, - C₀-C₆ alkyl-Ar and - C₀-C₆ alkyl-C₅-C₇ cycloalkyl;

R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl, - C₀-C₆ alkyl-Het, - C₀-C₆ alkyl-Ar and - C₀-C₆ alkyl-C₅-C₇ cycloalkyl;
R^{10} is selected from H, C_{1}-C_{6} alkyl, C_{3}-C_{6} alkenyl, C_{5}-C_{6} alkynyl, -C_{0}-C_{6} alkyl-Ar,
-C_{0}-C_{6} alkyl-Het and -C_{0}-C_{6} alkyl-C_{3}-C_{7} cycloalkyl;

each R^{11} and each R^{12} are independently selected from H, C_{1}-C_{6} alkyl,
C_{3}-C_{6} alkenyl, C_{5}-C_{6} alkynyl, -C_{0}-C_{6} alkyl-Ar, -C_{0}-C_{6} alkyl-Het and
-C_{0}-C_{6} alkyl-C_{3}-C_{7} cycloalkyl, or R^{11} and R^{12} together with the nitrogen to which they are
attached form a 4-7 membered heterocyclic ring which optionally contains one or more
additional heteroatoms selected from N, O, and S;

R^{13} is selected from C_{1}-C_{6} alkyl, C_{3}-C_{6} alkenyl, C_{5}-C_{6} alkynyl, -C_{0}-C_{6} alkyl-Ar,
-C_{0}-C_{6} alkyl-Het and -C_{0}-C_{6} alkyl-C_{3}-C_{7} cycloalkyl;

R^{14} and R^{15} are each independently selected from H, C_{1}-C_{6} alkyl, C_{3}-C_{6} alkenyl,
C_{5}-C_{6} alkynyl, -C_{0}-C_{6} alkyl-Ar, -C_{0}-C_{6} alkyl-Het, -C_{0}-C_{6} alkyl-C_{3}-C_{7} cycloalkyl,
-C_{0}-C_{6} alkyl-O-Ar, -C_{0}-C_{6} alkyl-O-Het, -C_{0}-C_{6} alkyl-O-C_{3}-C_{7} cycloalkyl,
-C_{0}-C_{6} alkyl-S(O)_{x}C_{1}-C_{6} alkyl, -C_{0}-C_{6} alkyl-S(O)_{x}Ar, -C_{0}-C_{6} alkyl-S(O)_{x}Het,
-C_{0}-C_{6} alkyl-S(O)_{x}C_{5}-C_{7} cycloalkyl, -C_{0}-C_{6} alkyl-NH-Ar, -C_{0}-C_{6} alkyl-NH-Het,
-C_{0}-C_{6} alkyl-NH-C_{3}-C_{7} cycloalkyl, -C_{0}-C_{6} alkyl-N(C_{1}-C_{4} alkyl)-Ar,
-C_{0}-C_{6} alkyl-N(C_{1}-C_{4} alkyl)-Het, -C_{0}-C_{6} alkyl-N(C_{1}-C_{4} alkyl)-C_{3}-C_{7} cycloalkyl,
-C_{0}-C_{6} alkyl-Ar, -C_{0}-C_{6} alkyl-Het and -C_{0}-C_{6} alkyl-C_{3}-C_{7} cycloalkyl, where x is 0, 1 or 2, or
R^{14} and R^{15}, together with the nitrogen to which they are attached, form a 4-7 membered
heterocyclic ring which optionally contains one or more additional heteroatoms selected
from N, O, and S, wherein said C_{1}-C_{6} alkyl is optionally substituted by one or more of the
substituents independently selected from the group halo, -OH, -SH, -NH_{2},
-NH(unsaturated C_{1}-C_{6} alkyl), -N(unsaturated C_{1}-C_{6} alkyl)(unsaturated C_{1}-C_{6} alkyl),
unsaturated -OC_{1}-C_{6} alkyl, -CO_{2}H, -CO_{2}(unsaturated C_{1}-C_{6} alkyl), -CONH_{2},
-CONH(unsaturated C_{1}-C_{6} alkyl), -CON(unsaturated C_{1}-C_{6} alkyl)(unsaturated
C_{1}-C_{6} alkyl), -SO_{2}H, -SO_{2}NH_{2}, -SO_{2}NH(unsaturated C_{1}-C_{6} alkyl) and
-SO_{2}N(unsaturated C_{1}-C_{6} alkyl)(unsaturated C_{1}-C_{6} alkyl);

R^{16} is C_{1}-C_{6} alkyl, -C_{0}-C_{6} alkyl-Ar or -C_{0}-C_{6} alkyl-Het; and
R^{17} is H, C_{1}-C_{6} alkyl, -C_{0}-C_{6} alkyl-Ar or -C_{0}-C_{6} alkyl-Het;
or a pharmaceutically acceptable salt or solvate thereof.
13. The method according to any one of Claims 1 to 8, wherein the LXR modulator comprises a compound of formula (V):

![Chemical Structure Image]

(V)

or a pharmaceutically acceptable derivative thereof.

14. The method according to any one of Claims 1 to 8, wherein the LXR modulator comprises a compound of formula (VI):

![Chemical Structure Image]

(VI)

or a pharmaceutically acceptable derivative thereof.

15. The method according to any one of Claims 1-14, wherein the LXR modulator is an LXR agonist.

16. Use of an LXR modulator in the preparation of a medicament for the treatment or prophylaxis of stroke, Alzheimer's disease, fronto-temporal dementias, peripheral neuropathy, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, said method comprising the step of administering to said patient an effective amount of an LXR modulator in combination with a carrier.
17. Use of an LXR modulator in the preparation of a medicament for the treatment or prophylaxis of diseases or conditions characterised by neuron degeneration, inflammation in the CNS, injury or impaired plasticity.

18. Use according to Claim 16 or Claim 17, wherein the disease is selected from psychiatric disorders such as schizophrenia and depression.

19. Use according to Claim 16 or Claim 17, wherein the disease is selected from those conditions associated with head or spinal cord injury, including trauma.

20. Use according to Claim 16 or Claim 17, wherein said LXR modulator is selected from the group consisting of: an LXR agonist and an LXR antagonist.

21. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (I)

```
       X^1
       /   \
      X^2   X^3
      /     /   \
     R^1--Ar----Y--R^2
      /     /     \
     X^4   X^5   X^6
```

(I)

wherein:

Ar represents an aryl group; R^1 is -OH, -O-(C1-C7)alkyl, -OC(O)-(C1-C7)alkyl,

-OC(O)-(C1-C7)alkyl, -CO_2H, -NH_2,

-NH(C1-C7)alkyl, -N((C1-C7)alkyl)_2 or -NH-S(O)_2-(C1-C5)alkyl;

R^2 is (C1-C7)alkyl, (C1-C7)heteroalkyl, aryl and aryl(C1-C7)alkyl;

X^1, X^2, X^3, X^4, X^5 and X^6 are each independently H, (C1-C5)alkyl, (C1-C5)heteroalkyl, F or Cl, with the proviso that no more than three of X^1 through X^6 are H,

(C1-C5)alkyl or (C1-C5)heteroalkyl; and

Y is -N(R^{12})S(O)m^+ -N(R^{12})S(O)mN(R^{13})^- -N(R^{12})C(O)^- -N(R^{12})C(O)N(R^{13})^-,

-N(R^{12})C(S)^- or -N(R^{12})C(O)^-, wherein R^{12} and R^{13} are each independently hydrogen, (C1-C7)aryl, (C1-C7)heteroalkyl, aryl and aryl(C1-C7)alkyl, and optionally when Y is -N(R^{12})S(O)m^+ or -N(R^{12})S(O)mN(R^{13})^- , R^{12} forms a five, six or seven-membered ring fused to Ar or to R^2 through covalent attachment to Ar.
or R², respectively. In the above Y groups, the subscript m is an integer of from 1 to 2;
or a pharmaceutically acceptable derivative thereof

22. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (II):

wherein:
X is OH or NH₂;
p is 0-6;
each R¹ and R² are the same or different and are each independently selected from the group consisting of H, C₁₋₃alkyl, C₁₋₃alkoxy and C₁₋₃thioalkyl;
Z is CH or N;
when Z is CH, k is 0-4;
when Z is N, k is 0-3;
each R³ is the same or different and is independently selected from the group consisting of halo, –OH, C₁₋₃alkyl, C₂₋₃alkenyl, C₁₋₃alkoxy, C₂₋₃alkenylxoxoy, –S(O)₅R⁶, –NR³R⁷, –COR⁶, COOR⁶, R¹⁰COOR⁶, OR¹⁰COOR⁶, CONR³R⁸, –OC(O)R⁹, –R¹⁰NR³R⁷, –OR¹⁰NR³R⁷, 5-6 membered heterocycle, nitro, and cyano;
a is 0, 1 or 2;
R⁶ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₃alkoxy and C₂₋₃alkenyl;
each R⁷ and R⁸ are the same or different and are each independently selected from the group consisting of H, C₁₋₃alkyl, C₂₋₃alkenyl,
C₃₋₅alkynyl;
R⁹ is selected from the group consisting of H, C₁₋₃alkyl and -NR³R⁷;
R¹⁰ is C₁₋₃alkyl;
n is 2-8;
q is 0 or 1;
R⁴ is selected from the group consisting of H, C₁₋₃alkyl, C₁₋₃alkenyl, and alkenyloxy;
Ring A is selected from the group consisting of C₃₆-cycloalkyl, aryl, 4-8 membered heterocycle, and 5-6 membered heteroaryl;

each ring B is the same or different and is independently selected from the group consisting of C₃₆-cycloalkyl and aryl;

or a pharmaceutically acceptable derivative thereof.

23. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (III):

![Chemical Structure](image)

wherein:

X is selected from C₁-C₆ alkyl, halo, -OR¹⁰, -NR¹⁴⁻¹⁵, nitro, cyano, -COOR¹⁰, -COR¹³, -OCOR¹¹, -CONR¹⁴⁻¹⁵, -N(R¹⁷)COR¹³, -N(R¹⁷)CONR¹⁴⁻¹⁵, -N(R¹⁷)COOR¹³, -SO₂H, -SO₂NR¹⁴⁻¹⁵, -C(=NR¹⁷)NR¹⁴⁻¹⁵, -N(R¹⁷)SO₂R¹⁶, and a 5 or 6-membered heterocyclic group;

or X and an adjacent R³, taken together with the atoms to which they are bonded, form an alkylenedioxy moiety;

Z is CH, CR³ or N, wherein when Z is CH or CR³, k is 0-4 and t is 0 or 1, and when Z is N, k is 0-3 and t is 0;

Y is selected from -O-, -S-, -N(R¹⁰)-, and -C(R⁵)(R⁵)-;

W¹ is selected from C₁-C₆ alkyl, C₅-C₆ cycloalkyl, aryl and Het, wherein said C₁-C₆ alkyl, C₅-C₆ cycloalkyl, Ar and Het are optionally unsubstituted or substituted with one or more groups independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₅-C₆ alkenyl, C₅-C₆ alkyny, -C₀-C₆ alkyl-CO₂R¹⁰, -C₀-C₆ alkyl-C(O)SR¹⁰, -C₀-C₆ alkyl-CO-NR¹¹⁺¹², -C₀-C₆ alkyl-COR¹³, -C₀-C₆ alkyl-NR¹¹⁺¹², -C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SO₂H, -C₀-C₆ alkyl-SO₂NR¹¹⁺¹², -C₀-C₆ alkyl-SO₂R¹⁰, -C₀-C₆ alkyl-SOR¹³, -C₀-C₆ alkyl-OCOR¹³, -C₀-C₆ alkyl-OC(O)NR¹¹⁺¹², -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-NR¹¹⁻¹₂-C(O)OR¹³, -C₀-C₆ alkyl-NR¹¹⁻¹₂-C(O)NR¹¹⁺¹², and -C₀-C₆ alkyl-NR¹₁⁻¹₂-COR¹³, where said C₁-C₆ alkyl, is optionally unsubstituted or substituted by one or more halo substituents;
W² is selected from H, halo, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, 
-C₆-C₆ alkyl-NR¹¹R¹₂, -C₆-C₆ alkyl-SR¹₀, -C₆-C₆ alkyl-OR¹₀, -C₆-C₆ alkyl-CO₂R¹₀, 
-C₆-C₆ alkyl-C(O)SR¹₀, -C₆-C₆ alkyl-CONR¹¹¹R¹₂, -C₆-C₆ alkyl-COR¹₃, 
-C₆-C₆ alkyl-OCOR¹₃, -C₆-C₆ alkyl-OCONR¹¹¹R¹₂, -C₆-C₆ alkyl-NR¹¹¹CONR¹¹¹R¹₂, 
-C₆-C₆ alkyl-NR¹¹¹COR¹₃, -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and 
-C₆-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl is optionally unsubstituted or 
substituted by one or more halo substituents, and wherein the C₃-C₇ cycloalkyl, Ar and Het 
moieties of said -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and -C₆-C₆ alkyl-C₃-C₇ cycloalkyl are 
optionally unsubstituted or substituted with one or more groups independently selected from 
halo, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, -C₆-C₆ alkyl-CO₂R¹₀, 
-C₆-C₆ alkyl-C(O)SR¹₀, -C₆-C₆ alkyl-CONR¹¹¹R¹₂, -C₆-C₆ alkyl-COR¹₃, 
-C₆-C₆ alkyl-NR¹¹¹R¹₂, -C₆-C₆ alkyl-SR¹₀, -C₆-C₆ alkyl-OR¹₀, -C₆-C₆ alkyl-CO₂H, 
-C₆-C₆ alkyl-SO₂NR¹¹¹R¹₂, -C₆-C₆ alkyl-SO₂R¹₀, -C₆-C₆ alkyl-SOR¹₃, -C₆-C₆ alkyl-OCOR¹₃, 
-C₆-C₆ alkyl-OC(O)NR¹¹¹R¹₂, -C₆-C₆ alkyl-OC(O)OR¹₃, -C₆-C₆ alkyl-NR¹¹¹C(O)OR¹₃, 
-C₆-C₆ alkyl-NR¹¹¹C(O)NR¹¹¹R¹₂, and -C₆-C₆ alkyl-NR¹¹¹COR¹₃, where said C₁-C₆ alkyl, is 
optionally unsubstituted or substituted by one or more halo substituents; 
W³ is selected from the group consisting of: H, halo, C₁-C₆ alkyl, 
-C₆-C₆ alkyl-NR¹¹¹R¹₂, -C₆-C₆ alkyl-SR¹₀, -C₆-C₆ alkyl-OR¹₀, -C₆-C₆ alkyl-CO₂R¹₀, 
-C₆-C₆ alkyl-C(O)SR¹₀, -C₆-C₆ alkyl-CONR¹¹¹R¹₂, -C₆-C₆ alkyl-COR¹₃, 
-C₆-C₆ alkyl-OCOR¹₃, -C₆-C₆ alkyl-OCONR¹¹¹R¹₂, -C₆-C₆ alkyl-NR¹¹¹COR¹₃, 
-C₆-C₆ alkyl-NR¹¹¹CONR¹¹¹R¹₂, -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and 
-C₆-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl is optionally unsubstituted or 
substituted by one or more halo substituents; 
Q is selected from C₃-C₆ cycloalkyl, Ar and Het; wherein said C₃-C₆ cycloalkyl, Ar 
and Het are optionally unsubstituted or substituted with one or more groups independently 
selected from halo, cyano, nitro, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, 
-C₆-C₆ alkyl-CO₂R¹₀, -C₆-C₆ alkyl-C(O)SR¹₀, -C₆-C₆ alkyl-CONR¹¹¹R¹₂, -C₆-C₆ alkyl-COR¹₃, 
-C₆-C₆ alkyl-NR¹¹¹R¹₂, -C₆-C₆ alkyl-SR¹₀, -C₆-C₆ alkyl-OR¹₀, -C₆-C₆ alkyl-CO₂H, 
-C₆-C₆ alkyl-SO₂NR¹¹¹R¹₂, -C₆-C₆ alkyl-SO₂R¹₀, -C₆-C₆ alkyl-SOR¹₃, -C₆-C₆ alkyl-OCOR¹₃, 
-C₆-C₆ alkyl-OC(O)NR¹¹¹R¹₂, -C₆-C₆ alkyl-OC(O)OR¹₃, -C₆-C₆ alkyl-NR¹¹¹C(O)OR¹₃, 
-C₆-C₆ alkyl-NR¹¹¹C(O)NR¹¹¹R¹₂, and -C₆-C₆ alkyl-NR¹¹¹COR¹₃, where said C₁-C₆ alkyl is 
optionally unsubstituted or substituted by one or more halo substituents; 
p is 0-8; 
n is 2-8; 
m is 0 or 1; 
q is 0 or 1;
t is 0 or 1;

each $R^1$ and $R^2$ are independently selected from H, halo, $C_1$-$C_6$ alkyl, $C_3$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-NR$_{11}$R$_{12}$, $-C_0$-$C_6$ alkyl-OR$_{10}$, $-C_0$-$C_6$ alkyl-SR$_{10}$, $-C_1$-$C_6$ alkyl-Het, $-C_1$-$C_6$ alkyl-Ar and $-C_1$-$C_6$ alkyl-$C_2$-$C_7$ cycloalkyl, or $R^1$ and $R^2$ together with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O, and S, where any of said $C_1$-$C_6$ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each $R^3$ is the same or different and is independently selected from halo, cyano, nitro, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-Ar, $-C_0$-$C_6$ alkyl-Het, $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl, $-C_0$-$C_6$ alkyl-CO$_2$R$_{10}$, $-C_0$-$C_6$ alkyl-C(O)SR$_{10}$, $-C_0$-$C_6$ alkyl-C(ONR$_{11}$R$_{12}$, $-C_0$-$C_6$ alkyl-COR$_{10}$, $-C_0$-$C_6$ alkyl-$C_0$-$C_6$ alkyl-NR$_{11}$R$_{12}$, $-C_0$-$C_6$ alkyl-SR$_{10}$, $-C_0$-$C_6$ alkyl-OR$_{10}$, $-C_0$-$C_6$ alkyl-SO$_2$H, $-C_0$-$C_6$ alkyl-SO$_2$NR$_{11}$R$_{12}$, $-C_0$-$C_6$ alkyl-SO$_2$R$_{10}$, $-C_0$-$C_6$ alkyl-SOR$_{11}$, $-C_0$-$C_6$ alkyl-OCOR$_{10}$, $-C_0$-$C_6$ alkyl-OC(O)NR$_{11}$R$_{12}$, $-C_0$-$C_6$ alkyl-OC(O)OR$_{13}$, $-C_0$-$C_6$ alkyl-NR$_{11}$C(O)OR$_{13}$, $-C_0$-$C_6$ alkyl-NR$_{11}$C(O)NR$_{11}$R$_{12}$, and $-C_0$-$C_6$ alkyl-NR$_{11}$COR$_{13}$, wherein said $C_1$-$C_6$ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

each $R^4$ and $R^5$ is independently selected from H, halo, $C_1$-$C_6$ alkyl, $-C_0$-$C_6$ alkyl-Het, $-C_0$-$C_6$ alkyl-Ar and $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl;

$R^6$ and $R^7$ are each independently selected from H, halo, $C_1$-$C_6$ alkyl, $-C_0$-$C_6$ alkyl-Het, $-C_0$-$C_6$ alkyl-Ar and $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl;

$R^8$ and $R^9$ are each independently selected from H, halo, $C_1$-$C_6$ alkyl, $-C_0$-$C_6$ alkyl-Het, $-C_0$-$C_6$ alkyl-Ar and $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl;

$R^{10}$ is selected from H, $C_1$-$C_6$ alkyl, $C_3$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-Ar, $-C_0$-$C_6$ alkyl-Het and $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl, or $R^{11}$ and $R^{12}$ together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S;

$R^{13}$ is selected from $C_1$-$C_6$ alkyl, $C_3$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-Ar, $-C_0$-$C_6$ alkyl-Het and $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl;

$R^{14}$ and $R^{15}$ are each independently selected from H, $C_1$-$C_6$ alkyl, $C_3$-$C_6$ alkenyl, $C_3$-$C_6$ alkynyl, $-C_0$-$C_6$ alkyl-Ar, $-C_0$-$C_6$ alkyl-Het, $-C_0$-$C_6$ alkyl-$C_3$-$C_7$ cycloalkyl, $-C_0$-$C_6$ alkyl-O-Ar, $-C_0$-$C_6$ alkyl-O-Het, $-C_0$-$C_6$ alkyl-O-$C_3$-$C_7$ cycloalkyl, $-C_0$-$C_6$ alkyl-S(O)$_x$-$C_1$-$C_6$ alkyl, $-C_0$-$C_6$ alkyl-S(O)$_x$-Ar, $-C_0$-$C_6$ alkyl-S(O)$_x$-Het,
-C₆H₅ alkyl-S(O)$_x$-C₇ cycloalkyl, -C₆H₅ alkyl-NH-Het, -C₆H₅ alkyl-NH-C₇ cycloalkyl, -C₆H₅ alkyl-N(C₇-N₄ alkyl)-Ar, -C₆H₅ alkyl-N(C₇-N₄ alkyl)-Het, -C₆H₅ alkyl-N(C₇-N₄ alkyl)-C₇ cycloalkyl, -C₆H₅ alkyl-Ar, -C₆H₅ alkyl-Het and -C₆H₅ alkyl-C₇ cycloalkyl, where $x$ is 0, 1 or 2, or R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S, wherein said C₁-C₆ alkyl is optionally substituted by one or more of the substituents independently selected from the group halo, -OH, -SH, -NH₂, -NH(unsaturated C₁-C₆ alkyl), -N(unsaturated C₁-C₆ alkyl)(unsaturated C₁-C₆ alkyl), un satu rated -OC₁-C₆ alkyl, -CO₂H, -CO₂(unsaturated C₁-C₆ alkyl), -CONH₂, -CONH(unsaturated C₁-C₆ alkyl), -CON(unsaturated C₁-C₆ alkyl)(unsaturated C₁-C₆ alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsaturated C₁-C₆ alkyl) and -SO₂N(unsaturated C₁-C₆ alkyl)(unsaturated C₁-C₆ alkyl);

R¹⁶ is C₁-C₆ alkyl, -C₆H₅ alkyl-Ar or -C₆H₅ alkyl-Het; and

R¹⁷ is H, C₁-C₆ alkyl, -C₆H₅ alkyl-Ar or -C₆H₅ alkyl-Het; or a pharmaceutically acceptable salt or solvate thereof.

24. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (IV):

![Chemical Structure](image)

wherein:

X is CH or N;

Y is N(R¹⁶), O, or S, wherein $t$ is 0 or 1 when $Y$ is N(R¹⁶) or O, and $t$ is 0 when $Y$ is S;

U is selected from halo, -OR¹⁰, -NR¹⁴R¹⁵, nitro, cyano, -COOR¹⁰, -COR¹³, -OCOR¹³, -CONR¹⁴R¹⁵, -N(R¹⁴)COR¹³, -SO₂H, -SO₂NR¹⁴R¹⁵, -C(=NR¹⁵)NR¹⁴R¹⁵, -N(R¹⁴)SO₂R¹⁵, and a 5 or 6-membered heterocyclic group;
A is a phenyl fused ring moiety or a pyridyl fused ring moiety, wherein when
A is a phenyl ring moiety, k is 0-3 and t is 0 or 1 and when A is a pyridyl ring
moiety, k is 0-2 and t is 0;

W is selected from C₃-C₈ cycloalkyl, aryl and Het, wherein said C₃-C₈ cycloalkyl,
5 Ar and Het are optionally unsubstituted or substituted with one or more groups
independently selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl,
-C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-COR¹⁴, -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-OR¹⁴,
-C₆-C₆ alkyl-SO₂R¹⁴, -C₆-C₆ alkyl-SO₂R¹⁴, -C₆-C₆ alkyl-SOR¹⁴, -C₆-C₆ alkyl-OCOR¹⁴,
-C₆-C₆ alkyl-OC(O)NR¹⁴, -C₆-C₆ alkyl-OC(O)NR¹⁴, -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-OR¹⁴,
10 -C₆-C₆ alkyl-C(phenyl)NR¹⁴, -C₆-C₆ alkyl-C(phenyl)NR¹⁴, and -C₆-C₆ alkyl-NR¹⁴, where said C₁-C₆ alkyl, is
optionally unsubstituted or substituted by one or more halo substituents;

W is selected from H, halo, C₁-C₆ alkyl, C₃-C₈ alkenyl, C₃-C₈ alkynyl,
-C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-SR¹⁴, -C₆-C₆ alkyl-OR¹⁴, -C₆-C₆ alkyl-CO₂R¹⁴,
15 -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-COR¹⁴, -C₆-C₆ alkyl-SOR¹⁴,
-C₆-C₆ alkyl-OCOR¹⁴, -C₆-C₆ alkyl-OCOR¹⁴, -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-NR¹⁴,
-C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-Het,
20 -C₆-C₆ alkyl-Ar and -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and -C₆-C₆ alkyl-C₃-C₇ cycloalkyl are
optionally unsubstituted or substituted with one or more groups independently selected from
halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₆-C₆ alkyl-CO₂R¹⁴,
-C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-COR¹⁴, -C₆-C₆ alkyl-NR¹⁴,
25 -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-SR¹⁴, -C₆-C₆ alkyl-SOR¹⁴, -C₆-C₆ alkyl-OCOR¹⁴,
-C₆-C₆ alkyl-OC(O)NR¹⁴, -C₆-C₆ alkyl-OC(O)OR¹⁴, -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-NR¹⁴,
-C₆-C₆ alkyl-C(phenyl)NR¹⁴, -C₆-C₆ alkyl-C(phenyl)NR¹⁴, and -C₆-C₆ alkyl-NR¹⁴, where said C₁-C₆ alkyl, is
optionally unsubstituted or substituted by one or more halo substituents;

W is selected from the group consisting of: H, halo, C₁-C₆ alkyl,
30 -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-SR¹⁴, -C₆-C₆ alkyl-OR¹⁴, -C₆-C₆ alkyl-CO₂R¹⁴,
-C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-CONR¹⁴, -C₆-C₆ alkyl-COR¹⁴, -C₆-C₆ alkyl-SOR¹⁴,
-C₆-C₆ alkyl-OCOR¹⁴, -C₆-C₆ alkyl-OCOR¹⁴, -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-NR¹⁴,
35 -C₆-C₆ alkyl-NR¹⁴, -C₆-C₆ alkyl-Het, -C₆-C₆ alkyl-Ar and
-C₆-C₆ alkyl-C₃-C₇ cycloalkyl, wherein said C₁-C₆ alkyl is optionally unsubstituted or
substituted by one or more halo substituents;
Q is selected from C₂-C₆ cycloalkyl, Ar and Het; wherein said C₃-C₆ cycloalkyl, Ar
and Het are optionally unsubstituted or substituted with one or more groups independently
selected from halo, cyano, nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl,
-C₉-C₆ alkyl-CONR¹¹², -C₀-C₆ alkyl-C(Ο)SR¹₀, -C₀-C₆ alkyl-CΟ₂R¹⁰,
-C₀-C₆ alkyl-NR¹¹², -C₀-C₆ alkyl-OR¹⁰, -C₀-C₆ alkyl-SR¹⁰,
-C₀-C₆ alkyl-N₂R¹¹², -C₀-C₆ alkyl-OR¹₀, -C₀-C₆ alkyl-CONR¹¹²,
-C₀-C₆ alkyl-OC(O)NR¹¹², -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-N₂R¹¹²,
-C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-CONR¹¹², and -C₀-C₆ alkyl-N₂R¹¹²,
where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo substituents;

p is 0-8;

n is 2-8;

m is 0 or 1;

q is 0 or 1;

t is 0 or 1;

15 each R¹ and R² are independently selected from H, halo, C₁-C₆ alkyl, C₃-C₆ alkenyl,
C₃-C₆ alkynyl, -C₀-C₆ alkyl-N₂R¹¹², -C₀-C₆ alkyl-OR¹₀, -C₀-C₆ alkyl-SR¹⁰,
-C₁-C₆ alkyl-Het, -C₁-C₆ alkyl-Ar and -C₁-C₆ alkyl-C₇-C₇ cycloalkyl, or R¹ and R² together
with the carbon to which they are attached form a 3-5 membered carbocyclic or heterocyclic
ring, wherein said heterocyclic ring contains one, or more heteroatoms selected from N, O,
and S, where said C₁-C₆ alkyl is optionally unsubstituted or substituted by one or more halo
substituents;

each R³ is the same or different and is independently selected from halo, cyano,
nitro, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, -C₀-C₆ alkyl-Ar, -C₀-C₆ alkyl-Het,
-C₀-C₆ alkyl-C₇-C₇ cycloalkyl, -C₀-C₆ alkyl-CΟ₂R¹⁰, -C₀-C₆ alkyl-C(Ο)SR¹₀,
-C₀-C₆ alkyl-CONR¹¹², -C₀-C₆ alkyl-CΟ₂R¹⁰, -C₀-C₆ alkyl-CΟ₂R¹₀,
-C₀-C₆ alkyl-CONR¹¹², -C₀-C₆ alkyl-CONR¹¹², -C₀-C₆ alkyl-N₂R¹¹², -C₀-C₆ alkyl-SR¹⁰,
-C₀-C₆ alkyl-SR¹⁰, -C₀-C₆ alkyl-CONR¹¹², -C₀-C₆ alkyl-OC(O)NR¹¹²,
-C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-OC(O)OR¹³, -C₀-C₆ alkyl-N₂R¹¹²,
-C₀-C₆ alkyl-N₂R¹¹², wherein said C₁-C₆ alkyl is optionally unsubstituted or substituted
by one or more halo substituents;

each R⁴ and R⁵ is independently selected from H, halo, C₁-C₆ alkyl,
-C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₇-C₇ cycloalkyl;

R⁶ and R⁷ are each independently selected from H, halo, C₁-C₆ alkyl,
-C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₇-C₇ cycloalkyl;

35 R⁸ and R⁹ are each independently selected from H, halo, C₁-C₆ alkyl,
-C₀-C₆ alkyl-Het, -C₀-C₆ alkyl-Ar and -C₀-C₆ alkyl-C₇-C₇ cycloalkyl;
R¹⁰ is selected from H, C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₅₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar,
-C₀₋C₆ alkyl-Het and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

each R¹¹ and each R¹² are independently selected from H, C₁₋C₆ alkyl,
C₃₋C₆ alkenyl, C₅₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het and
-C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl, or R¹¹ and R¹² together with the nitrogen to which they are
attached form a 4-7 membered heterocyclic ring which optionally contains one or more
additional heteroatoms selected from N, O, and S;

R¹³ is selected from C₁₋C₆ alkyl, C₃₋C₆ alkenyl, C₅₋C₆ alkynyl, -C₀₋C₆ alkyl-Ar,
-C₀₋C₆ alkyl-Het and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl;

R¹⁴ and R¹⁵ are each independently selected from H, C₁₋C₆ alkyl, C₃₋C₆ alkenyl,
-C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het, -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl,
-C₀₋C₆ alkyl-O-Ar, -C₀₋C₆ alkyl-O-Het, -C₀₋C₆ alkyl-O-C₃₋C₇ cycloalkyl,
-C₀₋C₆ alkyl-S(O)ₓ-C₁₋C₆ alkyl, -C₀₋C₆ alkyl-S(O)ₓ-Ar, -C₀₋C₆ alkyl-S(O)ₓ-Het,
-C₀₋C₆ alkyl-S(O)ₓ-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-NH-Ar, -C₀₋C₆ alkyl-NH-Het,
-C₀₋C₆ alkyl-NH-C₃₋C₇ cycloalkyl, -C₀₋C₆ alkyl-N(C₁₋C₄ alkyl)-Ar,
-C₀₋C₆ alkyl-N(C₁₋C₄ alkyl)-Hет, -C₀₋C₆ alkyl-N(C₁₋C₄ alkyl)-C₃₋C₇ cycloalkyl,
-C₀₋C₆ alkyl-Ar, -C₀₋C₆ alkyl-Het and -C₀₋C₆ alkyl-C₃₋C₇ cycloalkyl, where x is 0, 1 or 2, or
R¹⁴ and R¹⁵, together with the nitrogen to which they are attached, form a 4-7 membered
heterocyclic ring which optionally contains one or more additional heteroatoms selected
from N, O, and S, wherein said C₁₋C₆ alkyl is optionally substituted by one or more of the
substituents independently selected from the group halo, -OH, -SH, -NH₂,
-NH(unsuсhstитuted C₁₋C₆ alkyl), -N(unsuсhstитuted C₁₋C₆ alkyl)(unsuсhstитuted C₁₋C₆ alkyl),
unsuсhstитuted -OC₁₋C₆ alkyl, -CO₂H, -CO₂(unsuсhstитuted C₁₋C₆ alkyl), -CONH₂,
-CONH(unsuсhstитuted C₁₋C₆ alkyl), -CON(unsuсhstитuted C₁₋C₆ alkyl)(unsuсhstитuted
C₁₋C₆ alkyl), -SO₃H, -SO₂NH₂, -SO₂NH(unsuсhstитuted C₁₋C₆ alkyl) and
-SO₂N(unsuсhstитuted C₁₋C₆ alkyl)(unsuсhstитuted C₁₋C₆ alkyl);

R¹⁶ is C₁₋C₆ alkyl, -C₀₋C₆ alkyl-Ar or -C₀₋C₆ alkyl-Het; and
R¹⁷ is H, C₁₋C₆ alkyl, -C₀₋C₆ alkyl-Ar or -C₀₋C₆ alkyl-Het;

or a pharmaceutically acceptable salt or solvate thereof.
25. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (V)

![Chemical Structure V]

or a pharmaceutically acceptable derivative thereof.

5

26. Use according to any one of Claims 16-20, wherein the LXR modulator comprises a compound of formula (VI):

![Chemical Structure VI]

or a pharmaceutically acceptable derivative thereof.

10

27. Use according to any one of Claims 16-26, wherein the LXR modulator is an LXR agonist.
Figure 1

LXR alpha

<table>
<thead>
<tr>
<th>Time</th>
<th>Sham</th>
<th>MCAO</th>
</tr>
</thead>
<tbody>
<tr>
<td>24hr</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>1wk</td>
<td>30</td>
<td>50</td>
</tr>
<tr>
<td>2wk</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>4wk</td>
<td>35</td>
<td>40</td>
</tr>
</tbody>
</table>

% GAPDH
Figure 2

![Graph showing the relationship between [Example 1] M and the percentage of LPS/IFN-stimulated control for different cytokines: MTT, PGE2, TNFα, NOx, and IL6. The graph illustrates the suppression of these cytokines as the [Example 1] M concentration increases.]

2/6
Figure 3

ATGTCTTGTGCTGGGCGCCCTGTGCTGACATTCCTCCTGACTCTGCAGTGG
AGCTGTGGAAGCCAGCCACAGGATGCAAGCAGCCAGCCCAGGGAGGCAGC
AGCTGCATCCTCAGAGAGGACGCAAGCCAGTGCCACTCTGCTGGGATCTGCA
GGGTGGGCTGGAGGCTGCAGAGCCACCACAGCCTGCTCAGAGGCGAGGC
CCCTCAAGAAAACAGAGATCCGTCCACAAAAGAGGGAAGAGGGCCAGCC
CCAAAATGCTGGGGAACAGGACTTATGCACTGCTGTGGGACAAAGCGGCGCC
TTCCACTACAATGTTTCTAGCTGCGAGGGGCTGGAAGGATTTCTTCGCGCGAGC
GTACATCAAGGGAGGCGACTACATCTGCGACACAGTGCGGACACTGCCCATTAGAC
ACCTAAGTCGTCAGAAGGAGGATGTGTCCTCTGCAAGAAACAGATCCGCTGAAGAAACT
GAAGCGCAAGGAGAGGAGGACACGTCATGCGACATCCCTGCCCCCAAGGGCGTT
CCCTACCCCCCAATCTGCCCCAGCTCGACCCCCGGAAACAATGGCGCATGTAGC
AGAAGCTCCTGCTGCTGCGACCAACAGTGTAACCCGGCCTCTTTCCTGACCGGC
TTGAGTCACGCCCTTGCGGCAATTGCAGACATCCCAAGCGGAGGACGGCGTC
AGCAGCGTTTGGCCACCTTCACTGAGCTGCGCCATCGTCTCTGAGTGGGATAG
TTGACTTTTGGCTAAACAGCTACCGCGCCTTCTGACAGCTCGACCGGGGAGGACGAGA
TTGCCCCCTGCTGAGAAGACCTCTGCGATCGAGTGATCTCTTGAGACATCGGA
GGTCAACAACCTTGGAGGATGAGATGTACATCCTTCTCAAGGATTTACATATTACC
GGGAAAGACTTTTGGCAAAGCAGGCTGCAAGTGGAATTCAATCACCACCACCATCTTCG
AGTTTCTCAGGCGCATGAAATTGACTGCAACTTAATGAGATCCGAGATTTGCCCTTG
TCAATTGCTACGACATCCTTCTCTGACAGACCGCCACACGTCAGGACCACAGCTCC
AGGTGGAGAGGCCTGACACACATATGGAAAGCCTGCAATGCTACAGTCTCCA
TCCACCACCCCCATGACCGAGTATGTTCCACAGGATGCTAATGAAACTGTTGGA
GCCTCAGGACCCTTGAAGCAGCTCCACTCAGACGCAAGTGTGGTGACACTGCGTCTGC
AGGACAAAAAGCCTCCACCAGCTGCTCTGAGATCTGGGATGTGACAGAATGA
Figure 4

MSLWLGAPVPDIIPDASVELWKPGAQDASSQAQGGSSCILREEARMPHSAGGTAG
VGLEAAEPTALLTRAEPSEPTEIRPQKRKGPAKMLGNELCSVCGDKASGFHYN
VLSCEGCKGFRRRVSIVKHGYICHSGGHCPMDTYMRRKCRCEQLRKRKCQARMREE
CVLSEEQIRLKKLKRQEEEQAHATSLSPPRSSPAILPSPEQLMGIEKLVAAQQQC
NRRSFSDRLRLRPWPMAPDPSREARQQRFAQHELAIYSVQEIVDFAKQLPGFLQL
SREDQIALLKSAIEVMILETSRRYNPGSITFLKDFSYNREDFAKAGLQVEFINPIF
EFSRAMNELQLNDAEFALLAISARSADRPNVQDQLQVERLQHTYVEALHAYVSIHH
PHDRLMFPRMLMKLVSLRTLSVHSEQVFALRLQDKKLPLPLLSEIWDVHE
Figure 5

ATGTCCCTCTCTACTACCGAGGTCTCCCTGGGATACCCCCCTGCTGGGAAATGGCCCC
CTCGCAGCTGGCGCCTCTCTCTCTCTCCACACTGAGAGGAGAGGCTCCGGAGC
CGTGCCCCGCGGTTCCGCCAGCCACTGAGGACTGGAGGGGACGGCAAGCTCAG
CTTCGATCGGTACCTGCCTTCTGCACCCTACACTACGTGCTAGCTGCGAAGGCTGAA
GGCTTCTCTCCGGCGCAGTGCGTCGCTGCTGCTGCGGACGGCATGCTTGGCC
GGGTGGCCAGCAGCTGAGGACGCTTTCATGCAGCGCAAGTAGCTGCAAGAAT
GCCGCGTGCAGCAAGGAGAGCCAGGAGAGGAGGAGAGAGGAGAGGAGGAG
CGAGGGTGTCTCAGCTAAGACGCGGTCAAGAATAATGATCCAGCAAGTTGGTG
CGCCCAACTGCAAGTGCAAAACGCTCTTCTCTCGACCAGCCAAAGCCTAAGC
CTCGCCCTCCGGGAGACCGCCAGCTCGGAGATGCAGCAGCCACAGCAAGCTTG
CCACTTTACGGAGCTGCCACTCATCTCATGAGGAGATCTGAGCTCAGTA
AGCAAGTGGCTGGCCCTCTCAGCTGCGAAGGAGGAGCTGCCCTCCCTCTGA
AGGCATCCACTATCGAGATCATGTGCAGTAGACACCAGCCAGGCTCAACAC
GACACAGATGTATCATACCTCTTGAGGACACTTACCTACAGCAAGGACACTTC
CACCCTGCAGGCCTGAGTTGAGATCTGACCAACCACATTCTCGAGTTCTCGGG
GGCATCCGGCGGCTGCTGCGGACAGCGCTGATACGCCCTGCTGTCATGGCCATC
AACATCTCTCCGGCAGCGGGCCCAACCTGAGGAGCCGGCGCGCTGGAGGC
GTGGCAGACGCCTACGGGAGGCGCTGGTCGTCCTAACAGGCCATCAGAGGCC
GCAGACCAGTGCGCTCTCGCCGCATGCTCATGAAAGCTGTGGAGCCCTGCGAC
GCTGAGCTCTGTGACCTGAGAGCTTCTCCTCCCTGGCGCTCCAGAGCGAAGAA
GCTGCCCGCTCTGGCTGAGATCTGGGACGTCACGGAGTGA
Figure 6

MSSPTTSSLDTLPNGPPQPGAPSSSPTVKEEGPEWPGPDPDVPGTEDASSACSTDWVIPDPEEPERKRKKGPAPKMLGHELRCVCGDKASGFHYNVLSCEGCKGFRRSVVRRGGARRYACRGGCTCMADAFMRRKCCQRCRLRCKEAGMREQCVLSCEEQIRKKIRKQQQQESQSQSPVGPQGSSSSASPGASPGGSEAGSGSGSSEGEGVQLTAAQELMIQQLVAAQLQCNKRSDQPKVTWPLGADPSRDARQRFAHTELAIISVQEIVDFAKQVPGFLQLGREDQIALLKASTIEMLLETARRYNHETECTIFLKDFTYSKD
DFHRAGLQVEFINPFEFSRAMRRLGLDDAYALLIAINFSAADRPNVQEPGRVEALQQPYVEALLSRYTRIKRPQDLRFPRMLMKLVSRLTSSLVSEQVFALRLQDKKLPLLSEIWADVHE
<110> Burbidge, Stephen A.
Cairns, William J.
Irving, Elaine A.
Parsons, Andrew A.
Richardson, Jill C.
Soden, Peter E.

<120> Methods of Treatment with LXR Modulators

<130> P51332

<140> Not Yet Assigned

<141> 2003-03-26

<150> 60/368,424
<151> 2002-03-27

<160> 6

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1344
<212> DNA
<213> Homo sapien

<400> 1
atgtccttgt ggcctgggggc ccctgtgcct gacattcctc ctgaactctgc ggtggagctg 60
tggaagccag gcgcacagga tgcaagcagc caggcccagg gaggcagcag ctgcattcctc 120
agagaggaag ccaggatgcc ccactctgct ggggtactg cagggggtggg gctggaggct 180
gcgagccca cagccccctct caccagggga caggccccttt cagaacccac agagatccgt 240
cacacaagcc ggaaaaaggg gcagcccccc aaaaatgcttg gggaagagct atgcagcgtg 300
tgtggggaca aggcctcggg cttccactac aatgtttctga gctgcggagg ctgcaagggg
360
ttcctccgcc gcagcgtcct caagggaagc cactacatct gccacagtgg cggccactgc
420
cccatggaca cctacatgcg tcgcaagtgc caggagttgc ggtttcggaa atgccaatgc
480
gctggcatgc gggaggagtg tgtctctgtca gaagaacaga tccgcctgaa gaaactgaag
540
cggcaagagg aggaacaggg tcattgcaca tcctttgcccc ccaaggcttc ctcaaccccc
600
caaatcttgt cacagctcag ccgggaacaa ctgggccatga tcgagaagct ctgctgcctgcc
660
cagcaacagt gtaaccggcg ctccttttct gacccggttc gattcagcgc ttggcccatg
720
gcaccagata cccatagccg ggaggcccggt cagcagctgt ttgccccactt cactgagctg
780
gccatcgtct cttgtgcagga gatagttgac tttgctaaac agctacccgg ccctctgcag
840
cctagcgggg agaggccagat tgcctcgtct aagaacctctg cgatcgaggt gatgtttctg
900
gagacatctc ggaggtaaca cccctggaggt gagaattatca cttctctcga ggatttcagt
960	tataacgggg aagacttttg ccaagccagg ctgcaagtgg aatccatcga ccccatcttc
1020
gagtttctcga gggccatgaa tgagctgcga cttcaatgtag cegagtttgc cttgctoatt
1080
gctatcagca tctttctctgc agacccggccc aacggtgcagg accagctcga ggtggagagg
1140
cctgcagcaca catatggtga agcccctgcat gcctacgttc ccattcaca ccccatgtcgc
1200
cgactgtagt tcccagctgt gctaatgaaa cttggtgacc ctcggaccct gacagcgcctc
1260
cactcgagac aagtgttttctg acctgcgtcg agggaaaaa agcctccacc gotggctctct
1320
gagatctggg atgtgcaacga atga
1344

<210> 2
<211> 447
<212> PRT
<213> Homo Sapien

<400> 2
Met Ser Leu Trp Leu Gly Ala Pro Val Pro Asp Ile Pro Pro Asp Ser
1 5 10 15
Ala Val Glu Leu Trp Lys Pro Gly Ala Gln Asp Ala Ser Ser Gln Ala
20 25 30
Gln Gly Gly Ser Ser Cys Ile Leu Arg Glu Ala Arg Met Pro His
35 40 45
Ser Ala Gly Gly Thr Ala Gly Val Gly Leu Glu Ala Ala Glu Pro Thr
50 55 60
Ala Leu Leu Thr Arg Ala Glu Pro Pro Ser Glu Pro Thr Glu Ile Arg
65 70 75 80
Pro Gln Lys Arg Lys Lys Gly Pro Ala Pro Lys Met Leu Gly Asn Glu
85 90 95
Leu Cys Ser Val Cys Gly Asp Lys Ala Ser Gly Phe His Tyr Asn Val
100 105 110
Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Val Ile Lys
115 120 125
Gly Ala His Tyr Ile Cys His Ser Gly Gly His Cys Pro Met Asp Thr
130 135 140
Tyr Met Arg Arg Lys Cys Gln Glu Cys Arg Leu Arg Lys Cys Arg Glu
145 150 155 160
Ala Gly Met Arg Glu Cys Val Leu Ser Glu Glu Gln Ile Arg Leu
165 170 175
Lys Lys Leu Lys Arg Gln Glu Glu Glu Gln Ala His Ala Thr Ser Leu
180 185 190
Pro Pro Arg Arg Ser Ser Pro Pro Gln Ile Leu Pro Gln Leu Ser Pro
195 200 205
Glu Gln Leu Gly Met Ile Glu Lys Leu Val Ala Ala Gln Gln Gln Cys
210 215 220
Asn Arg Arg Ser Phe Ser Asp Arg Leu Arg Val Thr Pro Trp Pro Met
225 230 235 240
Ala Pro Asp Pro His Ser Arg Glu Ala Arg Gln Gln Arg Phe Ala His
245 250 255
Phe Thr Glu Leu Ala Ile Val Ser Val Gln Glu Ile Val Asp Phe Ala
260 265 270
Lys Gln Leu Pro Gly Phe Leu Gln Leu Ser Arg Glu Asp Gln Ile Ala
275 280 285
Leu Leu Lys Thr Ser Ala Ile Glu Val Met Leu Leu Glu Thr Ser Arg
290 295 300
Arg Tyr Asn Pro Gly Ser Glu Ser Ile Thr Phe Leu Lys Asp Phe Ser
305 310 315 320
Tyr Asn Arg Glu Asp Phe Ala Lys Ala Gly Leu Gln Val Glu Phe Ile
325 330 335
Asn Pro Ile Phe Glu Phe Ser Arg Ala Met Asn Glu Leu Gln Leu Asn
<table>
<thead>
<tr>
<th></th>
<th>340</th>
<th>345</th>
<th>350</th>
<th>355</th>
<th>360</th>
<th>365</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Asp</td>
<td>Ala</td>
<td>Glu</td>
<td>Phe</td>
<td>Ala</td>
<td>Leu</td>
</tr>
<tr>
<td></td>
<td>Arg</td>
<td>Pro</td>
<td>Asn</td>
<td>Val</td>
<td>Gln</td>
<td>Asp</td>
</tr>
<tr>
<td></td>
<td>Tyr</td>
<td>Val</td>
<td>Glu</td>
<td>Ala</td>
<td>Leu</td>
<td>His</td>
</tr>
<tr>
<td></td>
<td>Arg</td>
<td>Leu</td>
<td>Met</td>
<td>Phe</td>
<td>Pro</td>
<td>Arg</td>
</tr>
<tr>
<td></td>
<td>Leu</td>
<td>Ser</td>
<td>Ser</td>
<td>Val</td>
<td>His</td>
<td>Ser</td>
</tr>
<tr>
<td></td>
<td>Lys</td>
<td>Lys</td>
<td>Leu</td>
<td>Pro</td>
<td>Pro</td>
<td>Leu</td>
</tr>
</tbody>
</table>

| 15 |     |     | <210> | 3 |
|    |     |     | <211> | 1383 |
|    |     |     | <212> | DNA |
|    |     |     | <213> | Homo sapien |

| 20 |     | <400> | 3 |
|    |     |      |     |
|    | atgttccttc ctaccacag ttccttggt acccccccgc ctggaatgg cccccctcag 60 |
|    | cctggccgcc ctttttttcc aaccactgta aaggaggagg gtcgggcagcc gtggcgcggg 120 |
|    | ggtcccgacc ctgatgtccc aggcaactgt gaggccagct cagctgcag cacagactgg 180 |
|    | gtcctcccg ggatcagcag ggacggagac cagctggtcg ccacctgagt ccccaaggg 240 |
|    | atggtgccggcac cgagctttgt cctgtctgtt ggaggcaaggg ccttcggcct ccctactacaac 300 |
|    | ggtcgctagt gcgaagggctg caagggccttc ttgctggcga gttgtggctcg tgggtggggc 360 |
|    | aggggtctag ccggcgcccc ttggccgagac tgcacatgct acggggatgc gggggcaaggg 420 |
|    | tcgccagcagt gccccgtgcc caagtgagga gaggccggga tggagggaga ggtgggttcct 480 |
|    | ttgtaagaac agatcgggaa gagaagacc gcggacacac gcagggagtc aagtccagcg 540 |
|    | tggcgctcaag ctgcgggcagcg ccagggccag gcagagctcg cctggtggcct tgggggttccc 600 |
|    | cctgtggcatt gtgagggcag ccagggccag tccgggggaag gcgggggttg ccaagtaaca 660 |
gctgttaag  aactaatgtg  cagcagttg  gtggcgccc  aactgcagtg  caaccaacgc  
720
tctttctcg  cccagccctaa  agtccagccc  tggcccctgg  gcgcagaccc  ccagtcgcga  
780
gatgcagggcc  agcaagcttt  gcgcaccttc  acggagctgg  ccactcatct  agtccaggag  
840
atcgtggact  tgctaaagca  agtgctctgtt  ttctctgcagc  tgggcogggga  ggaccagatc  
900
gcctgcttga  aggcattccac  tatacgagtc  atgctgtctag  acagacccag  gcgcctacaac  
960
cagagacag  agtgatatcac  ccctcttgaag  gacttcacct  acagcaagga  cgacttccac  
1020
cgtgcagggcc  tcgcctggtga  gtctcataac  ccctctctcg  agtctctgcg  gcgcattgcgg  
1080
cggcgctggcc  tggacgacgc  tgagttgagcc  ccgctgctag  ccactcaaacat  ctctctgcccc  
1140
gacccggccca  acgtgcagga  gcgcgcccgcg  gtggaggcgt  tgccagcagcc  ccagcttgag  
1200
gcgcctgctgt  cctacacgcc  catcaagagg  ccgcaggacc  agctgcgcttt  cccggcagtg  
1260
cctatgaagc  tggcctagctt  gcgcctggtc  agtctctgtgc  actcggagca  ggtctctgcgc  
1320
ttgcggctcc  aggcacagaa  gtgtgcctgct  ctgctgttggg  agatctgagga  gcgcacagag  
1380
tga  
1383

<210>  4
<211>  460
<212>  PRT
<213>  Homo sapien

<400>  4
Met Ser Ser Pro Thr Thr Ser Ser Leu Asp Thr Pro Leu Pro Gly Asn
35  1  5  10  15
Gly Pro Pro Gln Pro Gly Ala Pro Ser Ser Ser Pro Thr Val Lys Glu
20  20  25  30
Glu Gly Pro Gly Pro Trp Pro Gly Gly Pro Asp Pro Asp Val Pro Gly
35  35  40  45
Thr Asp Glu Ala Ser Ser Ala Cys Ser Thr Asp Trp Val Ile Pro Asp
40  50  55  60
Pro Glu Glu Glu Pro Glu Arg Lys Arg Lys Lys Gly Pro Ala Pro Lys
65  70  75  80
Met Leu Gly His Glu Leu Cys Arg Val Cys Gly Asp Lys Ala Ser Gly
  85
Phe His Tyr Asn Val Leu Ser Cys Glu Gly Cys Lys Gly Phe Phe Arg
  100
Arg Ser Val Val Arg Gly Gly Ala Arg Arg Tyr Ala Cys Arg Gly Gly
  115
Gly Thr Cys Gln Met Asp Ala Phe Met Arg Lys Cys Gln Gln Cys
  130
Arg Leu Arg Lys Cys Lys Glu Ala Gly Met Arg Glu Gln Cys Val Leu
  145
Ser Glu Glu Gln Ile Arg Lys Lys Lys Ile Arg Lys Gln Gln Glu Glu
  165
Ser Gln Ser Gln Ser Gln Ser Pro Val Gly Pro Gln Gly Ser Ser Ser
  180
Ser Ala Ser Gly Pro Gly Ala Ser Pro Gly Gly Ser Glu Ala Gly Ser
  195
Gln Gly Ser Gly Glu Gly Gly Val Gln Leu Thr Ala Ala Gln Glu Glu
  210
Leu Met Ile Gln Leu Val Ala Ala Gln Leu Gln Cys Asn Lys Arg
  225
Ser Phe Ser Asp Gln Pro Lys Val Thr Pro Lys Ala Ala Asp
  245
Pro Gln Ser Arg Asp Ala Arg Gln Glu Arg Phe Ala His Phe Thr Glu
  260
Leu Ala Ile Ile Ser Val Gln Glu Ile Val Asp Phe Ala Lys Gln Val
  275
Pro Gly Phe Leu Gln Leu Gly Arg Glu Asp Gln Ile Ala Leu Leu Lys
  290
Ala Ser Thr Ile Glu Ile Met Leu Leu Glu Thr Ala Arg Arg Tyr Asn
  305
His Glu Thr Glu Cys Ile Thr Phe Leu Lys Asp Phe Thr Tyr Ser Lys
  325
Asp Asp Phe His Arg Ala Gly Leu Gln Val Glu Phe Ile Asn Pro Ile
  340
Phe Glu Phe Ser Arg Ala Met Arg Arg Leu Gly Leu Asp Asp Ala Glu
  355
Tyr Ala Leu Leu Ile Ala Ile Asn Ile Phe Ser Ala Asp Arg Pro Asn
  370
Val Gln Glu Pro Gly Val Glu Ala Leu Gln Gln Pro Tyr Val Glu
  385
Ala Leu Ser Tyr Thr Arg Ile Lys Arg Pro Gln Asp Gln Leu Arg
  405
Phe Pro Arg Met Leu Met Lys Leu Val Ser Leu Arg Thr Leu Ser Ser
  415
Val His Ser Glu Gln Val Phe Ala Leu Arg Leu Gln Asp Lys Lys Leu Pro Pro Leu Leu Ser Glu Ile Trp Asp Val His Glu

<210> 5
<211> 20
10 <212> DNA
<213> Artificial Sequence

<220>
<223> LXR-alpha left primer
15 <400> 5
agttttgca cttcgctgc 20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> LXR-alpha right primer
25 <400> 6
gtaagccttc agtgcgtggc 20